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ABSTRACT
The activation of phospholipase D (PLD) by the G protein-coupled
receptor (GPCR) family was investigated with special attention paid to the
interaction of receptors with small G proteins such as ADP-ribosylation
factor (ARF) and RhoA. Agonist-stimulated activation of PLD by the M3
muscarinic, B2 bradykinin and Hi histamine receptors was sensitive to
brefeldin A (BFA), an inhibitor of guanine-nucleotide exchange on ARF.
In contrast the thrombin and thromboxane A2 receptors stimulated a PLD
response insensitive to BFA. The Rho inhibitor C3 exoenzyme from
Clostridium botulinum and a negative functional construct of RhoA
markedly reduced PLD activity stimulated by the M3 muscarinic but not
the thrombin receptor. The receptors investigated which couple to PLD
by a mechanism involving ARF all contain in their seventh
transmembrane domain (TMD 7), the amino acid sequence AsnProX2-
3Tyr (where X is any amino acid). In contrast, the receptors such as
thrombin which activate PLD in an ARF-independent manner have an
AspProX2-3Tyr motif. The importance of this highly conserved motif was
further indicated by studies on the mouse gonadotropin-releasing
hormone (GnRH) receptor which contains the AspProX2-3Tyr sequence
and a mutant form of the GnRH receptor where the aspartate at position
318 is replaced with an asparagine thereby restoring the AsnProX2-3Tyr
motif present in the majority of group I GPCRs. The wild-type GnRH
receptor stimulated PLD in a BFA-insensitive manner, while the Asn318
mutant GnRH form gained BFA-sensitivity. The co-
immunoprecipitation of the agonist-treated Asn318 mutant but not wild-
type GnRH receptor using antibodies raised to ARF 1/3 and RhoA
indicated that a direct physical association between the receptor and small
G proteins occurs and appears to be dependent on the presence of the
AsnProX2-3Tyr motif. In a similar fashion the M3 receptor could be
immunoprecipitated using antibodies to ARF 1/3 and RhoA as shown by
specific [3H]N-methyl scopolamine binding. Immunoreactive ARF and
Rho could correspondingly be immunoprecipitated using antibodies to
the M3 receptor or the similarly AsnProX?-3Tyr containing ATi
angiotensin receptor. Receptors from group II, the
VIP/PACAP/calcitonin family of GPCRs were also shown for the first
time to activate PLD in a potent agonist-induced manner. The VIPi, VIP2
and PACAPiong receptors all activated PLD in a BFA-sensitive fashion.
However the PACAPsh0rt receptor coupled to PLD in an ARF-
independent manner which involved phospholipase C (PLC), as shown
by its sensitivity to the PLC inhibitor U73122. The PACAPiong receptor
possesses an extra 28 amino acid "hop-1" cassette in the third intracellular
loop (i3). The importance of the hop-1 cassette and the surrounding i3 in
receptor coupling to PLD was studied using chimaeric receptor constructs
comprising the VIP2 receptor with the i3 loop replaced by that of either
the PACAPghort or iong receptor. The VIP2/PACAPiong receptor chimaeric
displayed a BFA-sensitive activation of PLD not seen with the
VTT^/PACAPghort receptor construct.
Thus activation of PLD by a number of receptors of the GPCR
family involves their association with small G proteins of the ARF and
Rho families and distinct receptor domains such as TMD 7 and i3 have
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A large number of hormones, neurotransmitters, chemokines, local
mediators, and sensory stimuli exert their effects on cells and the
organism by binding to guanine nucleotide-binding (G) protein-coupled
receptors (GPCRs). Almost 2000 such receptors are known, and more are
being discovered all the time. Despite the wide range of ligands that
activate these receptors, the receptors themselves share a surprising
amount of structural homology, both primary and secondary. The
overall structural features of the GPCR family are highly conserved: all of
these receptors contain seven hydrophobic domains, postulated to span
the plasma membrane, connected by hydrophilic extracellular and
intracellular loops.
The tertiary organisation of these structures is also thought to be highly
conserved. The breakdown of phospholipids is now globally recognised
as an important mechanism used by GPCRs to transduce the signal of
receptor stimulation. In this context the breakdown of
phosphatidylcholine by phospholipase D has emerged as a major pathway
by which class I (rhodopsin) family GPCRs may regulate the activity of the
cell. The activation of PLD has been associated with the respiratory burst
in neutrophils, control of protein trafficking and secretion, mitogenesis
and changes in cell morphological and motility (Bocckino, S. B. and J. H.
Exton 1996, Exton, J. H. 1997). However the elucidation of the mechanism
of PLD activation has moved slowly; hampered by the difficulty in
purifying the enzyme to homogeneity. Recently small G proteins of the
ADP-ribosylation factor (ARF) and Rho families have been shown to
function as activators of partially purified PLD (Bowman, E. P., et al. 1993,
Brown, H. A., et al. 1993, Cockcroft, S., et al. 1994), and the cloned PLD1
enzyme (Hammond, S. M., et al. 1995, Hammond, S. M., et al. 1997, Park,
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S.-K., et al. 1997). Despite recent advances in resolving the regulators and
co-factors that are involved in the activation of PLD, the mechanism by
which GPCRs utilise these activators is still poorly understood.
Furthermore the question of stimulation of PLD by other families of
GPCRs has been almost completely overlooked.
1.1 AIMS OF THIS STUDY
The primary aim of this study was to determine the method of
phospholipase D (PLD) by G-protein coupled receptors (GPCRs) from class
I and II. Receptors from class I which are characterised by their coupling
to the G protein Gq, and ability to activate phospholipase C (PLC) and thus
the breakdown of phosphatidylinositol 4,5-bisphosphate were studied.
The activation of PLD by receptors for Vasoactive Intestinal Peptide (VIP)
and Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP), which
belong to class II and couple tightly to GS/ was also examined. The main
questions addressed in this project have been:
• What is the mechanism of PLD activation by selected class I GPCRs: is
there an involvement of the small G proteins ARF and RhoA and
PLC?
• Does the highly conserved Asn/Asp-Pro-X2-3Tyr motif in class I
receptors have any influence on receptor coupling to PLD?
• Is there a close association between class I GPCRs and ARF and RhoA?
• Do the class II receptors; VIPi, VIP2 receptors and long and short splice
variants of the PACAP receptor stimulate PLD and what is the
mechanism of activation?
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• What is the role if any of the third intracellular loop of the
PACAPshort and iong receptors in coupling to PLD?
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1.2 G PROTEIN-COUPLED RECEPTORS
Almost 2000 G protein-coupled receptors have been reported since the
cloning of bovine rhodopsin in 1983 (Nathan, J. and D. S. Hogness 1983)
and the (3-adrenergic receptor in 1986 (Dixon, R. A., et al. 1986). All GPCRs
have an extracellular N-terminal segment, seven a-helical
transmembrane domains (TMDs), three extracellular and intracellular
loops, and an intracellular C-terminal tail, which can form a fourth
cytoplasmic loop when the C-terminal segment is palmitoylated on
cysteine and the modification allows membrane association. GPCRs have
been classified by their sequence homology, ligand structure and receptor
function into 3 major subfamilies; the rhodopsin (class I),
VIP/PACAP/secretin (class II) and the metabotropic glutamate receptor
(mGluR) family, which includes the Ca2+-sensing receptor (class III)
(Conn, P. J. and J.-P. Pin 1997). The class I family have been the focus in
the investigation of receptor function, with the rhodopsin, adrenergic,
and muscarinic acetylcholine receptors being the most extensively
studied. The VIP/PACAP/secretin and the metabotropic glutamate
family have been relatively neglected in comparison to the class I family,
although the basic signal transduction characteristics of class II and III
receptors has been studied. The class I and II families have been the
subject of this study, with the mechanism of receptor coupling to PLD
partially characterised. Receptors are proposed to consist of two
functional regions, the ligand binding domain involving the N-terminal
segment, extracellular loops and/or the pocket formed by the 7 TMDs. In
addition there is the G protein-binding domain, which is generally
considered to be defined by the intracellular loops (and perhaps elements
of the transmembrane domain close to the intracellular surface).
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1.2.1 Heterotrimeric G proteins
G proteins are composed of a, (3 and y subunits and although there are
numerous gene products encoding each subunit (20 a, 6 (3, and 12 y gene
products are known). There are four main classes of G proteins defined
by the interaction of the a subunits with their effectors. These are: GS/
which activates adenylate cyclase; Gi, which inhibits adenylate cyclase; Gq,
which activates PLC; and G12 and G13, which are of unknown function
(Hamm, H. E. 1998). G12 and G13 have been implicated in the control of
DNA synthesis (Aragay, A. M., et al. 1995), activation of Jun kinases
(Prasad, M. V., et al. 1995) and the control of the actin cytoskeleton in a
Rho-dependent manner (Buhl, A. M., et al. 1995). G12 and G13 have been
shown to modulate the action of a Rho-specific exchange factor. (Hart, M.
J., et al. 1998, Kozasa, T., et al. 1998). Within the four major classes of G
proteins there are closely related proteins with divergent functions. A G
protein G0if, is a member of the Gs family and is stimulated by odorant
receptors and activates adenylate cyclase. The G; family also contains G0,
Gt, Gz, G12 and GgUSt proteins. G0 proteins regulate calcium and
potassium channels, Gt (transducin), is the G protein that is stimulated by
the rhodopsin receptor and activates cGMP phosphodiesterase and Gz
proteins inhibit adenylate cyclase. Within the Gq family (Gq, Gn, G14, G15
and Gi6) all members activate PLC (Conklin, B. R. and H. R. Bourne 1993,
Hamm, H. E. and A. Gilchrist 1996).
G proteins are inactive in the GDP-bound, heterotrimeric state and are
activated by receptor-catalysed guanine nucleotide exchange resulting in
GTP binding to the a subunit. GTP binding leads to the dissociation of
the Ga-GTP from G(3y subunits and the stimulation of downstream
effectors by both activated Ga-GTP and free G(3y subunits (Clapham, D. E.
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and E. J. Neer 1997, Hamm, H. E. 1998). In the past, the (3y subunits of
heterotrimeric G proteins were not recognised as distinctly important in
the signal transduction processes stimulated by agonist. Recently
however the influence of Py subunits on numerous targets has been
extensively described. Once dissociated from Ga, Py subunits stimulate
PLCpl-3 (Camps, M., et al. 1992, Sternweis, P. C. 1994), PLA2 (Jelsema, C. L.
and J. Axelrod 1987) inward rectifying potassium channels (Logothetis, D.
E., et al. 1987), phosphatidylinositol 3-kinase (PI3-K) (Stephens, L., et al.
1994), G protein-coupled receptor kinases (GRKs) (Pitcher, J. A., et al. 1992)
and the MAP kinase cascade (Crespo, P., et al. 1994, Hawes, B. E., et al.
1995, Koch, W. J., et al. 1994, van Biesen, T., et al. 1995).
The coupling of GPCRs to the mitogenic Ras/MAPK signalling pathway
through Py subunits has been observed for many of the Gt-coupled
receptors such as the thrombin, lysoPA and a2-adrenergic receptors
(Alblas, J., et al. 1993, Hordijk, P. L., et al. 1994, Howe, L. R. and C. J.
Marshall 1993, Moolenaar, W. H. 1995, van Corven, E. J., et al. 1993).
However agonists also acting on Gs-, Gq-, along with Gi-coupled receptors
stimulated MAPK, and both the Ga and GPy subunits were implicated in
the signalling processes (Delia Rocca, G. J., et al. 1997, Faure, M., et al. 1994,
Wan, Y. and X.-Y. Huang 1998). Activation of the MAP kinase cascade by
receptors (including GPCRs) often starts with the tyrosine
phosphorylation of an adaptor protein, SH2-domain-containing a2-
collagen related (She), which then associates with growth-factor-receptor-
bound-protein 2 (Grb2) and son of sevenless (SOS) proteins through their
SH2 and SH3 domains. Sos is a cytoplasmic guanine-exchange factor and
stimulatory of Ras function. The phosphorylation of the She adaptor
protein and the formation of the Shc-Grb2-Sosl complex has been
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reported in the activation of MAPK by Gt and Gq-linked receptors. In
addition, there is evidence for a separate PKC-dependent/p21ras
-independent pathway for the activation of MAPK by Gq-linked receptors
(reviewed in (Denhardt, D. T. 1996, van Biesen, T., et al. 1995, van Biesen,
T„ et al. 1996)).
1.2.2 Rhodopsin family (class I) GPCRs
Although no high-resolution structure of a GPCR has yet been
determined, a recently obtained low resolution electron diffraction' J
structure of rhodopsin, a model GPCR, shows the position and
orientation of the 7 TMDs (Baldwin, J. M. 1993, Baldwin, J. M. 1994,
Schertler, G. F. X., et al. 1993, Unger, V. M., et al. 1997). According to the
Baldwin model , TMDs 4, 6 and 7 are nearly perpendicular to the plane of
the membrane, whereas TMDs 1, 2 and 3 are tilted (Schertler, G. F. X. and
P. A. Hargrave 1995, Schertler, G. F. X., et al. 1993, Unger, V. M. and G. F.
X. Schertler 1995). The use of site-directed mutations, site-directed spin
labelling techniques and nuclear magnetic resonance are beginning to
define structures for intracellular loops in several receptors. In rhodopsin
and muscarinic receptors, all three approaches indicate that the amino-
terminal residues of the third cytoplasmic loop (i3) form a-helical
extensions of TMD 5. Some evidence suggests that the carboxy-terminal
residues of i3 immediately preceding TMD 6 are also a-helices (Bliiml, K.,
et al. 1994, Burstein, E. S., et al. 1995, Flill-Eubanks, D., et al. 1996, Yang, K.,
et al. 1996). Both mutagenesis and biochemical experiments using the
labelling of rhodopsin and ^-adrenergic receptor residues with fluorescent
probes suggest that when a receptor is activated by the binding of ligand,
there are changes in the relative orientations of the transmembrane
helices (Altenbach, C., et al. 1996, Bukusoglu, G. and D. D. Jenness 1996,
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Farahbakhsh, Z. T., et al. 1993, Farahbakhsh, Z. T., et al. 1995, Farrens, D.
L., et al. 1996, Gether, U., et al. 1997). There is proposed to be a 30° twist in
TMD 6 and this change in the orientation of the TMDs is suggested to
unmask regions of the receptor that can interact with G proteins. These
movements of the TMDs will change the conformation of the i3 loop
which connects TMDs 5 and 6, the region of the receptor that has been
shown by studies using mutagenesis and chimaeric receptors to
determine G protein coupling (Dohlman, H. G., et al. 1991, Gudermann,
T., et al. 1996, Savarese, T. M., et al. 1992, Strader, C. D., et al. 1994).
1.2.3 Multiple signals from GPCRs
Many GPCRs can couple to more than one G protein and thus evoke
diverse intracellular signals. The thrombin receptor is a good example of
this behaviour with evidence for coupling to proteins from the Gq, Gi
and G12 families (Offermans, S., et al. 1994). Mi and M3 muscarinic
receptors can similarly couple to Gq and Gi (Offermanns, S., et al. 1994).
However the thyrotropin releasing hormone (TRH) receptor can couple
to all four G protein families (GS/ Gi, Gq, and G12) (Laugwitz, K. L., et al.
1996).
The existence of related receptor subtypes introduces a further level of
versatility into the generation of second messengers by one stimulus;
examples are the 12 mammalian 5-hvdroxytryptamine (serotonin), 10
adrenergic and 5 muscarinic receptor subtypes identified by molecular
cloning (Hoyer, D., et al. 1994, Watson, S. and S. Arkinstall 1994).
Furthermore, alternatively spliced variants of receptors can lead to
alternative signalling as in the case of the dopamine D2 receptor, which
exists in a short and long form. The introduction of 29 amino acids into
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the i3 of the D2Short receptor which couples to G,3, generates a longer
splice variant which displays a preferential coupling to Gi2 (Guiramand,
J., et al. 1995, Monsma, F. J., et al. 1989). Similarly a longer splice variant
of the turkey Pi-adrenergic receptor does not readily desensitize or
downregulate in response to agonist as is observed with the normal form
of the receptor (Hertel, C., et al. 1990).
1.2.4 Desensitization of GPCRs
The control of receptor desensitization is probably the most intensively
investigated aspect of GPCR signalling. This is the waning
responsiveness of a GPCR in the face of persistent stimulation (Ferguson,
S. S. G., et al. 1996, Hausdorff, W. P. 1990). There are three families of
regulatory proteins that have been clearly implicated in the process of
desensitization of heptahelical receptors: the second messenger-regulated
kinases (e.g. protein kinase A (PKA), and PKC), G protein-coupled
receptor kinases (GRKs) (e.g. (3ARK, rhodopsin kinase) and the arrestins
(visual and non-visual). The phosphorylation of GPCRs by PKA or PKC
on the C-terminal tail or i3 (Hausdorff, W. P. 1990, Sibley, D. R., et al. 1987)
and the resulting impairment of receptor coupling to G protein is seen as
heterologous desensitization as it is not agonist-specific. In such cases, as
any stimulant that elevates cAMP or DAG levels can activate PKA and
PKC and thus potentially desensitise any GPCR containing an appropriate
PKA and/or PKC consensus phosphorylation site.
Homologous desensitization of GPCR-mediated responses involves the
phosphorylation of the agonist-occupied receptor by a GRK and then the
binding of an arrestin protein which blocks receptor-G protein coupling
(Ferguson, S. S. G., et al. 1996, Inglese, J., et al. 1993, Lefkowitz, R. J. 1998).
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There are 6 members of the GRK family at the moment and at least 6
members of the arrestin family. The recruitment of GRKs to the receptor
(GRKs 2 and 3 are cytosolic proteins) is mediated by the (3y subunits of the
trimeric G protein activated upon agonist stimulation (Daaka, Y., et al.
1997, Lefkowitz, R. J. 1998). The effects of the different GRKs appear to be
receptor-specific as shown by the selective desensitization of the [3-
adrenergic but not the angiotensin II receptor in cardiac cells
overexpressing GRK5 (Rockman, H. A., et al. 1996). Furthermore a
GRK2/G(3y complex forms after lysoPA and (3-adrenergic, but not
thrombin receptor stimulation (Daaka, Y., et al. 1997). Also there appears
to be a selective interaction between different G(3y complexes and GRK
isoforms; the carboxy terminus of GRK2 binds G[3l and G(32, but not G(33,
while GRK3 binds all three (Daaka, Y., et al. 1997).
1.2.5 VIP/PACAP/secretin family (class II) GPCRs
This new family of receptors (Segre, G. V. and S. R. Goldring 1993) binds
small peptide ligands and share characteristics which also make them
distinct from the class I family of GPCRs, with which they share less than
12% homology. However work by Donnelly shows that the arrangement
of the transmembrane domains in the class II family is likely to be almost
identical to the arrangement of rhodopsin family TMDs as reported by
Baldwin (Baldwin, J. M. 1993, Baldwin, J. M. 1994, Donnelly, D. 1997). In
the course of this project the activation of PLD by the VIPi (Ishihara, T., et
al. 1992), VIP2 (Lutz, E. M., et al. 1993), PACAPshort and PACAPiong
receptors (Hashimoto, H., et al. 1993, Hosoya, M., et al. 1993, Morrow, J. A.,
et al. 1993, Pisegna, J. R. and S. A. Wank 1993, Spengler, D., et al. 1993,
Svoboda, M., et al. 1993), was studied. The short and long suffixes for the
PACAP receptor refer to two of the 6 splice variants of the PACAP
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receptor which were cloned by Spengler and colleagues (Journot, L., et al.
1995, Spengler, D., et al. 1993). The PACAP receptor is found in a short
form and 5 longer variants which contain either singly or in combination
to produce 28 amino acid inserts in the i3 of the receptor. There are 3
possible inserts; hop-1, hop-2 and hip which can be found individually
within the receptor i3, and two receptors which carry a combination of
either hop-l-hip, or hop-2-hip. The PACAPiong receptor used here
contains the 28 amino acid hop-1 insert.
The other receptors within this family include the receptors for the
following: glucagon (Jelinek, I. J., et al. 1993), glucagon-like peptide-1
(Thorens, B. 1992), calcitonin (Lin, H. Y., et al. 1991), calcitonin gene-
related peptide (Aiyar, N., et al. 1996), gastric inhibitory peptide (Usdin, T.
B., et al. 1993), secretin (Ishihara, T., et al. 1991), parathyroid hormone,
parathyroid hormone-related peptide (Juppner, H., et al. 1991), growth
hormone-releasing hormone (Mayo, K. E. 1992), corticotrophin-releasing
factor (Chang, C. P., et al. 1993), insect diuretic hormone (Regan, J. D.
1994), and two more distantly related receptors, the EMR1 (EGF module-
containing mucin-like hormone receptor) (Baud, V. 1995) and the
leukocyte activating antigen CD97 receptor (Hamann, J. 1995).
VIP was isolated from small intestine in 1970 (Said, S. I. and V. Mutt
1970), and PACAP from ovine hypothalamus during the search for a
hypophysiotrophic factor (Miyata, A., et al. 1989, Miyata, A., et al. 1990).
PACAP exists in two amidated forms, PACAP-38 and a shorter form
PACAP-27, which contain 38 and 27 amino acids respectively (Miyata, A.,
et al. 1989, Miyata, A., et al. 1990). The VIPi, VIP2, PACAPsh0rt and
PACAPiong receptors, in common with the rest of the class II family of
GPCRs, activate adenylate cyclase (Ishihara, T., et al. 1992, Lutz, E. M., et al.
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1993, Morrow, J. A., et al. 1993, Spengler, D., et al. 1993, Usdin, T. B., et al.
1994). The VIP and PACAP peptides are closely related to each other (51%
homology) (Arimura, A. and S. Shioda 1995, Mivata, A., et al. 1990).
PACAP and VIP share binding sites in a variety of tissue types. These
polypeptides bind to two major groups of sites: type I sites, which prefer
PACAP-38 and PACAP-27 over VIP, and type II sites which have
approximately equal high affinity for PACAP-38, PACAP-27 and VIP
(Arimura, A. 1992, Christophe, J. 1993, Rawlings, S. R. and M. Hezareh
1996). The VIPi and VIP2 receptors are equivalent to type II sites, whereas
PACAP receptors prefer PACAP-38 and -27 over VIP, like the type I sites.
The ability of the peptides to interact with more than one receptor subtype
may be important in vivo, by providing another layer of receptor control.
Despite the obvious differences in receptor primary sequence as compared
to class I receptors, the class II family appear to couple to many of the
same signal transduction pathways, and these will be discussed in Chapter
5. The regulation of receptor function shares many parallels with the
rhodopsin family including the importance of receptor phosphorylation
in desensitization of the second messenger response e.g. heterologous
desensitization of the glucagon-like peptide-1, secretin and glucagon
receptors (Buggy, J. J., et al. 1997, Holtmann, M. H., et al. 1996, Widmann,
C., et al. 1996). There was also a recent report of the phosphorylation of
the secretin receptor by GRKs 2 and 5, and the involvement of an arrestin
in the desensitization of the receptor-evoked cAMP response (Shetzline,




Phosphatidylcholine (PtdCho) is the principal phospholipid class in
mammalian tissues and constitutes up to 50% of the total cellular
phospholipid content (Billah, M. M. and J. C. Anthes 1990, Tronchere, H.,
et al. 1994). In comparison phosphatidylinositol (Ptdlns) represents less
than 10% of the total and the preferred substrate of Pl-phospholipase C
(PLC), phosphatidylinositol 4,5-bisphosphate (PIP2), accounts for less than
0.5% of phosphatidylinositols (Billah, M. M. and J. C. Anthes 1990,
Tronchere, H., et al. 1994). PtdCho-specific phospholipases C (PLC), A2
(PLA2) and PLD brings about the release of various lipidic second
messengers: unsaturated fatty acids, diacylglycerol or PA, with an
associated release of either phosphocholine, lysoPC and choline. These
are also involved in the synthesis of PtdCho, therefore in arrangement
analogous to that for Ptdlns, there is a cycle of PtdCho turnover in cells
(Billah, M. M. and J. C. Anthes 1990, Tronchere, H., et al. 1994).
1.4 PHOSPHOLIPASE D
1.4.1 Enzymology of PLD
In addition to the above PtdCho PLD, enzyme activities effective on
phosphatidylethanolamine and phosphatidylinositol have also been
described. The hydrolysis of phosphatidylethanolamine by a PLD activity
has been reported in microsomes prepared from canine brain (Natarajan,
V., et al. 1984) and in cultured cells (Kiss, Z. and W. B. Anderson 1989,
Kiss, Z. and W. B. Anderson 1989) Balsinde et al. have described a PLD
activity in human neutrophils and plasma that hvdrolysed Ptdlns but not
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PtdCho (Balsinde, J., et al. 1988, Balsinde, J. and F. Mollinedo 1990).
Furthermore a glycosyl-phosphatidylinositol-specific PLD is an enzyme
that hydrolyses the inositol-phosphate linkage in proteins such as
alkaline phosphatase and acetylcholinesterase, that are anchored to the
membrane by a phosphatidylinositol-glycan moiety (Low, M. G. 1989,
Low, M. G. and D. B. Zilversmit 1980, Malik, A.-S. and M. G. Low 1986).
However the regulation and physiological implications of these activities
have not received the attention paid to the PtdCho-specific PLD activity
which is the subject of investigation presented here.
Phospholipase D was first described in plants in 1947 (Hanahan, D. J. and
I. L. Chaikoff 1947, Hanahan, D. J. and I. L. Chaikoff 1948) and is
widespread in the plant kingdom having been purified to homogeneity
from cabbage leaves (Abousalham, A., et al. 1993) and castor bean
endosperm (Wang, X., et al. 1993). PLD has also been found in simple
eukaryotes such as the slime mould Dictostelium discoideum (Cubitt, A.
B., et al. 1993)and the budding yeast Saccharomyces cerevisiae (Ella, K. M.,
et al. 1995, Waksman, M., et al. 1996). Additionally the prokaryotes
Cornyebacterium pseudotuberculosis and Arcanobacterium
haemolyticum express sphingomyelin-specific PLDs (Ceuvas, W. A. and J.
G. Songer 1993, Hodgson, A. L. M., et al. 1990). PLD was long thought to
be absent from mammalian tissues until its presence was reported in
detergent-solubilized rat membranes (Saito, M. and J. Kanfer 1973). PLD
catalyses the hydrolysis of phospholipids at their terminal phosphodiester
bond, thus producing phosphatidic acid (PA) and the free head group.
The enzyme was subsequently partially purified by Kanfer's group and the
ability of PLD to catalyse a transphosphatidylation reaction (the transfer of
the phosphatidyl moiety from one alcohol to another) was demonstrated
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(Kanfer, J. N. 1980, Kobayashi, M. and J. N. Kanfer 1987). In the presence
of glycerol or a primary alcohol such as ethanol, propanol or butanol the
respective phosphatidylalcohol accumulated at the expense of PA (Kanfer,
J. N. 1980). The transphosphatidvlation reaction is regarded as
unequivocal evidence of PLD activity. Phosphatidic acid produced by the
hydrolysis of PtdCho by PLD is further metabolised by phosphatidate
phosphohydrolase (PPH) to produce diacylglycerol, an activator of protein
kinase C (PKC) (Brindley, D. N. and D. W. Waggoner 1996, Siddiqi, R. A.
and J. H. Exton 1992, Smith, S. W., et al. 1957). Although there is some
controversy over whether the diglycerides species produced by PLD are
good activators of PKC (Hodgkin, M. N., et al. 1998, Pettitt, T. R., et al.
1997). PA can also be hydrolysed by a PA-specific PLA2 activity thereby
producing free fatty acid and lysophosphatidic acid (lysoPA) (Dennis, E. A.
1994), which is suggested to have numerous physiological effects to be
discussed later.
The existence of multiple isoforms of PLD has been suggested by
numerous biochemical studies investigating the subcellular distribution
of PLD enzymes and mechanisms of activation. Massenburg et al.
purified two PLD activities from rat brain (Massenburg, D., et al. 1994),
one was activated by the small G protein ARF and PIP2 and is most likely
related to the ARF and Rho-dependent PLD activity described by other
groups (Bowman, E. P., et al. 1993, Brown, H. A., et al. 1995, Brown, H. A.,
et al. 1993, Cockcroft, S., et al. 1994, Singer, W. D., et al. 1995). This ARF
and PIP2-activated PLD had an Mr of 95,000 as determined by
hydrodynamic analysis (Brown, H. A., et al. 1995). The second PLD
activity resolved by Massenburg et al. was an oleate-activated form
(Massenburg, D., et al. 1994) previously identified by others (Chalifa, V., et
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al. 1990, Kobayashi, M. and J. N. Kanfer 1987, Siddiqi, R. A. and J. H. Exton
1992), and recently purified (Okamura, S. and S. Yamashita 1994). The
oleate-activated PLD appears to be more tightly associated with the
membrane than the ARF-activated PLD. The oleate-activated PLD
enzyme could not be solubilized from the membrane by high salt
concentrations (1 M NaCl) (Danin, ML, et al. 1993), whilst the ARF-
dependent PLD was solubilized by 0.4 M NaCl (Brown, H. A., et al. 1993).
The purified form of this oleate-activated PLD had a Mr of 190,000
(Okamura, S. and S. Yamashita 1994). In addition to the membrane
associated PLD isoforms, there have been reports of cytosolic PLD activity
in bovine heart and lung, HL-60 cells and human placenta (Bocckino, S.
B. and J. H. Exton 1996, Siddiqi, A. R., et al. 1995, Vinggaard, A. M., et al.
1997, Wang, P., et al. 1991).
1.4.2 Cloning and characterisation of PLD enzymes
The cloning of a cDNA for a higher eukaryote PLD was initially reported
by Wang et al. (Wang, X. M., et al. 1994), who isolated the cDNA for castor
bean (Ricinus communis L) PLD by using oligonucleotide probes based on
the amino-terminal amino acid sequences of the purified protein (Wang,
X., et al. 1993). PLD enzymes have subsequently been cloned and
sequenced from Streptomyces antibioticus (Iwasaki, Y., et al. 1994), rice
and maize plants (Ueki, J., et al. 1995). Furthermore the SP014 gene of
Saccharomyces cerevisiae reported to be essential for meiosis, was
identified as the yeast PLD gene (Ella, K. M., et al. 1996, Honigberg, S. M.,
et al. 1992, Rose, K., et al. 1995, Waksman, M., et al. 1996).
The first cloned mammalian homologue of a plant PLD was PLD1, and a
shorter hPLDlb splice variant has been identified, which lacks the 38
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amino acids from 585-624 present in hPLDla (Hammond, S. M., et al.
1995, Hammond, S. M., et ai. 1997). A rat PLD1 (rPLDl) has also been
cloned recently and this exhibited similar properties to hPLDl (Park, S.-K.,
et al. 1997). This enzyme is membrane associated and activated by PIP2,
ARF, RhoA (and also Rac-1 and Cdc42), and PKC-a, and probably
represents the PLD activity reported by Brown and colleagues in rat brain
(Brown, H. A., et al. 1993). A second isoform of PLD, PLD2 was recently
cloned from mouse (mPLD2) (Colley, W. C., et al. 1997) and rat (rPLD2)
(Kodaki, T. and S. Yamashita 1997). The human homolog of PLD2
(hPLD2) has also recently been cloned from a B cell library and partially
characterised (Lopez, I., et al. 1998).
The cloning and sequence analysis of human hPLDl shows that it has
none of the recognised Src homology (SH) domains; SH2 and SH3, or the
pleckstrin homology (PH) domain (Hammond, S. M., et al. 1995). This is
in contrast to the various isoforms of PLC, which contain these domains.
Furthermore no similarity exists between hPLDl and the
phosphatidylinositol-glycan-specific PLD or PLC (Hammond, S. M., et al.
1995). However the cloned PLD enzymes contain conserved regions that
are homologous to other proteins involved in phospholipid biosynthesis
and make them members of a new family of proteins. Comparison of the
sequences encoding hPLDl, SP014 and castor bean PLD showed that they
shared four homologous regions denoted I, II, III and IV (Morris, A. J., et
al. 1996). The PLD homologue from Streptomyces shares some of the
conserved sequences present in regions I, HI and IV. Moreover portions
of the sequences in domains I and IV are found in Escherichia coli
cardiolipin synthase (CL) and phosphatidylserine synthase (PSS), enzymes
that catalyse the final step in phospholipid production. PLD enzymes, CL
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and PSS can all catalyse the transphosphatidylation reaction that is
characteristic of PLD in mammalian cells (Morris, A. J., et al. 1996).
Ponting and Kerr proposed that these proteins are members of members
of a wider family that include a pair of vaccinia virus encoded proteins;
p37K and K4, an endonuclease (nuc) and a helicase-like protein (o338)
(Ponting, C. P. and I. D. Kerr 1996). The p37K protein from vaccinia virus
when mutated in the HxKxxxxD motif shared with PLD, is no longer able
to efficiently infect cells (Sung, T. C., et al. 1997). The HxKxxxxD motif
which is present twice in PLD has been proposed to be involved in the
catalytic pathway for the hydrolysis of PtdCho by PLD (Sung, T. C., et al.
1997).
The mouse isoform of PLD2 was reported to be highly active in the
presence of PIP2, both in vitro and in vivo and could not be further
stimulated by ARF or Rho proteins or PKC-a (Colley, W. C., et al. 1997).
Similarly the rat isoform of PLD2 was active in the presence of PIP2/ but
not ARF or Rho proteins. However the activity was relatively low
compared to that reported for mPLD2 (Kodaki, T. and S. Yamashita 1997).
Moreover hPLD2 was not highly active and displayed low basal activity,
furthermore hPLD2 could be stimulated by recombinant ARF1 in the
presence of PIP2 (Lopez, I., et al. 1998). However, the stimulation of
hPLD2 by ARF1 was 8 fold lower than that observed for hPLDl and there
was no stimulation of hPLD2 activity by RhoA, Racl and PKC-a (Lopez, I.,
et al. 1998). The constitutive activity observed for mPLD2 may be due to
the loss of inhibitory factors upon purification for use in enzyme assays.
When hPLD2 and mPLD2 were expressed in the same Hi5 insect cell line,
they exhibited similar basal activities (Lopez, I., et al. 1998). There are
uncharacterized inhibitors of PLD2 partially purified from bovine brain
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(Colley, W. C., et al. 1997). Other inhibitors of PLD have been described
including fodrin, a non-erythroid spectrin protein (Lukowski, S., et al.
1996) and synaptojanin (a phosphatidylinositol 5-phosphatase) (Chung, }.-
K., et al. 1997), which appear to reduce levels of PIP2 (Lukowski, S., et al.
1998, McPherson, P. S., et al. 1996) a co-factor for PLD activation. Also an
apparently direct inhibition of PLD was reported for clathrin assembly
protein 3 (AP3) (Lee, C., et al. 1997), and arfaptin the ARF-docking protein,
inhibits PLD activity perhaps by binding directly to ARF (Tsai, S.-C., et al.
1998). In the study of hPLDla and lb, rPLDl and hPLD2, oleate was
inhibitory, suggesting that the oleate-activated form of PLD reported by
various groups and purified recently by Okamura et al. may still be
undiscovered (Chalifa, V., et al. 1990, Kobayashi, M. and J. N. Kanfer 1987,
Massenburg, D., et al. 1994, Okamura, S. and S. Yamashita 1994, Siddiqi, R.
A. and J. H. Exton 1992).
PLD activity has been found to have a wide distribution within the cell
and it has been found on plasma membrane and cytoplasm (Bocckino, S.
B. and J. H. Exton 1996, Brown, F. D., et al. 1998, Edwards, J. S. and A. W.
Murray 1995, Morgan, C. P., et al. 1997, Provost, J. J., et al. 1996, Whatmore,
J., et al. 1996), nucleus (Balboa, M. A. and P. A. Insel 1995), and other
membranes such as golgi, mitochondrial and endoplasmic reticulum (ER)
(Decker, C., et al. 1996, Edwards, J. S. and A. W. Murray 1995, Ktistakis, N.
T., et al. 1995) and secretory vesicles/endosomes (Brown, F. D., et al. 1998,
Morgan, C. P., et al. 1997). Using the newly cloned PLD1 and PLD2
proteins epitope-tagged with the influenza haemagluttinin (HA) protein,
the localisation of these enzymes in rat embryo fibroblasts was
investigated by Colley et al. (Colley, W. C., et al. 1997). PLD1 was reported
to be present exclusively on the peri-nuclear region of the cell, on the
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golgi, ER and late endosomes but not in the cytoplasm or on the plasma
membrane in quiescent or serum-stimulated cells (Colley, W. C., et al.
1997). However Brown et al. report that PLDlb localised to secretory
granules and lysosomes and not the golgi (Brown, F. D., et al. 1998). The
PLDlb enzyme was expressed as a fusion protein with green fluorescent
protein in COS 1 and RBL-2H3 cells and was found to translocate from the
secretory granules etc. to the plasma membrane upon stimulation with
agonist and phorbol ester (Brown, F. D., et al. 1998). Colley et al. also
reported that PLD2 was predominantly associated with the plasma
membrane in quiescent cells and redistributed to submembranous
vesicles in serum-stimulated cells. (Colley, W. C., et al. 1997).
1.4.3 Regulation of PLD by small G proteins
The activation of PLD by GTPyS in permeabilized HL-60 cells was
reported to decline with time as cytosolic proteins leaked from the cells
(Geny, B. and S. Cockcroft 1992, Geny, B., et al. 1993). This activity could
be restored by addition of a factor within brain cytosol found to be -16
kDa. This factor was purified to homogeneity by two groups and shown
to be the small G protein ARF (Brown, H. A., et al. 1993, Cockcroft, S., et
al. 1994). ARF was originally isolated by Kahn and Gilman as a protein
which was essential for the ADP-ribosylation of Gas by cholera toxin
(Kahn, R. A. and A. G. Gilman 1984). The advent of the molecular
cloning of mammalian PLD1 has shown that ARF is an activator of PLD
(Hammond, S. M., et al. 1995, Hammond, S. M., et al. 1997, Park, S.-K., et
al. 1997).
The translocation of ARF from the cytosol to membranes in response to
agonist has been reported (Cavenagh, M. M., et al. 1996, Houle, M. G., et
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al. 1995, Riimenapp, U., et al. 1995). Furthermore this translocation is
associated with activation of PLD in HL-60 cells (Houie, M. G., et al. 1995).
The translocation and association of ARF1, 3, 4 and 5 to golgi membranes
was inhibited by brefeldin A (BFA) (Cavenagh, M. M., et al. 1996). BFA is
an inhibitor of guanine nucleotide-exchange on ARF (Donaldson, J., et al.
1992, Helms, }. B. and J. E. Rothman 1992, Randazzo, P. A., et al. 1993).
ARNO an exchange factor with a Sec-7 homology domain (Sec-7 is a
protein from yeast that is involved in secretion) promotes guanine-
exchange on ARF (Chardin, P., et al. 1996, Morinaga, N., et al. 1996).
However ARNO is insensitive to BFA as is another factor isolated from
spleen (Strader, C. D., et al. 1995), although a large BFA-sensitive ARF-
guanine exchange protein has recently been cloned and described
(Morinaga, N., et al. 1997).
ARF proteins are required for the binding of clathrin AP-1 and AP-2
adaptor proteins to golgi membranes; these proteins being components of
pathway that controls endocytosis and transport from the trans-Golgi
network to prelysosomal/endosomal compartments (Stamnes, M. A. and
J. E. Rothman 1993, Traub, L. M., et al. 1993, West, M. A., et al. 1997, Zhu,
Y., et al. 1998). Furthermore ARF proteins are necessary for the binding of
the non-clathrin coatomer protein complex to golgi membranes and the
formation of coatomer-coated vesicles which play a part in the trafficking
of proteins from the ER to the golgi (Donaldson, J. G., et al. 1992, Palmer,
D. J., et al. 1993, Serafini, T., et al. 1991). Brefeldin A is reported to block
secretion (Fujiwara, T., et al. 1988, Lippincott-Schwartz, J., et al. 1989,
Misumi, Y., et al. 1986), and also prevents the assembly of coatomer-
coated vesicles on golgi (Orci, L., et al. 1991). Thus ARF is proposed to be
involved in regulation of the secretory pathway. PLD has been found on
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the golgi membrane and its activation by ARF is inhibited by BFA
(Ktistakis, N. T., et al. 1995). Furthermore Ktistakis et al. suggest that PLD
may mediate ARF-dependent formation of coatomer-coated golgi vesicles
(Ktistakis, N. T., et al. 1996).
The involvement of Rho in the activation of PLD was first described in
neutrophil lysates by Bowman et al. (Bowman, E. P., et al. 1993). The
stimulation of PLD by Rho in other tissues has been reported (Kwak, J. Y.,
et al. 1995, Malcolm, K. C., et al. 1996, Malcolm, K. C., et al. 1994, Ohguchi,
K., et al. 1995, Ohguchi, K., et al. 1996). Moreover the stimulation of PLD
in HL-60 cell membranes by RhoA reported by Ohguchi et al. was
disputed by Martin et al. who propose that only endogenous ARF
activates PLD in these cells (Martin, A., et al. 1996, Ohguchi, K., et al. 1995,
Ohguchi, K., et al. 1996). Similarly Park et al. reported that constitutively
active ARF but not RhoA activated endogenous PLD in COS 7 cells, and
that constitutively active RhoA but not ARF activated expressed rPLDl
(Park, S.-K., et al. 1997). Work done by Hammond et al. showed that
RhoA, Racl and Cdc42 all activated hPLDl to a similar extent, that was
not additive (Hammond, S. M., et al. 1995, Hammond, S. M., et al. 1997).
Synergism between ARF and Rho proteins in the activation of hPLDl was
also reported (Hammond, S. M., et al. 1997), in agreement with previous
reports on partially purified PLD activities (Kuribara, H., et al. 1995,
Siddiqi, A. R., et al. 1995, Singer, W. D., et al. 1995, Singer, W. D., et al.
1996). A 50 kDa factor partially purified appears to be enhance the
activation of PLD by GTPyS activation of Rho (Kwak, J. Y., et al. 1995,
Malcolm, K. C., et al. 1994, Ohguchi, K., et al. 1995). In agreement with
these reports Vinggaard and colleagues, report the loss of RhoA but not
ARF activation of PLD after partial purification of the enzyme from
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human placenta (Vinggaard, A. M., et al. 1997). This unknown 50 kDa
factor is uncharacterized at present. Rho is a regulator of the actin
cytoskeleton and controls the production of stress fibres and focal
adhesions in cells (Chrzanowska-Wodnicka, M. and K. Burridge 1996,
Ridley, A. J. and A. Hall 1992). PA has been shown to stimulate actin
polymerisation in IIC9 cells (Ha, K.-S. and J. H. Exton 1993) , moreover
PLD has been implicated in the formation of stress fibres in porcine aortic
endothelial (PAE) cells in a Rho-dependent manner (Cross, M. J., et al.
1996). Rho like ARF, also regulates the activity of phosphatidylinositol 4-
phosphate 5-kinase (PIP-5K), the enzyme that is involved in the
production of PIP2 (Chong, L. D., et al. 1994), PA also stimulates this
enzyme (Moritz, A., et al. 1992). Thus the rearrangement of the
cytoskeleton ascribed to Rho activity may be due to the involvement of
PLD.
The stimulation of PLD by the tyrosine kinase v-Src has been reported to
involve the small G proteins Ras and RalA (Jiang, H., et al. 1995). Active
PLD can be precipitated from cell lysates with immobilised GST-RalA
fusion protein (Jiang, H., et al. 1995). The immunoprecipitated PLD
activity is PLD1 and the interaction is a direct one (Luo, J. Q., et al. 1997).
Further work by Luo and colleagues has shown that the direct interaction
of RalA with PLD does not effect the PLD activity and that ARF is
required and directly involved in an active complex with RalA and PLD1
(Luo, J., et al. 1998). Thus ARF, RalA and PLD may interact in a ternary
complex when stimulated through a heptahelical receptor.
1.4.4 Regulation of PLD by Protein Kinase C
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There is much evidence that the activation of PLD by PKC involves the
initial activation of PLC and hydrolysis of PIP2, since many agonists that
activate PLD are also activators of PLC (Bocckino, S. B. and J. H. Exton
1996, Singer, W. D., et al. 1997, Yeo, E.-J. and J. H. Exton 1995, Yeo, E.-J., et
al. 1994, Zheng, L., et al. 1994). The subsequent hydrolysis of PIP2 by PLC
generates inositol 3,4,5 trisphosphate (IP3) and diacylglycerol (DAG), an
activator of PKC. Inhibition of PKC using H7, staurosporine,
chelerythrine, calphostin C and bisindolylmaleimide, or downregulation
of PKC enzymes by prolonged treatment of cells with phorbol esters point
to a partial or complete dependence of agonist regulation of PLD on PKC
in many cell types. For example the downregulation of PKC enzymes has
been shown to completely block the ability of agonists such as carbachol,
bradykinin, or gonadotropin-releasing hormone (GnRH) to activate PLD
(Liscovitch, M. and A. Amsterdam 1989, Martin, T. W., et al. 1989,
Martinson, E. A., et al. 1989, van Blitterswijk, W. J., et al. 1991, van
Blitterswijk, W. J., et al. 1991). Singer et al. first identified that PKC-a was
the factor in porcine brain that activated PLD (Singer, W. D., et al. 1995,
Singer, W. D., et al. 1996). The activation of PLD by PKC has been reported
to be independent of phosphorylation and suggested to represent a
protein to protein docking role (Conricode, K. M., et al. 1992, Conricode,
K. M., et al. 1994, Ohguchi, K., et al. 1996, Singer, W. D., et al. 1996). The
activation of the cloned hPLDla, lb and rPLDl isoforms by PKC-a was
phosphorylation-independent (Hammond, S. M., et al. 1997, Park, S.-K., et
al. 1997). Although the activation of hPLDl with PKC-a was synergistic
with ARF and Rho proteins, there was no synergy between ARF, Rho and
PKC-a in the activation of rPLDl (Park, S.-K., et al. 1997).
1.4.5 Regulation of PLD by tyrosine kinases
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Growth factors receptors such as those for platelet-derived growth factor
and epidermal growth factor with intrinsic tyrosine kinase activity, are
able to activate PLD (Kaskin, M., et al. 1992, Plevin, R., et al. 1991, Yeo, E.-
J., et ai. 1994). Also as noted in section 1.4.3, PLD activity was stimulated
by v-Src transformation of cells in a Ras-RalA and ARF-dependent
fashion. A role for a tyrosine kinase(s) in the activation of PLD by G
protein coupled receptors has been suggested. Inhibitors of tyrosine
kinase activity have been reported to block thrombin-stimulated PLD
activity in platelets and carbachol-evoked PLD activity in HEK cells
expressing the M3 receptor (Schmidt, M., et al. 1994).
1.4.6 Physiological implications of PLD activation
The hydrolysis of PtdCho by PLD is proposed to provide the choline
precursor for the synthesis of the neurotransmitter acetylcholine (ACh) in
human neuronal (LA-N-2) cells (Lee, C. H., et al. 1993). The levels of ACh
are reduced in tissue taken from patients with Alzheimer's disease, along
with the activity of PLD and choline acetyl-transferase (an enzyme
responsible for acetylcholine formation) (Kanfer, J. N., et al. 1986).
Thereby implicating PLD in the production of ACh in vivo, and the
pathophysiology of this disease.
The induction of the transcription factor AP-1 is proposed to be
downstream of PLD activation in human T lymphoid Jurkat cells. The
involvement of PLD in the activation of this factor is suggested by the co-
activation of both PLD and AP-1 in Jurkat cells. Furthermore the
activation of AP-1 was blocked by the presence of ethanol, and propanolol
(an inhibitor of PPH) (Mollinedo, F., et al. 1994). In addition, AP-1 was
stimulated after the addition of PA (Mollinedo, F., et al. 1994). The
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activation of PLD by platelet-activating factor (PAF) and GnRH is reported
to regulate the expression of the immediate early response genes c-fos and
c-jun, which are components of the AP-1 transcription factor (Bohmann,
D. and R. Tijan 1989, Cesnjaj, M., et al. 1995, Liu, B., et al. 1997).
The production of PA is implicated in the regulation of the respiratory
burst in neutrophils, which results in the release of reactive oxygen
species that kill bacteria and mediate the inflammatory response. PA has
been linked to the stimulation of NADPH oxidase (the enzyme that
catalyses the production of superoxide (Cb-) species), and this activation
was shown to be inhibited in the presence of primary alcohols such as
ethanol and butanol (Bauldry, S. A., et al. 1991, Bonser, R. W., et al. 1989,
Rossi, F., et al. 1990).
The production of PA and its rapid dephosphorylation by phosphatidate
phosphohydrolase to generate DAG produces a potential activator of PKC.
It is not clear however that the side chain composition of the diglycerides
(Flodgkin, M. N., et al. 1998, Pettitt, T. R., et al. 1997) and perhaps also its
compartmentalisation are ideal for this role. Nevertheless the activation
of PKC by agonist stimulation is commonly reported to be biphasic, with a
rapid activation of PKC that is transient and a longer term stimulation of
PKC. This profile of PKC activation has been proposed to reflect the
differential production of DAG by PLC and PLD activities. PLD is
suggested to be responsible for the prolonged formation of DAG and
activation of PKC (Exton, J. H. 1994). Some reports indicated that PC-
derived DAG was ineffective in activating PKC (Kiley, S. C., et al. 1991,
Martin, T. W., et al. 1989), however work done in IIC9 fibroblasts by Fla et
al. showed that PtdCho-derived DAG translocated PKC-£ to the
membrane in a sustained manner (Ha, K.-S. and J. H. Exton 1993). The
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PIP2 breakdown evoked by thrombin in IIC9 cells caused only a transient
translocation of PKC-a, whilst the second peak of DAG derived from
PtdCho breakdown was associated with a sustained membrane association
of PKC-e, which is a calcium-independent isozyme, thus there was a PKC
isozyme-specific translocation of PKC enzymes (Ha, K.-S. and J. H. Exton
1993).
Experiments carried out in vitro have suggested that PA is a regulator of
numerous proteins involved in signal transduction, although the
hydrolysis of PA by a PA-specific PLAi or PLA2 (Higgs, H. N. and J. A.
Glomset 1996, Higgs, H. N., et al. 1998, Thomson, F. J. and M. A. Clark
1995), thereby producing lysoPA may complicate this view. PA has been
proposed as an activator of PKC-C (Limatola, C., et al. 1994, Nakanishi, H.
and J. H. Exton 1992) and other protein kinases (Bocckino, S. B., et al. 1991,
Khan, W. A., et al. 1994, McPhail, L., et al. 1995). Also PA has been
suggested as an stimulator of a protein tyrosine phosphatase (Tomic, S., et
al. 1995, Zhao, Z., et al. 1993), Ptdlns-PLC-y (Jacowski, S. and C. O. Rock
1989, Jones, G. A. and G. Carpenter 1993) and PIP-5K (Moritz, A., et al.
1992). In addition PA has been reported to regulate the GTPase activating
proteins (GAPs) for small G proteins e.g. the stimulation of n-chimaerin,
an activator of Rac GAP (Ahmed, S., et al. 1993) and the inhibition of Ras
GAP (Tsai, M., et al. 1989). PA is also reported to bind to Raf-1 kinase
(Ghosh, S., et al. 1996). PA has been observed to stimulate arachidonic
acid release from fibroblasts implying activation of PLA2 (Muravama, T.
and M. Ui 1987) although a similar effect is seen with lysoPA which acts
as agonist at its own GPCR (van Corven, E. J., et al. 1989). Moreover the
stimulation of PtdCho-PLD by PA or lysoPA has also been reported (Ha,
K.-S. and J. H. Exton 1993, Ha, K.-S. and J. H. Exton 1994, van der Bend, R.
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L., et al. 1992), suggesting a positive feedback loop. LvsoPA is a potent
mitogen (Jalink, K., et al. 1994), and its mitogenic effect is inhibited by
pertussis toxin, indicative of a Gai/0-mediated mechanism. The cloning
of cDNAs for a LysoPA-specific receptor has been reported, and the
receptor couples to Gi/0 and Gq (An, S., et al. 1998, Dickens, A. S., et al.
1997, Guo, Z., et al. 1996, Hecht, J. H., et al. 1996). It is likely that the
majority of the mitogenic effects of LysoPA involve the Ras/mitogen-
activated protein (MAP) kinase pathway, as suggested by numerous
reports (Hordijk, P. L., et al. 1994, Howe, L. R. and C. J. Marshall 1993,
Kumagai, N., et al. 1993, McLees, A., et al. 1995, Moolenaar, W. H., et al.
1997). In other systems however, the GnRH and PAF-induced activation
of c-fos and c-jun synthesis may depend on a PLD-mediated pathway
(Cesnjaj, M., et al. 1995, Liu, J., et al. 1995).
There is a great deal of data suggesting that PLD is a major regulatory
component of protein secretion and transport. The cloned hPLDl
enzyme was found to localise to secretory granules in human
neutrophils, COS 1 and RBL-2H3 cells and upon stimulation with agonist
it translocates to the plasma membrane, implicating hPLDl in protein
exocytosis (Brown, F. D., et al. 1998, Morgan, C. P., et al. 1997). In
agreement with this, Caumont et al. reported that ARF6 translocated
from secretory granules to the plasma membrane in stimulated
chromaffin cells and this was associated with an increase in PLD activity
and the secretion of catecholamines. The use of a synthetic peptide to
block the interaction of ARF6 with its target proteins blocked both the
activation of PLD and the secretory response. (Caumont, A.-S., et al. 1998).
Purified PLD directly stimulates the release of secretory vesicles from the
trans-golgi network in an ARF-dependent manner (Chen, Y. G., et al.
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1997). The stimulation of the PIP-5K activity by PA (Moritz, A., et al.
1992), and the activation of PLD isoforms by PIP2 (Hammond, S. M., et al.
1995, Hammond, S. M., et al. 1997, Park, S.-K., et al. 1997) lead to the
proposal that PLD activities on secretory vesicles or at the donor and
target membrane for vesicle transport, would produce PIP2 and PA which
would both maintain PLD activitv and allow the fusion of vesicle and
J
target membranes, as PIP2 and PA are fusogenic lipids (Eastman, S. J., et al.
1992, Liscovitch, M. and L. C. Cantley 1995).
Therefore with this background, the present study aimed to address the
characteristics of the activation of PLD by class I and II GPCRs. The role of
the small G proteins ARF and Rho in the activation of PLD was
investigated, and the regions involved in the control of receptor coupling






Minimum essential medium (MEM), Dulbecco's modified Eagle medium
(DMEM), Medium 199, Earle's balanced salt solution (EBSS), Hank's
Buffered Saline Solution (HBSS) without calcium, magnesium or phenol
red, Ham's nutrient mixture F12, OptiMem, dimethylsulphoxide
(DMSO), newborn calf serum (NCS), ampicillin, tetracycline, penicillin,
streptomycin, geniticin (G418), trypsin, phosphate buffered saline (PBS),
80cm2 and 175 cm2 Nunclon flasks were all obtained from Gibco Life
Technologies, Paisley, Scotland U.K. Foetal calf serum was purchased
from Sera Lab, Crawley Down, Sussex, U.K. DEAE dextran was purchased
from Promega UK Ltd., Southampton, U.K. All other tissue culture
plasticware was purchased from Costar UK Ltd., Bucks, U.K. or Greiner
Laboritechnik Ltd., U.K.
Animals
COB-Wistar rats were obtained from Charles River U.K. Ltd., Margate,
Kent, U.K., or were obtained from a colony bred in this department which
were derived from Charles River Wistar rats.
Radiochemicals
[9,10-3H]palmitate (40 Ci/mmol), [3H]N-methyl scopolamine (85
Ci/mmol), [125I]PACAP-27 (2200Ci/mmol) were obtained from NEN
DuPont, Germany, Na 125I (400 mCi/mmol from ICN radiochemicals,
Irvine, CA, U.S.A. and ?nyo-[2-3H]inositol from Amersham International
pic, Aylesbury, Bucks, U.K.
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Agonists and Ligands
Gonadotropin-releasing hormone, angiotensin II, carbachol
(carbamylcholine chloride), histamine ((2-[4-imidazolyl]ethylamine),
thrombin, bradykinin, 5-hydroxytryptamine ((3-(2-aminoethyl)-5-
hydroxyindole; serotonin), sodium fluoride (NaF), beryllium chloride
(BeCU), GTPyS (guanosine 5'-0-(3-thiotriphosphate)), ionomycin (free
acid, Streptomyces conglobatus), and forskolin (Coleus forskohlii (7(3-
acetoxy-8,(3-epoxy-la,6[3,9a-trihydroxy-labd-14-en-ll-one) were all
purchased from Sigma-Aldrich Chemical Company, Poole, Dorset, U.K.,
U46619 (9,ll-dideoxy-9a,lla-methanoepoxy prostaglandin F2a) was
purchased from Affiniti Research Products Ltd., Mamhead Castle, Exeter,
U.K. Vasoactive Intestinal Peptide (VIP), pituitary adenylate-cyclase
activating polypeptide-38 (PACAP-38) and helodermin were purchased
from Calbiochem-Novabiochem (U.K.) Ltd., Nottingham, U.K. Ala-
pFPhe-Arg-Cha-HArg-Tyr-NUb (TRP) was purchased from Neosystem
Laboratoire, Croydon, Surrey, U.K. GPPCFbP (guanylyl-((3,y-methylene)-
diphosphate) was obtained from Biomol Ltd., Cheshire U.K.
Phosphatidylbutanol was obtained from Avanti Polar Lipids Inc.,
Alabaster, Alabama, U.S.A.
Biochemicals
Brefeldin A (from Penicillium brefeldianum, Y,4-dihydroxy-2-[6-hvdroxy-
l-heptenyl]-4-cvclopentanecrotonic acid X lactone), 2'-0-monosuccinyl-
adenosine 3': 5'-cyclic monophosphate tyrosyl methyl ester, Tween-20
(Polyoxyethylenesorbitan monolaurate), polyethylene glycol,
isobutylmethylxanthine (IBMX), aprotinin, protein G Sepharose CL-4B,
leupeptin, bacitracin, soybean trypsin inhibitor, pepstatin A, sodium
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orthovanadate (NasVCU), cholera toxin (Vibrio cholerae), pertussis toxin
(Bordatella pertussis), P-mercaptoethanol, phorbol 12,13-dibutyrate,
monensin, monodansylcadaverine, N-methyl atropine, HEPES (4-(20
hydroxyethyl)-l-piperazine ethanesulfonic acid), bovine serum albumin
(BSA: essentially fatty acid free and fraction V), Phosphatidylcholine and
phosphatidylserine were obtained from Sigma-Aldrich Chemical
Company, Poole, Dorset, U.K. U73122, |l-[6-((17p-3-methoxyestra-
l,3,5(10)-trien-17-yl)amino)hexyl]-lH-pyrrole-2,5-dione), C3 exoenzyme
(from Clostridium Botulinum) and GF109203X (bisindolylmaleimide I; 2-
[l-3(-dimethylaminopropyl)-lH-indol-3-yl]3-(lH-indol-3-yl)-maleimide)
were purchased from Calbiochem-Novabiochem (U.K.) Ltd.,
Nottingham, U.K. AEBSF (4-(2-aminoethyl)-benzenesulphonyl fluoride)
was purchased from Alexis Corporation (U.K.) Ltd., Nottingham U.K.
Pfu (Pyrococcus furiosus) DNA polymerase were obtained from
Stratagene Ltd., Cambridge, U.K. Hindi restriction enzyme and T4DNA
ligase were obtained from Promega UK Ltd., Southampton, U.K.
Immunological reagents
Sheep polyclonal anti-ARFl/3 immunoglobulin (antigen ARFI98-112)/
was a gift from M. J. O. Wakelam, Institute for Cancer Studies,
Birmingham University Medical School, Birmingham, U.K (Martin, A.,
et al. 1996). Rabbit polyclonal anti-M3 receptor serum (antigen M3
receptor56i-57s) was a gift from B. B. Wolfe, Department of Pharmacology,
Georgetown University School of Medicine, Washington, D. C. U.S.A.
(Wall, S. J., et al. 1991). Rabbit polyclonal anti-RhoA IgG (antigen
RhoA119-132), rabbit monoclonal anti-RhoA IgG (clone 26C4; antigen
RhoAi20-i5o) and rabbit polyclonal anti-ATi receptor IgG (antigen ATi
receptori5-24) were obtained from Santa Cruz Biotechnology, Santa Cruz,
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Ca, U.S.A. Mouse monoclonal anti-ARF IgG (clone 26) and mouse
monoclonal anti-Ras IgG (antigen entire p21ras) were obtained from
Transduction Laboratories, Affiniti Research Products, Mamhead Exeter,
U.K. Mouse monoclonal anti-ERKl/2 (antigen ERKI325-345) was obtained
from Zymed Laboratories, Cambridge BioScience, Cambridge, U.K.
Horseradish peroxidase-conjugated, donkey anti-rabbit and sheep anti-
mouse secondary antibodies and non-immune rabbit and sheep serum
were obtained from the Scottish Antibody Production Unit (SAPU), Law
Hospital, Carluke, Lanarkshire, U.K.
Plasmids
The plasmid pcDNAl/AMP was obtained from InVitrogen, R&D Systems
Europe Ltd., Abingdon, U.K. pcDNAl/AMP plasmids carrying the wild-
type, Asn318, Asp87-Asn318 mutant GnRH, and wild-type, Asp376
mutant 5-HT2A receptors were a gift from S. C. Sealfon, Fishberg Center
for Neurobiology and Department of Neurology, Mount Sinai School of
Medicine, New York, New York, U.S.A. (Sealfon, S. C., et al. 1995, Zhou,
W. C., et al. 1994). pBluescript was obtained from Stratagene Ltd.,
Cambridge, U.K. The pCMV5 construct carrying wild-type and a
dominant negative construct of RhoA were a gift from G. M. Bokoch,
Department of Immunology and Cell Biology, Scripps Research Institute,
La Jolla, CA. U.S.A. (Zhang, S., et al. 1995).
Oligonucleotide Primers
cDNA primers which spanned the junction site for the construction of
the VIP2-PACAP receptor chimaeric receptors, corresponding to the
coding region for TMD7 were synthesised by Cruachem Ltd., Glasgow,





Bicinchoninic acid and Coomassie protein determination kits were
purchased from Pierce U.K. Ltd., Cambridge, U.K. The plasmid maxi
purification kit was obtained from Qiagen Ltd., Crawley, West Sussex,
U.K. The Wizard cDNA purification system was purchased from
Promega UK Ltd., Southampton, U.K. Bond Elut and Brownlee
chromatography columns were obtained from Anachem Ltd., Luton,
Beds. LK5D silica gel thin layer chromatography plates were obtained
from Whatman International Ltd., Kent, U.K. Immobilon
(polyvinyldifluoride) membranes were purchased from Millipore,
Watford, U.K. Enhanced Chemi-Luminescence (ECL) detection system,
Hvpam and Phenisol photographic products were obtained from
Amersham International pic, Ayelsbury, Bucks., U.K. Standard
laboratory reagents of Analar grade and Chromacol glass vials were
obtained from BDH/Merck Ltd., Poole, Dorset, U.K.
2.2 METHODS
2.2.1 Cell culture
Cell lines were grown and maintained under a humidified atmosphere of
95% O?: 5% CO? at 37°C with fresh medium added every 3-4 days. The
cells were harvested by either trypsin digestion or a brief incubation with
Hank's Buffered Saline Solution (HBSS) without calcium, magnesium or
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phenol red containing 0.1% (w/v) EDTA. The cell medium was removed
and 0.25% trypsin (v/v) solution in Gibco solution A (0.4 g/1 KC1, 2.2 g/1
NaHC03, 6.8 g/1 NaCl, 1.0 g/1 glucose, 0.005 g/1 Phenol Red) was applied
(1 ml per 80 cm2 flask or 2 mis per 175 cm2 flask) to the cell layer and then
aspirated after approximately 15 seconds. After a further 10 minutes the
flask was agitated to dislodge cells and then they were washed off the
flask's surface with medium and pelleted by centrifugation at 200y for 5
minutes. The cells were then resuspended in medium and distributed
into new flasks (usually at a ratio of 1:3 or 1:4) or seeded into 12- or 24-
well plates for assay. Alternatively the HBSS/EDTA solution was applied
(1 ml per 80 cm2 flask or 2 mis per 175 cm2 flask) for 10 minutes before the
cells were washed off as described above. All cell lines were maintained
in 75 cm2 flasks (Costar Bucks, U.K.) unless otherwise stated.
For storage purposes, 0.5 ml volumes of cells at 106 cells/ml in medium
or Foetal Calf Serum containing 7-10% dimethylsulphoxide (v/v)
(DMSO) were aliquoted into cryosafe tubes and placed at -70°C overnight
in a polystyrene box. The tubes were then placed into liquid nitrogen. To
recover the cells from the liquid nitrogen the tubes were allowed to thaw
at room temperature and then warmed in a 37°C water bath for several
minutes. A small volume of medium was added to the tube and the cells
were removed and resuspended in approx. 8 mis of appropriate medium.
The cells were pelleted by centrifugation at 200g for 5 min before being
resuspended in medium and transferred into a 25 cm2 flask. The next day
the medium was aspirated off and fresh medium added to remove traces
of DMSO. The cells were then grown as normal
COS 7: Green Monkey kidney fibroblast cell line
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This monkey kidney fibroblast cell line was a gift from Janet Allen
(Glasgow University, Scotland, U.K.). These cells were maintained in
Dulbecco's Modified Eagle Medium (high glucose with 580 mg/1 1-
glutamine, 4500 mg/1 D-glucose, without sodium pyruvate)
supplemented with 10% newborn calf serum (v/v) and 100 units/ml
penicillin and 100 itg/ml streptomycin and were passaged every 5 to 7
days when close to 100% confluency. These cells were used for signal
transduction assays using transiently transfected exogenous receptors.
The cDNAs for the chimeric VIP2/PACAPshort and VIP2/PACAPlong
(VP/4/7b/2.1c and VP/4/7/2.lc, pCDNAl) receptors were transfected into
COS 7 cells using DEAE dextran as described below. The COS 7 cell line
was maintained in 175 cm2 flasks (Nunclon).
Chinese Hamster Ovary (CHO) cells
CHO cells, used to stably expressing transfected receptor cDNA (VIPi,
VIP2, PACAPshort and PACAPiong receptors), were grown and maintained
in Nutrient Mixture Ham's F12 medium supplemented with 10% NCS,
100 units/ml penicillin, 100 Jig/ml streptomycin and 300 pg/ml geniticin
(G418). Geniticin was present to allow selection of cells stably expressing
transfected DNA. Cells were passaged every 6-7 days when 80-90%
confluent.
1321N1 Human astrocytoma cells
1321N1 cells were maintained in DMEM supplemented with 10% NCS,
100 units/ml penicillin and 100 jig/ml streptomycin. Cells were passaged
every 6-7 days when 100% confluent.
2.2.2 Preparation of cDNA
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Transformation of competent cells
Approx. 100 ng of plasmid cDNA was added to a 50 |il aliquot of
MC1061/P3 competent cells (a strain of Escherichia coli bacteria, prepared
in house) before being mixed gently and left on ice for 30 minutes. The
cells were then heated for 45 seconds at 42°C and placed back on ice for 10
minutes. The cells were added to 1 ml of Luria Bertani (LB)-broth (10 g/1
tryptone, 5 g/1 yeast extract, 5 g/1 NaCl) and placed on a rotating mixer
(New Brunswick Scientific, Edison, N.J. U.S.A.) in a 37°C incubator for 1
hour. 100 pi of this suspension was spread onto LB-agar plates (LB-broth
+ 1% bactoagar) supplemented with ampicillin at 12.5 pg/ml (Sigma) and
tetracycline at 7.5 jig/ml (Gibco) to select for plasmid-containing cells.
The plates were left in the 37°C incubator overnight. A distinct colony
was selected from the plate and used to inoculate a 2 ml volume of LB-
broth containing ampicillin and tetracycline. The culture was incubated
overnight at 37°C on a rotator. The 2 ml culture was then used to
inoculate a 500 ml volume of L-broth containing ampicillin and
tetracycline in a conical flask which was left in an orbital shaking
incubator overnight at 37°C.
Plasmid purification
Plasmid purification was carried out using the Qiagen Plasmid Maxi Kit
(Qiagen) according to the manufacturer's instructions. The bacterial cells
were harvested by centrifugation at 6000y for 15 min at 4°C (Sorvall GSA
rotor). The supernatant was carefully decanted and the pellet
resuspended in 10 ml of Buffer PI (resuspension buffer: 50 mM Tris HC1,
pH 8.0; 10 mM EDTA) containing 100 jig/ml RNase A solution. After
resuspension, 10 ml of Buffer P2 (lysis buffer: 200 mM NaOH, 1% sodium
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dodecyl sulphate (w/v)) was added and the solution mixed gently by
inversion and left to incubate at room temperature for 5 min. The lysis
reaction causes the production of a viscous solution. 10 ml of chilled
Buffer P3 (neutralisation buffer: 3.0 M potassium acetate, pH 5.5) was
added, the solution was immediately mixed by inversion and incubated
on ice for 20 min. A viscous precipitate of genomic DNA, protein, cell
debris and SDS is visible at this point. The solution was mixed again and
loaded into polypropylene tubes for centrifugation in the Sorvall SS-34
rotor at 20,000g for 30 minutes at 4°C. The supernatant containing the
plasmid DNA was rapidly removed and recentrifuged for 15 min at
20,000g to remove particulate matter and prevent overloading of
purification columns. A Qiagen-tip 500 was equilibrated by the
application of 10 ml of QBT buffer (equilibration buffer: 750 mM NaCl; 50
mM MOPS (3-[N-morpholino] propanesulfonic acid), pH 7.0; 15%
isopropanol (v/v); 0.15% (v/v) Triton X-100). The supernatant was
applied to the column and washed with 2 x 30 ml of buffer QC (wash
buffer: 1.0 M NaCl; 50 mM MOPS, pH 7.0; 15% isopropanol (v/v)). The
DNA was eluted with 15 ml of buffer QF (elution buffer: 1.25 M NaCl; 50
mM Tris HC1, pH 8.5; 15% isopropanol (v/v)) and collected. The DNA
was precipitated by the addition of 10.5 ml of isopropanol at room
temperature, the solution was mixed and centrifuged at 15,000g for 30
min at 4°C (Sorvall SS-34 rotor). The outside of the tube was marked
beforehand to identify the position of the pellet which can be difficult to
see. The pellet was washed with 5 ml of room temperature 70% ethanol
(v/v) and centrifuged at 15,000g for 10 min. The last step was repeated
and then the pellet was air-dried for 10 minutes before being resuspended
in TE buffer (10 mM Tris HC1, pH 8.0; 1 mM EDTA) pH 8.0, for use in
transfection.
2-10
2.2.3 Transfection of recombinant DNA using DEAE dextran
COS 7 cells trypsinised or treated with EDTA as described earlier were
plated out into 80 cm2 flasks at approx. 50% confluency for transfection
the following day. The growth medium was removed and the cells
washed twice with prewarmed OptiMem for 10 min, before the
transfecting medium was added to the cells. The transfecting medium
consisted of the cDNA (pcDNAl carrying receptor cDNA) in OptiMem (30
jig of cDNA/flask) and DEAE dextran at 0.8 mg/ml (DEAE dextran stock
was at 10 mg/ml in PBS and filter-sterilised), 2 mis of this solution was
added to each flask and gently distributed over the cell layer. After 30
minutes incubation, 3 mis of OptiMem containing 0.4 mg/ml DEAE
dextran and 167 jiM chloroquine phosphate (Sigma) (10 mM stock made
up in PBS and filter-sterilised) was added to the solution and the flasks
were left to incubate for a further 3 hours. After this time the transfecting
medium was aspirated off and replaced with PBS containing 10% DMSO
for 2 minutes. This medium was then aspirated and replaced with the
growth medium for transfected COS 7 cells: DMEM supplemented with
2% UltroSer G (v/v) (Gibco), 100 units/ml penicillin and 100 ug/ml
streptomycin. 24 hours later the cells were trypsinised or treated with
EDTA and seeded into 24- or 12-well plates for assay (2 x 80 cm2 flasks per
plate). Alternatively for binding studies the medium in the flasks was
changed to DMEM with 10% foetal calf serum. The cells were assayed
after a further 40 hours
2.2.4 Production of CHO cell clones stably expressing the VIP or PACAP
receptors (by Dr Eve Lutz and Christine Morrison)
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The cDNAs encoding the VIPi, VIPz, PACAPshort and PACAPiong receptor
were introduced into the expression vector pCDNAl, containing the
neomycin resistance gene, the resulting recombinant constructs were
termed PV19, R4, R7b and R7. Chinese hamster ovary (CHO) cells were
transfected with the receptor plasmids by lipofection. 24 hours after
transfection, cells were trypsinised and plated into (Greiner) cloning
plates. 48 hours after transfection, geniticin-resistant cells were selected
by incubating in Ham's F12 nutrient media containing 10% newborn calf
serum (v/v, NCS), and 100 units/ml penicillin, 100 pg/ml streptomycin,
and supplemented with 500 mg/ml geneticin. After one month of
growing cells in geneticin-containing media, colonies were selected and
replated into 24 well plates, and maintained in the selection media.
Clonal lines expressing the different receptors were selected for their
ability to stimulate adenylate cyclase in response to VIP, PACAP and
other VIP-like peptides, using a cAMP radioimmunoassay. The
expression of the mRNA for the various receptors was also shown by
Northern analysis.
2.2.5 Liposome treatment and transfection of 1321N1 cells
1321N1 cells were seeded into 12-well plates, coated with fibronectin (5
jig/cm2). When 60-80% confluent the cells were treated with liposomes
prepared with 2.6 jil Lipofectamine reagent (Life Technologies/Gibco) in
420 jil OptiMem. Cells were transfected with liposomes carrying either
Clostridium Botulinum ADP-ribosyltransferase C3 (2 jig/well; 5 hours), or
CMV-RhoA constructs (0.5 jig DNA/well; 7 hours) or no additions. Rho-
construct transfected cells were returned to the normal growth medium
for 48 hours, prior to quiescing and labelling of cells for assay.
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2.2.6 Assay of Phospholipase D activity
Measurement in clonal cell lines
All cell lines to be used in a PLD assay were first plated into 12 well dishes
(Costar U.K.). Prior to assay, cells were quiesced for 18 hours in serum-
free medium and the fatty acid moiety of phosphatidylcholine was
labelled for 18 hours with 10 pCi/ml [9,10-3H] palmitate (40 Ci/mmol, Du
Pont). The activation of PLD normally leads to the production of
phosphatidic acid and choline. In the presence of a primary alcohol, PLD
catalyses the production of a phosphatidylalcohol by the transfer of the
phosphatidyl moiety of a phospholipid to the alcohol. PLD activity was
thus monitored as the production of [3H]phosphatidylbutanol
([3H]PtdBut)when cells were stimulated in the presence of 30 mM butan-
l-ol. The morning of the assay the labelling medium was removed and
the cells were washed twice with Minimum Essential Medium (MEM,
Gibco Life Technologies) + 1% Bovine Serum Albumin (w/v) (BSA,
Sigma, essentially fatty acid free), before being incubated with 0.5 ml MEM
+ 0.5% BSA (w/v). The assay was started with addition of agonist, all
agonist and drug treatments of cells was for 30 mins at 37°C in a
humidified atmosphere of 95% O2: 5% CO2 unless otherwise stated. The
assay was terminated by aspiration of the assay medium and addition of
0.5 ml ice-cold methanol. Cells were homogenised and the extraction of
the [3H]PtdBut product followed a method of lipid extraction described
previously (Bligh, E. G. and W. J. Dyer 1959). Samples transferred to 2 ml
glass vials (Chromacol, BDH), 500 pi chloroform and 400 pi EDO were
added to give a ratio of methanol/chloroform/EDO of 1:1:0.8. Samples
were vortexed and left for 15 mins, then spun for 8 mins in a centrifugal
evaporator (Gyrovap, V. A. Howe, Banbury, U.K.) to separate the aqueous
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and organic layers. The upper aqueous laver was removed and an aliquot
or all of the lower organic phase was evaporated under vacuum at 30°C
in the centrifugal evaporator for 30-50 min. The extract was resuspended
in 50 jil of a mix of chloroform and methanol in the ratios of 19:1. The
sample was applied to a LK5D, silica gel plate (Whatman). The plates
were developed using the organic phase of the mixture of ethyl
acetate/2,2,4-trimethylpentane/acetic acid/water, in the ratios of
110:50:20:100. The region of the TLC plate corresponding to [3H]PtdBut
was identified using iodine staining of phosphatidylbutanol standards
(Avanti Polar Lipids, U.S.A.), or a [14C]PtdBut standard (gift from R.
Randall, Wellcome Research Laboratories, Kent, U.K.). Also the agonist
or phorbol ester-stimulated [3H]PtdBut peak was lost in the absence of
butan-l-ol. This region was scraped into vials (Canberra Packard). 4 ml of
scintillant (Emulsifier-Safe LSC cocktail, Packard) was added to each vial,
samples then shaken briefly and counted on the Beckman LS 5801 Series
analyzer (Beckman).
Measurement in pituitary tissue
Adult male COB Wistar rats (250 g) were maintained under controlled
lighting (lights on from 05.00 to 19.00 hours) and temperature (22°C) with
free access to food pellets (CRM, Labsure, Manea, Cambs, U.K.) and tap
water. Rats were decapitated and the anterior pituitaries removed and
quartered then distributed into 2 conical flasks and incubated in warmed
MEM at 37°C under an atmosphere of 95% O2: 5% CO? to recover. The
tissue was washed twice with fresh MEM before tissue equivalent to 4.5
pituitaries was placed in 2 ml MEM, and labelled for 2 hours with 30 gl of
[9,10-3H] palmitate (75 jiCi/ml), whilst gently shaking. Pituitary tissue
was then washed with MEM containing 1% BSA (w/v) to remove any
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unincorporated label and pituitary quarters were distributed into assav
vials containing 400 jj.1 of MEM, plus 0.5% BSA (w/v). Stimulation of
PLD with agonists in the presence of 30 mM butan-l-ol, was for 30 min as
described above. The assay was terminated by the addition of 500 pi
methanol and then chloroform. Tissue was homogenised and the
[3H]PtdBut was extracted as described above. The rest of the assay
followed normal protocol.
Permeabilisation of 1321N1 cells and activation of PLD by GTP analogues
Confluent 1321N1 cells in fibronectinised 12-well plates were labelled and
washed as described above. Cells were preincubated as required with 100
pM carbachol, for 10 min at 37°C. The preincubation medium was
replaced with intracellular buffer (Riimenapp, U., et al. 1995) consisting of
6 |iM digitonin, 135 KC1, 5 mM NaHCC>3, 5 mM EGTA, 5.6 mM glucose, 4
mM MgCl2, 1.5 mM CaCl2, 20 mM HEPES, 2 mM ATP, 10 pM NAD, 6 pM
digitonin, 30 mM butan-l-ol. GTP analogues were included as required;
100 pM GTP7S, 200 pM GPPCH2P or 10 mM NaF in the presence of 30 pM
BeCl2. Brefeldin A was used at a concentration of 100 pM and C3
exoenzyme was used at a concentration of 1 pg/ml. PLD assays were
continued by the normal protocol.
2.2.7 Assay for [3H]inositol phosphate production
Cells in 12-well tissue culture plates, maintained at 37°C in a 95% 02 : 5%
C02 environment, were labelled with 0.5 or 1 pCi/ml of myo-[2-
3H]inositol (Amersham) for 16-18 hours in Earle's Balanced Salt Solution
with 10 mM glucose, 10 mM HEPES, pH 7.4 (NaOH). The cells were then
washed twice in Earle's Balanced Salt Solution with 10 mM glucose, 10
mM HEPES, 0.2% bovine serum albumin (Fraction V; Sigma), pH 7.4
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(NaOH) and preincubated for 10 minutes with 10 mM LiCl before agonist
stimulation. Reactions were stopped by aspiration of medium and
addition of 700 pi of ice-cold 1.34M trichloroacetic acid. The wells were
scraped and the solution transferred into a 1.5 ml eppendorf tube for
centrifugation to pellet the precipitated protein (5 minutes, 12,000y„ 4°C
Jouan MR 1815 centrifuge, Jouan U.K.), a 500 pi sample of the
supernatant was then added to 50 pi of 0.1 M ethvlenediaminetetraacetic
acid (EDTA) and 500 pi of a 1:1 mixture of 1,1,2-trichlorotrifluoroethane
and tri-n-octylamine. The sample was vortexed and centrifuged (5
minutes, 12,000y„ 4°C) and a 300 pi volume of the aqueous phase was
added to 200 pi of 1 M NaHCC>3 containing universal indicator. The
sample was applied to a 1 ml column of Dowex anion exchange resin
(1x8 resin, formate form, 200-400 mesh; Bio-Rad) and a stepwise gradient
of ammonium formate was used to elute the [3H] inositol phosphates, a
method previously described by Berridge et al. (1983).
The sample in the column was washed with:
• 15 ml of UHP water
• 5 ml of 50 mM ammonium formate
• 10 ml of 1 M ammonium formate/0.1 M formic acid. This fraction
contains the [3H] inositol phosphates and was collected in a Zinsser
scintillation vial (Zinsser Analytic GmbH)
• 5 ml of 2 M ammonium formate/0.1 M formic acid
• 15 ml of UHP water
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500 ul aliquots were distributed into Pony vials (two from each collected
fraction) and 4 ml of Emulsifier-Safe LSC cocktail (Packard) was added to
each Pony vial. The samples then shaken briefly and left overnight
before being counted by liquid scintillation counting, as described for the
PLD assay .
2.2.8 Radioimmunoassay for cAMP production
Iodination of cAMP
2'-0-Monosuccinyladenosine 3': 5'-cyclic monophosphate tyrosyl methyl
ester (Sigma U.K.) was radiolabeled with Na125I (Amersham
International, Aylesbury, Buckinghamshire), using the chloramine-T
method as described previously (Greenwood, F. C., et al. 1963). The
labelled peptide was purified by reverse-phase liquid chromatography,
using a 1 ml 'Bond Elut' column (Anachem Ltd., U.K.). The column was
washed with a gradient of methanol/trifluoroacetic acid (TFA).
Radiolabeled cAMP was eluted with 40-50% methanol/0.1%TFA (v/v).
Specific activities of 3 mCi/|Ug were routinely obtained.
Cells were washed in MEM-BSA (0.25%) and pre-incubated with 0.5 mM
isobutylmethylxanthine (IBMX) for 15 minutes before agonist
stimulation. The stimulation period was terminated by either: aspiration
of the medium and addition of a 500 ul volume of ice-cold 0.1M HC1 (for
intracellular cAMP measurement) or the addition of an equal volume of
ice-cold 0.2M HC1 to the medium (for total cAMP measurement). The
plates were then frozen at -70°C. After thawing, the cells were
homogenised by trituration. Duplicate 50 ul aliquots were taken from
each well and assayed for cAMP content by radioimmunoassay.
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All solutions were made up in 50 mM sodium acetate buffer (pH 6.0),
0.1% BSA (fraction V), 0.1% sodium azide (w/v) and the assays carried
out in polypropylene microrack tubes (1.2 ml, Alpha Labs). RIB7
antiserum at a final concentration of 1:166,000 was used as a primary
antibody, 125I-cAMP at approx. 10,000 cpm per tube was added and the
tubes were mixed by Vibrax and left at 4°C overnight. Donkey anti-rabbit
IgG (at a titre of 1:400) was used as a secondary antibody and non-immune
rabbit serum was also added at a titre of 1:40 for a final assay volume of
275 jj.1. The tubes were mixed and incubated at 4°C for 3 hours. 700 u.1 of
ice-cold PEG-8000 (8.7%) in 0.1M sodium phosphate buffer (pH 7.7) was
then added to each tube in order to aid the precipitation of the 125j_
cAMP/antibody complex and the tubes were spun at l,500y for 25 minutes
at 4°C. The supernatant was then aspirated off and the gamma radiation
remaining in the pellet, and thereby the cAMP content, was determined
using the Cobra Autogamma counter (Packard) and the associated
software. The specific binding was typically 40% of the total applied
counts and the non-specific binding typically comprised less than 10% of
the specific binding. The assay included a cAMP standard curve running
from 1 to 512 nM cAMP. The cAMP concentration of the unknowns were
determined by interpolation of the % bound counts and the log of the
cAMP concentration.
2.2.9 Solubilization and immunoprecipitation of M3 receptors labelled
by [3H]N-methyl scopolamine ([3H]NMS) and thrombin receptors
labelled with [125I]Ala-pFPhe-Arg-Cha-HArg-Tyr-NH2 ([125I]TRP)
TRP (Calbiochem-Navobiochem (U.K.) Ltd., Nottingham) was
radiolabeled with Na125I (Amersham International, Aylesbury, Bucks),
using the chloramine-T method as described above. However labelled
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TRP was purified by reverse-phase liquid chromatography, using a
Brownlee 4.6 x 30 mm column (Anachem Ltd., U.K.) according to the
method of Harmar and Rosie (Harmar, A. J. and R. Rosie 1984).
Radiolabeled TRP was eluted with 70% methanol/0.1%TFA (v/v).
Specific activities of 200 jiCi/jig were routinely obtained.
1321N1 cells in 75 cm2 tissue culture flasks (pre-incubated with carbachol
(100 |iM) or the thrombin agonist Ser-Phe-Leu-Arg-Asn-NH? (30 jiM) for
10 min, were washed and homogenised in ice-cold buffer A with HEPES
20 mM, EDTA 3 mM NaOH pH 7.5, containing AEBSF 1 mM, aprotinin 2
jig/ml, leupeptin 4 jig/ml, pepstatin A 2 (ig/ml, soybean trypsin inhibitor
50 iig/ml, NaF 1 mM and sodium orthovanadate 1 mM. The
homogenate from the 1321N1 cells was spun at 12,000g, and the
pellet/membrane fraction was used in the solubilisation procedure.
Membranes were resuspended and solubilized in 15 volumes of 5 mM
CHAPS, 0.1% Na cholate, 1M NaCl with the protease and phosphatase
inhibitors used in the homogenisation step for 30 min at 4°C, whilst
rolling (rotamixer, Stuart Scientific, Philip Harris Scientific, Coatbridge,
U.K.). An equal volume of 20% (v/v) glycerol in CHAPS/cholate buffer
without NaCl was added (with 0.6 mg/ml phosphatidyl choline, PtdCho,
for M3 receptors). 30 gl of a 1:1 dilution of protein G Sepharose CL-4B
(Sigma), suspended in solubilization buffer was added to the solubilized
sample and the sample was rolled for a further 20 min at 4°C, and then
spun at 12,000y to remove proteins that bind non-specifically to protein G.
The precleared sample was split between 2 ml tubes and incubated with
sheep anti-ARFl/3 immunoglobulins (10-15 jil/ml), rabbit anti-RhoA IgG
(2-3 jig/ml Santa Cruz Biotechnology), or non-immune IgG controls from
sheep or rabbit (3 ug/ml) for 18 hours at 4°C on a tube roller. Antibody-
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blocking control peptides were used in controls at 6 pg/ml. Antigen-
antibody complexes were collected by addition of 50 pi/tube of the protein
G-Sepharose suspension, incubation for 3 hours at 4°C, then spun at
12,000#.. 150 pi aliquots of beads and supernatant from the previous spin
were assayed for solubilized receptor binding sites. M3 receptors were
assayed in 500 pi assays containing: 10 mM MgCb, 200 mM NaCl, 10%
(v/v) glycerol, 3 mg/ml PtdCho, 20 mM HEPES, pH 7.5, 10 nM [3H]N-
methyl scopolamine (85 Ci/mmol, Du Pont) with or without 10 pM N-
methyl atropine. After 40 min at 37°C, proteins were precipitated with
polyethylene glycol and label was measure by liquid scintillation
counting.
Thrombin receptors were assayed in 500 ul incubations containing: 10
mM MgCl2, 150 mM NaCl, 0.25% (w/v) BSA, 0.05% (v/v) bacitracin, 0.1
mM AEBSF, 2 pg/ml aprotinin, 7% (v/v) glycerol, 2 mg/ml
phosphatidylserine, in Tris HC1 (50 mM pH 7.4). [125I]TRP 10 mM (approx.
60,000 cpm/assay) with or without 300 nM unlabelled TRP to define non¬
specific binding and were carried out for 60 min at 4°C.
2.2.10 Modulation of agonist affinity at M3 receptor by GTP analogues
1321N1 cells, control or preincubated with 20 pM carbachol for 10 min at
37°C with or without 100 pM BFA were extensively washed before being
homogenised and a membrane fraction prepared as described above. The
effects of GTP analogues on the IC50 values from carbachol displacement
curves of specific [3H]NMS binding were assessed in 500 pi assays
containing: 10 mM MgCE, 100 mM NaCl, 20 mM HEPES, pH 7.5, 1 nM
[3H]NMS, with or without carbachol (10-3000 uM), GTPyS (100 uM),
GPPCH2P (200 pM), F~ (lOmM NaF in the presence of 30 pM BeCb) or N-
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methyl atropine (3 pM). After 60 min at 37 °C, assavs were quenched with
750 pi ice-cold 10 mM MgCl2/ 100 mM NaCl, 20 mM HEPES pH 7.5,
centrifuged and pellets taken for liquid scintillation counting.
2.2.11 Solubilization and immunoprecipitation of wild-type and Asn318
mutant GnRH receptors labelled with [125I]buserelin
Iodination of Buserelin
Ligand binding assays to the GnRH receptor were carried out with the
protected GnRH analogue buserelin (D-Ser(But)6 des Gly10 GnRH-
ethylamide, Calbiochem-Novabiochem (U.K.) Ltd., Nottingham)
Buserelin was radiolabelled as described for the thrombin ligand TRP.
Specific activities of 1100 Ci/mmol were routinely obtained.
COS 7 cells expressing either the wild type or Asn318 mutant GnRH
receptor, were preincubated with or without 100 nM GnRH for 15 min.
Membranes were prepared from these cells as described above for the
1321N1 cells. The GnRH receptors were solubilized from the crude
membrane fraction over a 30 min incubation at 4°C, using ice-cold buffer
containing 5 mM CHAPS, 1.5 mM NaCl, AEBSF 1 mM, aprotinin 2
pg/ml, leupeptin 4 pg/ml, pepstatin A 2 pg/ml, soybean trypsin inhibitor
50 pg/ml, NaF 1 mM and sodium orthovanadate 1 mM whilst rolling for
30 min at 4°C. The extracts were adjusted to 0.5M NaCl and pre-cleared of
proteins that bind non-specifically to protein G Sepharose as described
above. Pre-cleared extracts were incubated with the immunoprecipitating
antibodies for 18 hours on a tube roller, at 4°C; anti-ARFl/3
immunoglobulins (10 pl/ml), anti-RhoA IgG (1 pg/ml), or with control
antibodies at 1 pg/ml; mouse monoclonal anti-ERKl/2 IgG (Zvmed
Laboratories) or mouse monoclonal anti-Ras IgG (Transduction
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Laboratories), each being reported to recognise the native conformation of
their target protein. Antibody-blocking peptides were used in controls at
2 gg/ml. Antibody-antigen complexes were collected as described
previously incubation with protein G-Sepharose suspension, and washed
the solubilization buffer containing 5 mM CHAPS, 0.5M NaCl and
protease/phosphatase inhibitors. Receptors remaining in solution were
concentrated by polyethylene glycol precipitation and specific
[125I]buserelin binding was assayed in a volume of 500 |il containing 10-60
u.g protein, 25 mM Tris HC1 pH 7.4, 0.1% (w/v) BSA, 25 pM [125I]buserelin
(50,000 cpm) with or without 3 pM GnRH. After 90 min at 4°C, proteins
were precipitated with polyethylene glycol and bound ligand was
measured by y-spectrometry.
2.2.12 Modulation of agonist affinity at the wild-type and Asn318 mutant
GnRH receptors by GTP analogues
COS 7 cells transfected with wild type or Asn318 Mutant GnRH receptor
were seeded into fibronectin-coated tissue culture flasks (5 jug/cm2).
Experiments were carried out by the sequential addition of washes to cells
that had been previously equilibrated with [125I]buserelin over 90 min at
4°C in Medium 199 with 0.2% BSA (w/v). Non-specific binding was
defined with 3 uM GnRH. The cells were permeabilized with medium
199 containing 22 uM digitonin, and GTP analogues as required, lOOpM
GTPyS, 200 pM GPPCH?P or 10 mM NaF in the presence of 30 jiM BeCb-
Addition of medium at 37°C caused a rapid initial loss of over 80% of the
specifically bound ligand with a ti/2 which was indistinguishable between
wild-type and Asn318 receptors (ti/2 of 1.87 ± 0.11 min, mean ± SEM from
6 typical examples of each receptor type). This corresponds to the marked
reduction in GnRH agonist equilibrium binding to membranes resulting
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from transfer from 0°C to 37°C (Perrin, M. H., et al. 1989). After 15 mm,
ligand dissociation from permeabilized cells had reached a slower steady
state; a plot of ®/Bo against time (15-50 min) then revealed a good fit to a
linear component in each case: ti/2 control wild-type receptor 22 ± 3 min
and control Asn318 receptor 26 ± 3 min (means ± SEM, n = 6).
2.2.13 Ligand-binding studies on the VIP and PACAP receptors
Iodination of Helodermin
Helodermin (Calbiochem-Novabiochem (U.K.) Ltd., Nottingham) was
radiolabeled as described above for TRP. Specific activities of 200 pCi/pg
were routinelv obtained.
J
Homologous displacement of Helodermin,/PACAP-27 from whole cells at
37°C.
CHO cells stably transfected with either the VIPi, VIP2/ PACAPshort or
PACAPiong receptor cDNAs, were seeded into twelve well plates. The
cells were washed twice with warm (37°C) Medium 199 containing 0.2%
BSA, and the protease inhibitor, bacitracin (30pg/ml). The 0.5 ml wash
was replaced with the assay medium; 0.4 ml of Medium
199/BSA/bacitracin, 50 pi of increasing concentrations of unlabelled
("cold") helodermin/PACAP-27 peptide, and 50 pi of radiolabelled
helodermin/PACAP-27 (NEN DuPont, U.K.). The specific activity of
[125f]pACAP-27 and [125I]helodermin was 2200 Ci/mmol and 77 Ci/mmol
respectively. The iodinated ligands were diluted to 50,000 cpm/50 pi in
Med 199/BSA/bacitracin plus the protease inhibitor aprotinin to a final
concentration of 10 pg/ml and the addition of the labelled peptide
marked the start of the assay. The plates were incubated at 37°C for 10
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mins in a shaking water bath. The plates were placed on ice for 10
minutes then the assay medium was immediately removed by aspiration,
and the cells were washed three times with ice-cold Earle's Balanced Salt
Solution (EBSS) containing 0.1% BSA. Once the third wash was
removed, cells were washed with an ice-cold solution of 0.2M glacial
acetic acid/0.5M NaCl. The acid strip wash was removed from the wells
after 5 minutes and pipetted into eppendorf microtubes. This acid strip
procedure has been utilised by a number of groups such as those
investigating the gastrin-releasing peptide receptor (Grady, E. F., et al.
1995, Slice, L. W., et al. 1994), and is taken to represent the readily-
dissociated externally bound ligand. The cells were then lyzed using 4M
NaOH. The lysis solution was left on overnight and then the cells were
homogenised and transferred to eppendorf microtubes; this fraction
contained the internalised ligand. Gamma radiation was measured by y-
spectrometry. In each plate, 2 wells were washed with warmed EBSS and
then the cells were homogenised in a solution of 1% sodium lauryl
sulphate for protein determination
2.2.14 Western Blotting
Extracts from 1321N1 cells or male rat anterior hemipituitaries (pre-
incubated with 10 llM AT II for 10 min at 37°C) were homogenised and
solubilized in the buffer/detergent systems described above for 1321N1
cells. However in the solubilization step, no glycerol or PtdCho was
added. Immunoprecipitation was carried out as described above, using
sheep anti-ARFl/3 immunoglobulins at 20 jil/ml (peptide at 8 ug/ml),
rabbit anti-RhoA IgG at 5 ug/ml ( peptide at 20 ug/ml), rabbit anti-M3
receptor serum globulins (Wall, S. J., et al. 1991), or non-immune rabbit
IgG at 2,5 ug/ml and polyclonal anti-ATi receptor IgG at 5 pg/ml (Santa
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Cruz). Primary antibody complexes were collected with 15-20 pi protein
G-Sepharose and washed once with buffer A. Samples were then
solubilized by heating the immunoprecipitates to 100°C for 5 min, in 50
pi PAGE lysis buffer containing Tris HC1 pH 7.6, 2% sodium dodecvl
sulphate and 0.5% p-mercaptoethanol. Samples were flash-frozen to
-70°C until ready for electrophoresis and immunoblotting. On the day of
electrophoresis the thawed samples were heated for 5 minutes under hot
water tap (approx. 50°C) and centrifuged for 2 minutes at room
temperature in Eppendorf centrifuge to remove particulate material.
Sodium dodecyl sulphate-polyacrylamide gel electrophoresis
The 7.5% homogeneous polyacrylamide gel pre-cast onto a rigid polyester
film (PhastGel Homogeneous 7.5, Pharmacia) -was removed from its
wrapping and carefully placed onto 80 pi of UHP H2O on the gel bed of
the PhastSystem Separation and Control unit (Pharmacia Biotech AB,
Uppsala, Sweden) in such a manner as to exclude air bubbles. The gels
have a 13 mm stacking zone and 32 mm separation zone (dimensions; 43
x 50 x 0.45 mm). PhastGel SDS buffer strips were then positioned in the
buffer strip holder. The samples were loaded (4 ul) onto the sample strip
holder in a humidified chamber and the holder was positioned in the
apparatus. Low molecular mass standards of 97, 67, 43, 30, 20.1 and 14.4
kDa (Pharmacia) were used in all separations. The separation program
was run until 60 Vh had accumulated (approx. 30 min).
Electroblotting
Immobilon transfer membranes (polyvinyldifluoride, 10 cm x 10 cm, 0.45
uM pore size; Millipore) were cut to size (5 cm x 5 cm) and marked for
identification and orientation. The filters were immersed in methanol
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and then rinsed in UHP hbO briefly 5 times. The filters were then shaken
for 2x5 minutes in UHP H?0 and in blot buffer (25 mM Tris, 192 mM
glycine, 20% methanol, pH 8.3) for 3x5 minutes using the rotary shaker.
Once the proteins had been separated, the separation zone of the gel was
cut from its plastic backing using cheesewire. The Immobilon membrane
was placed over the separation zone of the gel and the gel was removed
from its backing whilst remaining in contact with the Immobilon. Three
pieces of PhastTransfer filter paper (50 mm x 50 mm) were soaked in blot
buffer and placed on the anode of the PhastSystem Development Unit.
More blot buffer was applied to the filters and the Immobilon placed on
top of them. Another three filters were then soaked and placed on top of
the immobilon/gel. The cathode was then placed on top of the filters and
pressed into place gently. The transfer of proteins was carried out using
90 Vh (approx. 45 min).
Imm unostaining
The blot was given 5 quick rinses in UHP H2O before being given 4x4
minute washes on the shaker. The blot was then stained for 5 minutes in
0.1% Coomassie blue-R250, 50% methanol before being given two or
more 1 minute washes in destain (50% methanol, 10% acetic acid) until
the protein bands were clearly visible against a clear or pale background.
Several 1 minute washes in UHP H2O were then carried out to stop the
destaining process and remove residual methanol. The blot was then
marked and the lanes cut up as appropriate. The blot was washed two or
more times for 2 minutes in methanol until the bands were no longer
visible. A further 3x4 minute washes in methanol were carried out
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before the blot was given 5x5 minute washes in UHP EDO to remove
residual methanol.
The blot was incubated overnight at 4°C in either 5% BSA (w/v)/PBS or
5% Marvel. The blot was given 2 quick rinses and 5x5 minute washes in
PBS/0.1% polyoxyethylenesorbitan monolaurate (Tween-20, Sigma). The
blot was incubated overnight with the primary antibody in 0.25%
BSA/PBS/0.05% Tween-20. An appropriate blocking peptide was mixed
with the primary antibody for use as a control.
The blot was given two quick rinses and five x 5 minute washes in 0.25%
BSA/PBS/0.1% Tween-20 and incubated for 1 hour with horseradish
peroxidase (HRP)-conjugated sheep-derived anti-mouse or donkey-
derived anti-rabbit polyclonal IgG antiserum (Scottish Antibody
Production Unit). Secondary antibodies were diluted 1:5000 or 1:2000 for
anti-mouse and anti-rabbit polyclonal IgG respectively. Dilution was in
0.25% BSA/PBS/0.05% Tween-20 and then the blot was then rinsed as
previously.
In the darkroom the blot was incubated for 1 minute in 2.5 ml of a 1:1
mixture of Enhanced Chemi-Luminescence (ECL) solutions A and B
(Amersham). Excess liquid was removed from the blot by touching the
edge with a mediwipe tissue. The blot was then sealed in clingfilm and
exposed against ECL film for between 30 seconds and 5 minutes. The film
was developed by incubation for 4 minutes in Phenisol developer,
rinsing in water, and a 1 minute incubation in Elypam fixer followed by a
minimum of 2 minutes in running water.
2.2.15 Assay of protein concentration
2-27
The concentration of protein in wells was determined using the Pierce
Bicinchoninic acid (BCA) system (Pierce). A 10 pi sample taken from
homogenised tissue was spotted into a 96 well microplate (Greiner) and
300 pi of BCA protein assay reagent was added, the plate was warmed to
37°C for 30 min. The absorbance of the sample was measured at 590 nm
using a Microplate Biokinetics Reader EL 312e (BIO TEK Instruments,
Vermont, USA). Sample values were compared to a standard curve
constructed using an albumin standard.
2.2.16 Data analysis
All values are expressed as mean ± standard error of the mean (SEM)
from data obtained from a number (n) of individual experiments.
Statistical analyses were carried out using the Mann-Whitney U-test
unless otherwise stated. The concentration of drug which could produce
50% of the maximal response (EC50 value) and the concentration of
inhibitors which inhibit 50% of a stimulus-evoked response (IC50) were
assessed by fitting the data with a non-linear, error weighted, iterative
curve-fitting programme, P.fit (Biosoft, Cambridge, U.K.) and represented
as mean ± SEM.
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CHAPTER 3
Activation of PLD by
rhodopsin family GPCRs
native to 1321N1 cells and
anterior pituitary tissue
3.1 INTRODUCTION
The majority of transmembrane signal transduction in response to
hormones and neurotransmitters is mediated by G protein-coupled
receptors (GPCRs). Moreover, GPCRs are the principal signal transducers
of sight and smell. GPCRs are integral membrane proteins characterised
by seven hydrophobic stretches of amino acids that are predicted to form
transmembrane domain (TMD) a helices, connected by alternate extra and
intracellular loops (Baldwin, J. M. 1993, Baldwin, J. M. 1994, Dohlman, H.
G., et al. 1991). Based on certain key sequences, GPCRs can be divided into
three major subfamilies, receptors related to rhodopsin (class I), receptors
related to those for VIP/calcitonin (class II) and the metabotropic
glutamate GABAg and Ca2+ sensor receptors (class III). The rhodopsin
subfamily is the most extensively studied and the position of the seven
transmembrane helices (as proposed by Baldwin, and based upon the low
resolution projection map for rhodopsin produced by Schertler (Baldwin,
J. M. 1993, Baldwin, J. M. 1994, Schertler, G. F. X., et al. 1993)), points to the
anticlockwise arrangement of the helices and the close proximity of TM
helices I, II and VII, as viewed from the extracellular surface (Baldwin, J.
M. 1993, Baldwin, J. M. 1994, Schertler, G. F. X., et al. 1993). Although
these receptors all possess the basic seven TMD structure, the number of
highly conserved amino acids shared by the rhodopsin subfamily of
GPCRs is relatively few (Probst, W. C., et al. 1992, Savarese, T. M. and C.
M. Fraser 1992) and the conservation of any amino acids points to an
important role in receptor function. One such conserved motif is the
characteristic N/DPX2-3Y sequence that is completely conserved in the
rhodopsin family, with NPX2-3Y present in TMD 7 of 95% of class I
GPCRs, the remaining 5% of receptors contain an aspartate residue at the
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first position (Probst, W. C., et al. 1992). Models of aminergic GPCRs
suggest that the NPX2-3Y sequence is ideally placed to mediate any signal
from the agonist-induced conformational changes in the ligand binding
region (Donnelly, D., et al. 1994, Findlay, J. B. C, et al. 1993). The NPX2-3Y
motif is similar to the NPXY internalisation sequence that was first
described in the cytoplasmic segment of the low-density lipoprotein
receptor (Trowbridge, I. S., et al. 1993). In recent studies, mutagenesis
pointed to a role for the tyrosine of the motif in regulation of agonist-
induced internalisation of the fH adrenergic receptor (Barak, L. S., et al.
1994). However further studies utilising mutagenesis of the fH-adrenergic
(P2)/ 5-HT2A/ angiotensin II type 1 (ATi), neurokinin-1 (NKi) and
thyrotropin-releasing hormone (TRH) receptors demonstrated that the
NPX2-3Y motif is not an generic internalisation motif, but it appears to
maintain the structural integrity of the receptor, allowing the receptor to
interact properly with both agonist and G proteins and thus transduce
extracellular signals across the membrane (Barak, L. S., et al. 1995, Barak,
L. S., et al. 1994, Bohm, S. K., et al. 1997, Hunyady, L., et al. 1995, Laporte, S.
A., et al. 1996, Perlman, J. H., et al. 1997, Sealfon, S. C., et al. 1995). Indeed
as demonstrated in the reports of receptor function, mutation of the
conserved tyrosine in the (32, NKi and ATi receptors to alanine
significantly inhibited the respective stimulation of adenylate cyclase,
calcium (Ca2+) mobilisation and inositol phosphate (InsP) production
(Barak, L. S., et al. 1995, Bohm, S. K., et al. 1997, Laporte, S. A., et al. 1996).
Moreover the replacement of the asparagine residue in the P2, 5-HT2A/
ATi, and TRH receptors with alanine abolished the adenylate cyclase
activity of the P2 receptor and either abolished or significantly reduced the
InsP responses of the remaining receptors (Barak, L. S., et al. 1995,
Hunyady, L., et al. 1995, Perlman, J. H., et al. 1997, Sealfon, S. C., et al.
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1995). Receptors which contain the alternative DPX2-3Y motif have not
been the focus of such a detailed analysis of the role that this conserved
amino acid sequence may have in receptor conformation and signal
transduction capabilities. However, studies on the gonadotropin-
releasing hormone (GnRH) receptor demonstrate that site-directed
mutagenesis of the aspartate at position 318, to asparagine (which is
conserved in 95% of the rhodopsin receptor family) attenuated coupling
of the receptor to the phospholipase C/InsP breakdown pathway (Awara,
W. M., et al. 1996, Mitchell, R., et al. 1998, Sealfon, S. C. and R. P. Millar
1995, Zhou, W. C., et al. 1994). In further studies (Chapter 4) on the
receptor motifs determining receptor linkages to PLD activation, the
GnRH receptor was used as a prototypical DPX2-3Y-containing receptor,
and the wild type (wt) receptor's ability to transduce signals in response to
agonist was compared to a mutant restoring the asparagine at position
318. The wt and Asn318 mutant GnRH receptors, expressed in COS-7 cells
were compared to the wt5-HT2A (NPX2-3Y) and mutant (DPX2-3Y)
receptor, carrying the reciprocal mutation. Modelling of GPCRs and other
proline containing proteins, suggest that as a result of ligand binding the
N/DPX2-3Y motif can act as a flexible hinge, around which the TMD 7 can
move (Konvicka, K., et al. 1998, Luo, X., et al. 1994, Trumpp-Kallmeyer, S.,
et al. 1992, Wess, J., et al. 1993), possibly involving cis-trans isomerization
of the Asn-Pro peptide bond (Brandl, C. J. and C. M. Deber 1986, Wess, J., et
al. 1993, Williams, K. A. and C. M. Deber 1991). The interaction of TMD 7
with the other TMDs is thought to lead to torsion in the a-helical
stretches of TMD 7 and consequently the exposure of the regions of the
receptor that couple to G proteins (Luo, X., et al. 1994). The region of the
receptor around TMDs 5 and 6, and the adjoining third intracellular loop,
are expected to be the focus of this movement, which is a domain well
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known to be crucial in receptor-G protein coupling (Dohlman, H. G., et al.
1991, Gudermann, T., et al. 1996, Savarese, T. M., et al. 1992, Strader, C. D.,
et al. 1994, Wess, J. 1997).
The activation of PLD by native NPX2-3Y and DPX2-3Y receptors was
studied in the 1321N1 cell line derived from primary cultures of a cerebral
glioma multiforme (Foster, S. J. and J. P. Perkins 1977, Macintyre, E. H., et
al. 1972). The 1321N1 cell line expresses NPX2-3Y receptors, such as the M3
muscarinic, Hi histamine and B2 bradykinin receptors (Hepler, J. R., et al.
1987, Masters, S. B., et al. 1984, Nakahata, N., et al. 1985, Wall, S. J., et al.
1991) and the DPX2-3Y-containing thromboxane A2 and thrombin
receptors (Nakahata, N., et al. 1989, Nieto, M., et al. 1994). All of these
receptors couple tightly to G proteins of the Gq/n family, and display the
expected stimulation of phosphoinositide breakdown in these cells. In
addition the activation of PLD by both NPX2-3Y and DPX2-3Y receptors in
1321N1 cells has been reported (Nieto, M., et al. 1994). The involvement
of small G proteins of the ARF and Rho families in the activation of PLD
was described recently, (Bowman, E. P., et al. 1993, Brown, H. A., et al.
1993, Cockcroft, S., et al. 1994), and as briefly outlined above, the N/DPX2-
3Y sequence is proposed as a regulator of receptor conformational change
and G protein activation. The direct and/or indirect coupling of ARF and
Rho proteins to the N/DPX2-3Y containing receptors, and activation of
PLD was the focus of this study. The results demonstrate that small
differences in the TMD 7 architecture can have dramatic effects on the
receptor signal transduction characteristics, and the findings presented
here are consistent with an important role for the N/DPX2-3Y motif in
regulation of phosphatidylcholine breakdown by PLD.
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3.2 RESULTS
Separation of [3H]PtdBut by thin layer chromatography
The production of [3H]PtdBut by the activation of PLD was measured as
described in Chapter 2. Figure 3.1 shows the running position of
[3H]PtdBut in LK5D thin layer chromatography plates, in a typical
experiment. The results show the increase in [3H]PtdBut production in
1321N1 cells stimulated with 200 pM carbachol or 0.5 units/ml thrombin,
and compared with basal activity in these cells. The increase in agonist-
evoked [3H]PtdBut production is shown for duplicate treatments of 12-
well plates containing 1321N1 cells.
Receptor-mediated activation of PLD: studies with selective signal
transduction inhibitors
The activation of PLD by selected receptors, endogenously expressed by the
1321N1 human astrocytoma cell line, was challenged with brefeldin A
(BFA), a fungal metabolite which acts as a selective inhibitor of guanine
nucleotide exchange on ARF (Donaldson, J., et al. 1992, Helms, J. B. and J.
E. Rothman 1992). These responses fall into 2 clear categories as described
recently by Mitchell et al. (Mitchell, R., et al. 1998). The M3 muscarinic, Hi
histamine, B? bradykinin, thrombin and thromboxane A2 (TXA2)
receptors (Debacker, M. D., et al. 1993, Hess, J. F., et al. 1992, Hirata, M., et
al. 1991, Peralta, E. G., et al. 1987, Vu, T. K. H., et al. 1991) all activate PLD
potently after exposure to the appropriate agonist: carbachol, histamine,
bradykinin, thrombin and U46619 (lla,9a-epoxymethano-PGH2)
respectively. We showed that the bradykinin receptor in these cells is
most likely to be of the B2 subtype, as the Bi receptor-selective agonist
kallidin, did not elicit any increase in [3H]PtdBut production over basal
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activity. PLD activity, as measured by the increase in
[3H]phosphatidylbutanol ([3H]PtdBut), stimulated by the M3 muscarinic,
Hi histamine and B2 bradykinin receptors was sensitive to BFA,
suggesting an involvement of ARF. However the thrombin and
thromboxane A2 receptor-mediated activation of PLD , measured under
identical conditions, was BFA-resistant (Figure 3.2). The PLD responses
elicited by the M3, B2 and Hi receptors were all significantly inhibited by
50 pM BFA (pcO.05), and in the presence of 200 pM BFA the PLD activity
was reduced to 15 ± 12%, 27 ± 7% and 32 ± 8%, of the maximal stimulated
responses respectively. The IC50 values for BFA (concentration of
inhibitor and/or antagonist required to block 50% of maximum response)
on the M3, B2 and Hi receptors were 72 ± 11, 78 ± 15 and 82 ± 13 pM
respectively, whereas the thrombin and thromboxane A2 receptors were
resistant to BFA up to 200 pM, with 79 ± 10% and 89 ± 7% of maximal
responses remaining at that concentration.
The M3 and thrombin receptors were further studied as prototypical
examples of NPX2-3Y and DPX2-3Y motif-containing receptors. The
concurrent activation of phospholipases C (PLC) and D upon agonist
stimulation of PLC-coupled receptors has been reviewed by Bocckino and
Exton (Bocckino, S. B. and J. H. Exton 1996). Moreover, the dependence of
PLD on PLC activation downstream of receptor for EGF, PDGF and GnRH
further implicates a role for PLC in those examples of receptor-evoked
phosphatidylcholine metabolism (Yeo, E.-J. and J. H. Exton 1995, Yeo, E.-J.,
et al. 1994, Zheng, L., et al. 1994). The results presented in Figure 3.3
suggest that the PLD response downstream of the thrombin, but not M3
receptor is dependent on the activation of phospholipase C (PLC) as there
was significant attenuation of the thrombin-induced PLD response, by the
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selective PLC inhibitor U73122 (Bleasdale, J. E., et al. 1989, Bleasdale, J. E.,
et al. 1990). In the presence of the highest concentration of U73122 used
(20 pM), there was 66 ± 8% inhibition of the thrombin-induced PLD
activity with an IC50 for U73122 of 14 ± 4 pM. In contrast, 20 pM U73122
caused only a 20 ± 13% inhibition of the M3 receptor-stimulated response
(p<0.05, n = 4-10).
We could find no evidence for involvement of the Gi/0 proteins in the
activation of PLD by either the M3 or thrombin receptors. Pre-treatment
of 1321N1 cells with pertussis toxin (PTx, 200 ng/ml, 18h) did not reduce
M3 or thrombin receptor-stimulated PLD activity (Figure 3.4). Ptx
inactivates G[/0 proteins by ADP-ribosylation of the cysteine residue, four
amino acids from the carboxyl terminus of the a-subunit (Neer, E. J., et al.
1984, Tsai, S. C., et al. 1984, West Jr, R. E., et al. 1985). The involvement of
Rho family G proteins in the activation of PLD by the M3 and thrombin
receptors was investigated using C3 ADP-ribosyltransferase (C3
exoenzyme from Clostridium botulinum)(Aktories, K., et al. 1988,
Aktories, K., et al. 1987). This enzyme ADP-ribosylates RhoA, B and C on
asparagine-41 and inactivates them (Paterson, H. F., et al. 1990, Ridley, A.
J. and A. Hall 1992, Sekine, A., et al. 1989). A role for Rho in the
activation of PLD was reported by Schmidt et al., who stably expressed M3
receptors in Human Embryonic Kidney (HEK) cells (Schmidt, M., et al.
1996). Also the activation of Rho by the thrombin receptor in 1321N1 cells
has recently been reported, where thrombin-stimulated cell rounding and
increase in DNA synthesis is blocked by pretreatment of cells with C3
exoenzyme (Majumdar, M., et al. 1998). In addition to the C3 exoenzyme
studies, a wild type (wt) and functionally negative construct
(CMV5Asnl9) of RhoA, were transfected into 1321N1 cells, as molecular
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tools to enhance or attenuate of Rho function (Zhang, S., et al. 1995). C3
exoenzyme and the CMV5Asnl9 RhoA construct significantly reduced
the M3 but not the thrombin receptor-mediated activation of PLD (Figure
3.4). C3 exoenzyme pretreament produced a 60 ± 15% inhibition of
carbachol-induced PLD activation, while the CMV5Asnl9 RhoA construct
reduced the PLD response to 64 ± 11% of maximum. The potency of the
negative Rho construct depends on the efficient translation of enough
protein to compete with the endogenous Rho in the activation of PLD,
the lower level of inhibition produced by CMV5Asnl9 RhoA may reflect
a low level of functionally active protein present within the cell. The
thrombin-induced PLD responses in the presence of C3 exoenzyme and
CMV5Asnl9 RhoA were 87 ± 13% and 122 ± 21% of maximum
respectively. As shown in Figure 3.4, the ability of wtRhoA to augment
the activation of PLD by low concentrations of carbachol but not
thrombin, is consistent with a role for Rho in M3 and not thrombin
receptor-mediated PLD activation. Pre-treatment of 1321N1 cells with
wtRhoA increased the PLD response to 20 pM carbachol to 169 ± 12% of
that with carbachol alone. However the PLD response to similar wtRhoA
pre-treatment and 0.2 Units/ml thrombin as agonist, was only 104 ± 8% of
the PLD activity in the presence of thrombin alone. Therefore it appears
that two groups of Gq/n-linked receptors exist in 1321N1 cells; those
whose PLD responses were either sensitive or resistant to BFA, C3
exoenzyme and the negative CMV5Asnl9 RhoA construct. The receptors
which couple to PLD in a manner sensitive to the small G protein
inhibitors (M3, Hi and B?) all contain the NPX2-3Y motif in TMD 7, while
the resistant group of receptors, contain the alternative DPX2-3Y motif
(thrombin, TXA2).
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Receptor association with small G proteins: ligand binding studies on
ARF/RhoA immunoprecipitates
The different pharmacology of PLD activation displayed by the M3 and
thrombin receptors suggests a divergence in their ability to couple with
ARF and RhoA. The possibility that the M3 and /or thrombin receptors
form close associations with small G proteins in their activation of PLD
was tested by attempting the co-immunoprecipitation of ARF1/3 and/or
RhoA together with any associated receptor binding sites. The results in
Figure 3.5 show that M3 receptors, as denoted by specific [3H]N-methyl
scopolamine ([3H]NMS) binding, could be solubilized from the membrane
and immunoprecipitated using sheep ARF1/3 or rabbit Rho polyclonal
antisera (Laudanna, C., et al. 1996, Martin, A., et al. 1996). The co-
immunoprecipitation of specific [3FI]NMS binding was dependent upon
prior cell exposure to carbachol (100 11M, 10 min). This 'priming' with
agonist is proposed to cause immediate events within the cell which
include allowing the close association of the receptor with small G
proteins e.g. translocation of monomeric G proteins to the nucleus.
Priming causes a significant 4.8 ± 0.7 fold increase in specific ARF 1/3-
precipitated [3FI]NMS binding (p<0.05, n = 6-9), compared to the unprimed
control, and this rise was inhibited by 84 ± 5% in the presence of excess
ARF 1/3 blocking peptide. Moreover the pre-treatment of cells with 100
uM BFA during priming also reduced by 74 ± 19% the level of [3H]NMS
binding co-precipitated using ARF 1/3 antiserum. Incubation with
polyclonal Rho antibodies significantly co-precipitated specific [3H]NMS
binding sites from the solubilized extract of primed 1321N1 cells, as
shown in Figure 3.5. Exposure of cells to carbachol caused an 1.8 ± 0.3 fold
increase in [3PI]NMS binding associated with Rho immunoprecipitates,
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and this was specifically reduced, using excess blocking peptide, by 57 ±
12%. A small level of [3H]NMS binding was associated with control non¬
immune sheep (NIS) and non-immune rabbit (NIR) IgG antibodies, used
singly or in combination, and this did not rise in response to priming
with carbachol. The number of [3H]NMS binding sites co-
immunoprecipitated using ARF 1/3 and Rho antibodies either alone or in
combination, was significantly higher than using a combination of non¬
immune reagents (NIR + NIS), but less than additive. Together ARF +
NIR and Rho + NIS co-immunoprecipitated 0.55 ± 0.09% and 0.42 ± 0.08%
of the added [3H]NMS ligand respectively. In combination, ARF + Rho
immunoprecipitates retained specific binding of 0.75 ± 0.14% of the added
[3H]NMS ligand (Figure 3.5). As summarised in Figure 3.6, binding of the
specific thrombin ligand [125I]Ala-pFPhe-Arg-Cha-HArg-Tyr-NH?
([125i]TRP) (Feng, D. M., et al. 1995), was not detectable in ARF 1/3 or Rho
immunoprecipitates from 1321N1 cells primed with the thrombin agonist
Ser-Phe-Leu-Arg-Asn-NH2. Although high affinity specific binding of the
ligand could be detected in 1321N1 membrane preparation and solubilized
extract (R. Mitchell, unpublished observations).
Immunodetection of receptor association with ARF and Rho in 1321N1
cells
The activation of PLD by the M3 receptor, in an ARF- and RhoA-
dependent manner, and the presence of [3H]NMS binding sites in
immunoprecipitates produced using carbachol-primed 1321N1 cells and
ARF and RhoA antibodies is indicative of a close association, if not direct
interaction of the M3 receptor and small G proteins. Immunoblotting was
used to further investigate the direct association of receptor and G
proteins and how this is modulated by exposure to agonist.
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Immunoprecipitates of ARF1/3, and RhoA from 1321N1 cells, prepared
using polyclonal antisera, were probed with monoclonal antibodies to
ARF and Rho to authenticate the specific immunoprecipitation of the
correct proteins. The results presented in Figures 3.7a and b, show that
the sheep polyclonal anti-ARFl/3 and rabbit polyclonal anti-RhoA
antibodies, correctly immunoprecipitated the appropriate proteins, and
that this was dependent on exposure to agonist and blocked by the
presence of excess peptide antigen. The co-precipitation of ARF and Rho,
using a rabbit polyclonal antiserum directed against the M3 receptor (Wall,
S. J., et al. 1991), provides further proof for the direct association of the
receptor with small G proteins and is consistent with the presence of
[3H]NMS binding sites in ARF1/3 and RhoA immunoprecipitates (Figure
3.8a and b). The presence of ARF and Rho in the M3 receptor
immunoprecipitates was also dependent on priming with carbachol and a
non-immune rabbit IgG control did not co-precipitate any detectable
immunoreactive ARF or Rho.
Studies on NPX2-3Y and DPX2-3Y receptors in normal tissue from rat
anterior pituitary gland
In order to substantiate that similar coupling events occur in normal
physiological tissue as opposed to a clonal cell line, experiments were
carried out on the ATia (NPX2-3Y) receptor and the GnRFl (DPX2-3Y)
receptor in male rat anterior pituitary tissue. Angiotensin II-stimulated
PLD activity in rat anterior pituitary slices was BFA-sensitive, with an IC50
of 58 ± 5 pM, which is comparable with that of the M3 receptor whereas
(as predicted) the response to GnRFl was unaffected up to 200 pM (see
Figure 3.9). Polyclonal antibodies raised against the angiotensin II type 1
(ATi) receptor were used to isolate the receptor and the
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immunoprecipitates from solubilized extracts of angiotensin II-primed rat
anterior pituitaries (which express ATi receptors exclusively, (Bottari, S.
P., et al. 1993)), were probed for the presence of ARF. The receptor closely
associated with ARF in an agonist-dependent manner as shown in Figure
3.10, and this was clearly blocked by the presence of excess peptide antigen
during the immunoprecipitation procedure.
Receptor-mediated activation of PLD and agonist recognition: effect of
GTP analogues
The specific association of the M3 receptor with ARF and Rho during the
stimulation of receptor with carbachol as shown above, was further
investigated by using GTP analogues to activate G proteins and modulate
the receptor affinity for ligand. This work summarises experiments done
with Rory Mitchell (R. Mitchell and D. McCulloch: manuscript in
preparation)
In membranes from 1321N1 cells (with or without prior priming of the
cells with 100 jiM carbachol for 10 mins at 37°C), the concentration of
carbachol required to displace bound [3H]NMS was monitored, in the
presence of non-hydrolyzable GTP analogues. The results presented in
Table 3.1a show that treatment of 1321N1 cells with; guanosine 5'-0-(3-
thio)-triphosphate (GTPyS), beryllium fluoride (BeF3~, an isostere of
aluminium fluoride, (AIF4-), both of which mimic GTP) or guanosine 5'-
[Py-methylenejtriphosphate (GPPCHbP), all decreased significantly the M3
receptor's affinity for carbachol. The effect of incubation with GTPyS,
BeFs~ and GPPCFbP, at the concentration used, was an increase in the IC50
for carbachol to displace [3H]NMS binding by 5.23 ± 0.97, 4.06 ± 0.80 and
2.31 ± 0.34 fold, compared to the IC50 determined in the absence of any
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GTP analogue. Prior exposure to 100 LiiVl carbachol however had different
consequences, on the inferred ability of the three GTP analogues to
activate cellular G proteins and produce a receptor state with low affinity
for agonist. Priming did not significantly change the increase in carbachol
IC50 induced by GTPyS, whereas the BeF3~effect was significantly
diminished and the result of GPPCFbP stimulation was potentiated, the
IC50 values are respectively 4.48 ± 0.34, 1.82 ± 0.31 and 3.46 ± 0.40 fold
increase in IC50 compared to unprimed control. Thus priming of 1321N1
cells with carbachol appears to selectively potentiate the activity of
GPPCHbP-sensitive G proteins, with a 1.5 ± 0.17 fold increase in the IC50
for carbachol compared to unprimed cells. The concurrent inclusion of
100 (iM BFA blocked the potentiating effect of carbachol priming and
lowered the fold increase in IC50 elicited by GPPCH?P to 1.97 ± 0.34, a 57 ±
10% decrease in the GPPCH?P-stimulated increase in agonist IC50 (p<0.05,
n = 4, results not shown). Moreover priming did not appear to stimulate
the population of G proteins activated by BeF3~ treatment, and the prior
exposure to carbachol partially restored the M3 receptors to the high
affinity state absent in BeFs- treated cells. Priming of BeF3~-stimulated
cells produced a 56 ± 17% drop in the IC50 for carbachol, this is consistent
with priming reducing the receptor linkage to G proteins that are
selectively activated by BeF3". The effect of GTPyS on receptor affinity
was not influenced by priming and this is consistent with the idea that
both the GPPChbP- BeF3~sensitive G proteins are activated by this
analogue.
The activation of PLD by GTPyS, BeF3~ and GPPCFbP in digitonin-
permeabilized 1321N1 cells could also be modulated by agonist priming,
and the differential effects of BFA and C3 exoenzvme observed on these
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responses are consistent with a role for ARF and Rho in PLD activation by
M3 receptors. Results presented in Table 3.1b show that in unprimed
1321N1 cells, GTPyS, BeF3~ and GPPCH2P, at the concentrations used,
increase PLD activity 150 ± 9, 115 ± 14, and 48 ± 8% as compared to basal
activity. GTPyS and BeF3~ were 3.10 ± 0.05 and 2.40 ± 0.07 fold more
effective than GPPCFbP, at stimulating PLD activity. Pre-treatment of
cells with BFA or C3 exoenzyme had no significant effect on the BeF3~-
stimulated PLD activity, whilst significantly reducing the GPPCFbP-
induced increase in PLD activity to 31 ± 3 and 27 ± 5% increase over basal
control respectively. Therefore the (By-methylene analogue of GTP does
appear to show a selectivity for the small G proteins ARF and Rho, not
exhibited by BeF3~, as suggested by Gill and Coburn (Gill, D. M. and J.
Coburn 1987). The activation of PLD by GTP analogues after agonist
priming, as with the experiments on receptor affinity described above,
implicates the selective activation of GPPCFbP-sensitive G proteins. The
prior exposure to 100 pM carbachol had no marked effect on the GTPyS-
stimulated increase in PLD activity, as compared with the unprimed
control, whereas priming significantly reduced the BeF3~-induced PLD
activity by 32 ± 9% of the unprimed response, to a 78 ± 10% increase over
basal. As with the results from the study of receptor agonist affinity,
priming potentiates the GPPCFbP effect, this time on phosphatidylcholine
breakdown, with a 56 ± 7% increase in the GPPCFbP-stimulated PLD
response after priming, to a 110 ± 12% increase in PLD activity over basal
control. The pre-incubation with BFA and C3 exoenzyme had no effect
on the BeF3~-stimulated response, while both inhibitors significantly
attenuated the augmented GPPCFFP-induced PLD activity. Treatment of
cells with 100 pM BFA (after priming) reduced the GPPCFbP-stimulated
PLD activity by 65 ± 8%, to a 38 ± 9 % increase over basal. The effect of C3
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exoenzyme treatment was equally striking with a 79 ± 6% inhibition of
the GPPChbP-induced response to 23 ± 7% increase in PLD activity over
basal. The ability of GPPCTbP to act apparently as a selective activator of
PLD through ARF and Rho is increased after exposure to agonist, as might
be expected due to the reported agonist-stimulated translocation of
ARF1/3 and RhoA from the cytoplasm to cell membranes, where
interaction with relevant targets can occur (Cavenagh, M. M., et al. 1996,
Houle, M. G., et al. 1995, Malcolm, K. C., et al. 1996, Riimenapp, U., et al.
1995). Meanwhile the exposure to carbachol is predicted to lead to
receptor-mediated activation of the trimeric G proteins, followed by their
breakdown into a and (3y subunits and thus a reduction in the ability of
BeF3_ to activate PLD.
3.3 DISCUSSION
Pathways to PLD
The activation of PLD by agonist stimulation of the M3, B2, Hi, TXA2 and
thrombin receptors in 1321N1 cells was differentially inhibited by BFA, as
shown in Figure 3.2. The endogenous M3 and thrombin receptors in
1321N1 cells have been shown to activate PLD (Nieto, M., et al. 1994). The
PLD responses mediated by activation of the M3, B2 and Hi receptor were
significantly reduced by BFA implicating a role for ARF. In contrast the
TXA2 and thrombin receptors activated PLD in a BFA-insensitive and so
ARF-independent manner. Work done on the M3 receptor expressed in
human embryonic kidney (HEK) cells also found that the PLD response
evoked by the M3 receptor was BFA-sensitive (Rtimenapp, U., et al. 1995).
These two groups of receptors differ in one important respect, as described
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above, the NPX2-3Y sequence motif within the TMD 7 of the M3, Eb and
Hi receptors and the alternative DPX2-3Y motif in the TXA2 and thrombin
receptors (Debacker, M. D., et al. 1993, Hess, J. F., et al. 1992, Hirata, M., et
al. 1991, Peralta, E. G., et al. 1987, Probst, W. C., et al. 1992, Vu, T. K. H„ et
al. 1991). Thus the different conserved sequences in the transmembrane
a-helix might affect the receptor's capacity to couple to PLD through ARF,
and other small G proteins. The variation in the amino acid composition
of TMD 7, does not appear to have a major influence on the coupling of
the M3, B2, Hi, TXA2 and thrombin receptors to Gq/n and the resulting
breakdown of inositol phosphates by PLC, since they all readily activate
the pathway (as described by previous studies carried out on the receptors
in 1321N1 cells) (Hepler, J. R., et al. 1987, Jones, L. G., et al. 1989, Masters, S.
B., et al. 1984, Nakahata, N., et al. 1985, Nakahata, N., et al. 1989, Nieto, M.,
et al. 1994). The sound coupling of the M3, B2, Hi, TXA2 and thrombin
receptors to PLC, and the involvement of PLC in the activation of PLD as
described in other systems, such as the PDGF, EGF and GnRH receptors
(Yeo, E.-J. and J. H. Exton 1995, Yeo, E.-J., et al. 1994, Zheng, L., et al. 1994),
suggested the possibility that PLD activation by the M3, B2, Hi, TXA2 and
thrombin receptors might be downstream of phosphoinositide hydrolysis.
The M3 and thrombin receptors were used as prototypical examples of an
NPX2-3Y and DPX2-3Y-containing receptors. The results of experiments
using the selective PLC inhibitor U73122, presented in Figure 3.3 suggest
that the thrombin receptor, but not the M3 receptor, activates PLD
primarily through PLC activation. The agonist-stimulated M3 and
thrombin receptors both stimulate PLC and bring about the almost
identical redistribution of PKCa and 8, the only PKC isoforms detectable
in 1321N1 cells (Nieto, M., et al. 1994, Trilivas, I., et al. 1991). Furthermore
the downregulation of PKC isoforms in 1321N1 cells by prolonged
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treatment with phorbol 12-myristate 13-acetate (PMA) blocked the
carbachol-stimulated activation of PLD (Martinson, E. A., et al. 1989,
Martinson, E. A., et al. 1990). This is in agreement with the role of PKC-a
as a co-factor for the activation of PLD. This role of PKC is proposed by
various investigators to be independent of protein phosphorylation
(Conricode, K. M., et al. 1992, Hammond, S. M., et al. 1997, Ohguchi, K., et
al. 1995, Ohguchi, K., et al. 1996, Singer, W. D., et al. 1995, Singer, W. D., et
al. 1996). Therefore the stimulation of PLD by the thrombin receptor in
1321N1 requires the activation of PLC with a probable rise in PKC activity
as reported for the activation of PLD by thrombin in human endothelial
and C2C12 myoblast cells (Garcia, J. G. N., et al. 1992, Vasta, V., et al. 1998).
However the M3 receptor appears to activate PLD largely via an
alternative, small G protein route with much lesser dependence on
phosphoinositide hydrolysis, yet may still require PKC acting as a
synergistic cofactor, perhaps independent of its kinase activity.
Diglyceride production by M3 receptor stimulation of PLD and
phosphatidic acid phosphohydrolase (PPH) may be enough to cause PKC
translocation in the presence of U73122, otherwise any residual PLC
activity not blocked by U73122 may cause the translocation. The apparent
absence of thrombin receptor coupling to ARF and RhoA in its activation
of PLD, may be a reflection of its different alpha-helical structure in TMD
7.
The coupling of the M3 and thrombin receptors to proteins of the Gi/0
family has been reported. The selective activation of Gcqi and Gai3 by the
Mi, M2 and M3 receptors expressed in HEK cells, and the binding of
GTPyS to G proteins stimulated by carbachol binding on transfected M3
receptors in Chinese hamster ovary (CHO) cells, was inhibited by PTx
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(Burford, N. T., et al. 1995, Offermanns, S., et al. 1994). Moreover the
activation of a PLC-mediated chloride current in Xenopus oocytes by the
M3 receptor was enhanced by co-expression of Ga0i (Fujii, K., et al. 1996).
Thrombin-stimulated activation the p21Ras/MAP kinase pathway via Gi/0
proteins is well reported. The rapid and transient activation of Ras by the
thrombin receptor in CCL39 cells, is sensitive to pertussis toxin (van
Corven, E. J., et al. 1993). Furthermore the mitogenic effect of thrombin in
1321N1 cells is dependent on the activation of Ras (LaMorte, V. J., et al.
1993). In addition stimulation of Ca2+ release and DNA synthesis in
CCL39 cells by a peptide agonist of the thrombin receptor, was inhibited by
micro-injection of antibodies to both Gotq and Ga0 (Baffy, G., et al. 1994).
Thrombin also inhibits agonist-stimulated adenylate cyclase activity in
both membrane preparations and intact human platelets (Brass, L. F., et al.
1991), and the activation of PLC by thrombin, in Chinese hamster CCL39
cells was sensitive to pretreatment with PTx (Paris, S. and J. Pouyssegur
1986). However the results presented in this study demonstrate that there
was no involvement of pertussis-sensitive G proteins from the Gi/0
family in the activation of PLD by either the M3 or thrombin receptors.
Incubation of 1321N1 cells with 200 ng/ml of PTx had no significant effect
on the carbachol and/or thrombin-evoked PLD activity (Figure 3.4).
Previous reports have also indicated that the M3 receptor in 1321N1 cells
do not interact with Gi/0 proteins in the receptor stimulation of
phosphoinositide hydrolysis and activation of a cAMP phosphodiesterase
(Hughes, A. R., et al. 1984, Masters, S. B., et al. 1985).
The involvement of the small G protein, Rho, in the activation of PLD
was first reported by Bowman et al., who demonstrated that the
stimulation of PLD by GTPyS in neutrophil cell lysates was inhibited by
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the Rho GDP-dissociation inhibitor (GDI) (Bowman, E. P., et al. 1993).
This work was confirmed by subsequent studies using membranes from
HL-60 cells, neutrophils, rat liver (Kwak, J. Y., et al. 1995, Malcolm, K. C.,
et al. 1994, Ohguchi, K., et al. 1995, Siddiqi, A. R., et al. 1995), and partially
purified extracts of rat and porcine brain, human placenta and porcine
aortic endothelial (PAE) cells (Cross, M. J., et al. 1996, Kuribara, H., et al.
1995, Singer, W. D., et al. 1995, Vinggaard, A. M., et al. 1997). Furthermore
the addition of recombinant forms of the Rho and the related Rho-family
proteins Racl and Cdc42 to membranes previously treated with Rho-GDI
(to extract Rho family proteins) resulted in restoration of GTPyS-
stimulation of PLD (Kwak, J. Y., et al. 1995, Malcolm, K. C., et al. 1994,
Siddiqi, A. R., et al. 1995). Recombinant Rac was also able to mediate
activation of PLD by treatment of fibroblasts with epidermal growth factor
(EGF) (Hess, J. A., et al. 1997), and recombinant Cdc42 is an activator of the
partially purified PLD activity from porcine brain (Singer, W. D., et al.
1995). Rho was defined as an activator of the cloned human PLD1
enzyme by Hammond et al. (Hammond, S. M., et al. 1997). Recent work
on the M3 receptor stably expressed in HEK cells has shown that
carbachol-stimulation of PLD in these cells is mediated in part by Rho
proteins. Rho can be inactivated by monoglucosvlation by Clostridium
difficile toxin B (Just, I., et al. 1994, Just, I., et al. 1995), and ADP-
ribosylation by Clostridium botulinum C3 exoenzyme (Aktories, K., et al.
1988, Aktories, K., et al. 1987, Paterson, H. F., et al. 1990, Ridley, A. J. and A.
Hall 1992, Sekine, A., et al. 1989). The activation of PLD by the M3
receptor expressed in HEK cells and direct stimulation by GTPyS and
AIF4", was sensitive to both toxin B and C3 exoenzyme (Schmidt, M., et al.
1996, Schmidt, M., et al. 1996). As shown in Figure 3.4, the Rho inhibitor
C3 exoenzyme significantly (p<0.05) reduced the carbachol- but not
3-20
thrombin-stimulated PLD response, compared to the agonist stimulated
response. The wtRhoA construct was able to increase the PLD response
elicited by a low concentration of carbachol (20 pM). However the
wtRhoA construct had no analogous effect on the PLD activity stimulated
by a low concentration of thrombin (0.2 Units/ml). Moreover the
negative RhoA construct inhibited the carbachol- but not the thrombin-
induced PLD activity. Therefore the M3, but apparently not the thrombin
receptor can couple to PLD through both ARF and RhoA in 1321N1 cells,
as already proposed for stably expressed M3 receptors in HEK cells
(Riimenapp, U., et al. 1995, Schmidt, M., et al. 1996, Schmidt, M., et al.
1996).
Close association of receptorwith G proteins
The interaction of receptor and G protein is a close one, and work done
using antibodies directed against G proteins, reconstitution experiments,
synthetic receptor intracellular loop peptides, mutation of i2 and i3 and
receptor-G protein crosslinking experiments loops all contribute to the
evidence for a close interaction (reviewed in (Bourne, H. 1997,
Gudermann, T., et al. 1996, Savarese, T. M., et al. 1992, Wess, J. 1997)). For
example the carboxy terminal tail of the a subunit of transducin (Gt),
especially the last 5 amino acids interact directly with rhodopsin (Conklin,
B. R., et al. 1993, Dratz, E. A., et al. 1993, Garcia, P. D., et al. 1995, Hamm, H.
E., et al. 1988). Also a peptide representing the Ci3 of the (^-adrenergic
receptor could be crosslinked to the alpha and beta subunits of G0 (Taylor,
J. M., et al. 1994). This direct association is further supported by the cross-
linking of the agonist bound VIPi receptor to Gs (Kermode, J. C., et al.
1992). Immunoprecipitation approaches have also shown a direct
interaction of the a2a-adrenergic, 5-HTia receptors with Gop (Okuma, Y.
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and T. Reisine 1992, Raymond, J. R., et al. 1993) and the ji and 5 opioid
receptors with Ga0 (Georgoussi, Z., et al. 1995). In our case the co-
precipitation of [3H]NMS binding sites with ARF1/3 and RhoA, supports
the close interaction of the M3 receptor with these small G proteins
(Figure 3.5). There was no specific association of thrombin receptor with
ARF1/3 and RhoA, as shown in Figure 3.6, by the lack of recovery of
thrombin receptor ligand (Feng, D. M., et al. 1995) i.e. [125I]TRP binding
sites in ARF1/3 and RhoA immunoprecipitates. The association of the
M3 receptor with ARF1/3 and RhoA was dependent on pre-exposure of
1321N1 cells to carbachol (100 llM, for 10 mins). The inability of the
polyclonal ARF1/3 and RhoA antibodies to co-precipitate [3FI]NMS
binding sites, from 1321N1 cells not exposed to agonist, is consistent with
the reports of the translocation of ARF1/3 and RhoA from the cytosol to
the cellular membranes in response to agonist (Floule, M. G., et al. 1995,
Malcolm, K. C., et al. 1996, Riimenapp, U., et al. 1995). We infer that the
redistribution of the ARF and Rho proteins allows the receptor to newly
interact with them and perhaps other cofactors. In addition, occupation of
the receptor by agonist may be a prerequisite for conformational changes
permissive to docking of ARF/Rho (or their intermediaries). The
incubation of the 1321N1 cells with 100 jiM BFA, during the priming
process, reduced the quantity of [3F1]NMS sites co-precipitated by ARF1/3
polyclonal antibodies by 74 ± 19% (data not shown). The effect of BFA will
be to block the exchange of guanine nucleotides on ARF, and this
inhibition will prevent the association of soluble ARF proteins with
membranes (Donaldson, J., et al. 1992, Helms, J. B. and J. E. Rothman 1992,
Randazzo, P. A., et al. 1993). This may prevent ARF interacting with other
cofactors and the receptor, or alternatively directly interacting with the
receptor. The co-precipitation of the M3 receptor could be dramatically
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reduced to control levels by the inclusion of excess ARF1/3 or RhoA
peptide antigen, demonstrating that the [3H]NMS binding sites were
associated with authentic ARF and Rho proteins. The lack of specific
[l25f]TRP binding in RhoA immunoprecipitates, is interesting as the
employment of Rho proteins, downstream of thrombin receptor
activation is widely reported. Other routes of Rho activation may of
course be involved in these circumstances, which do not relate to the
relatively direct docking processes seen for example with the M3 receptor.
Thrombin-stimulation of NIE-115, NG108-15 cells and astrocytes causes
neurite retraction and rounding of the cell body (Jalink, K. and W. FT
Moolenaar 1992, Jalink, K., et al. 1994), Moreover in NIE-115 and NG108-
15 cells, thrombin has been shown to activate Rho, and the reported
thrombin-evoked morphological changes were Rho-dependent and
blocked by treatment of these cells with C3 exoenzyme (Jalink, K. and W.
H. Moolenaar 1992, Jalink, K., et al. 1994). The Rho family of proteins are
known to regulate the morphological responses and actin cytoskeleton,
including formation of actin stress fibre and focal adhesions (Hall, A. 1992,
Ridley, A. J. and A. Hall 1992). More importantly thrombin was found to
induce an increase in DNA synthesis and the rounding of 1321N1 cells, a
reversal of their normally stellate morphology, moreover carbachol, LPA
and bradykinin-stimulation of 1321N1 cells did not cause cell rounding
(Majumdar, M., et al. 1998). The rounding of 1321N1 cells and the
increase in DNA synthesis was completely abolished by treatment of cells
with C3 exoenzyme. It is apparent that both the thrombin and M3
receptors can couple to Rho, however only the M3 receptor employs a
close association with Rho, and ARF, in the activation of PLD. The
coupling of the thrombin receptor to Rho in 1321N1 cells is upstream of
increases in DNA synthesis and cell rounding. Recently the coupling of
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the thrombin receptor to the increases in gene expression, increases in
DNA synthesis and mitogenesis in 1321N1 cells was shown to be
downstream of the receptor coupling to G12 (Aragay, A. M., et al. 1995,
Post, G. R., et al. 1996). Similarly the thrombin receptor in platelets
interacts with G12 and G13 (Offermans, S., et al. 1994). The G12 and G13
proteins have been shown to interact specifically with the mammalian
Rho guanine nucleotide exchange factor Lsc/pll5RhoGEF2, and
furthermore G13 stimulates GDP/GTP exchange on Rho in the presence of
Lsc/pll5Rb°GEF (Hart, M. J., et al. 1998, Kozasa, T., et al. 1998). The G12
protein can inhibit the stimulation of Rho GDP/GTP exchange by Gi3, and
may represent a mechanism by which GPCRs can moderate the level of
Rho activation (Hart, M. J., et al. 1998). It is also possible that G12
stimulates another closely related Rho guanine nucleotide exchange
factor. Thus the thrombin receptor may interact closely with G12 and Gi3,
leading to a subsequent increase in Rho activity and the rearrangement of
the actin cytoskeleton. Similarly the coupling of the TXA2 receptor to G12
and G13 in platelets suggests similar signalling characteristics for both
DPX2-3Y containing receptors (Offermans, S., et al. 1994).
The close association of the M3 receptor with small G proteins was further
investigated using the immunodetection of ARF and Rho in the
immunoprecipitates produced using polyclonal antiserum raised against
the M3 receptor (Wall, S. J., et al. 1991). The authenticity of the ARF and
Rho proteins in immunoprecipitates produced using polyclonal antisera
against ARF1/3 (Martin, A., et al. 1996), or RhoA (Laudanna, C., et al.
1996) was confirmed by immunoblotting of polyclonal
immunoprecipitates with monoclonal antibodies (Figure 3.7). As shown
in Figure 3.8 the immunoprecipitation of authentic ARF and Rho from
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the membrane fraction of 1321N1 cells, using M3 receptor antiserum, was
dependent on the exposure of cells to carbachol. Similarly, recovery of
authentic ARF1/3 and RhoA from membrane-derived
immunoprecipitates, directed against those proteins was greatly enhanced
by carbachol priming (Figure 3.7, and data not shown). This would be
consistent with the hypothesis that carbachol priming allows an essential
translocation of ARF and Rho to the membrane as reported previously
(Houle, M. G., et al. 1995, Malcolm, K. C., et al. 1996, Rumenapp, U., et al.
1995). The use of non-immune reagents did not co-precipitate
immunoreactive ARF or Rho, and antibody blocking with excess peptide
antigen confirmed the specificity of the interactions.
Close association of receptors and G proteins in ex vivo tissue
The body of work described here suggests that in response to agonist, the
GPCRs that contain the conserved NPX2-3Y, but not the DPX2-3Y motif,
activate PLD via a close association with the small G proteins ARF and
Rho. A prototypical NPX2-3Y receptor, the M3 muscarinic receptor, but
not the DPX2-3Y-containing thrombin receptor, can form a close
association with the small G proteins ARF and Rho. The presence of the
NPX2-3Y sequence within the TMD 7 is suggested as a key determinant,
controlling the selectivity of this coupling. The importance of the NPX2-
3Y motif in the close interaction of small G proteins was further
confirmed using the ATi receptor which is natively expressed in
lactotrophs of the male rat anterior pituitary gland. The ATi receptor
activates PLD in a BFA-sensitive manner, consistent with the idea of an
ARF-dependent mechanism being necessary. Moreover the
immunoprecipitation of ATi receptors with polyclonal antibodies also co-
precipitated immunoreactive ARF in an agonist-dependent manner, this
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is shown clearly in Figure 3.10. The co-precipitation of ARF with anti-
ATi receptor antiserum was specific for the ATi receptor, as the presence
of excess blocking peptide, prevented the co-precipitation of ARF.
Selectivity of NPX2-3Y/DPX2-3Y receptor interaction with G proteins
The interaction of the muscarinic M3 receptor with the selection of G
proteins in 1321N1 cells, and the modulation of receptor affinity for
agonist and PLD activation was further investigated. The stimulation of
cellular G proteins in digitonin-permeabilized 1321N1 cells with GTPyS,
BeF3~ or GPPCHnP, decreased the receptor affinity for carbachol, thereby
increasing the concentration of agonist required to displace 50% of the
bound [3H]NMS. GTPyS was the most potent agent at reducing the
receptor affinity for agonist, and its effectiveness did not significantly
change in control or agonist primed cells. BeFs" was more effective at
increasing the IC50 for carbachol, compared to GPPCHbP in control treated
cells. However once pre-exposed to 20 pM carbachol, GPPCH2P was more
effective than BeF3~ at decreasing receptor affinity for agonist, as shown in
Table 3.1a. The stimulation of G proteins with GTP analogues, is
generally considered to prevent their interaction with receptors and
convert the receptor to a state with low affinity for agonist. The priming
of 1321N1 cells appears to increase the receptor interaction with GPPCH2P-
activated G proteins, and not those sensitive to BeF3~. The BeF3~ induced
reduction in receptor affinity for carbachol was attenuated in the
membranes of cells that had been primed with agonist. In contrast,
priming potentiated the ability of GPPCH2P to decrease the receptor
affinity for carbachol. These results suggest that once exposed to agonist
the receptor increases its recruitment of GPPCH2P- but not the BeFs"-
sensitive G proteins and the association with receptor restores a high
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affinity receptor state, which can be observed by its uncoupling in the
presence of relevant GTP analogues. GTPyS is a potent activator of both
trimeric and small G proteins, whereas fluoride complexes of aluminium
have been shown to activate the Gs, Gi, and Gq, G proteins (Guillon, G., et
al. 1986, Howlett, A. C., et al. 1979, Katada, T., et al. 1984, Sternweis, P. C.
and A. G. Gilman 1982). However fluoride complexed to aluminium (or
beryllium, a more rigid isostere), have been proposed to be an activator of
trimeric but not small G proteins (Bigay, J., et al. 1987, Kahn, R. A. 1991).
Nonetheless, AIF4-, has recently been shown to bind to the GDP-bound
form of Ras, Ran, Rap and Cdc42, although whether activation ensued
was not shown, and effects on ARF were not also not reported
(Ahmadian, M. R., et al. 1997). Analogues of GTP containing (3y-
methylene groups such as GPPCH2P, are known to be potent activators of
ARF, Rab5 and other small G proteins, although they are ineffective
stimulators of trimeric G proteins and Ras (Gill, D. M. and J. Coburn 1987,
Hoffenberg, S., et al. 1996). Therefore it seems likely that priming recruits
small G proteins to the receptor and this might be the mechanism by
which the M3 receptor is maintained in a high affinity state. The
distribution of trimeric G proteins at the plasma membrane would allow
them to be activated first by the ligand bound receptor. The translocation
of small G proteins from the cytosol to the receptor may represent a
secondary effect initiated by of agonist binding.
The activation of PLD was also modulated by the incubation of
permeabilized 1321Nls with GTP analogues. GTPyS, BeF3~ and GPPCH2P,
stimulated a 150 ± 9, 115 ± 14 and 48 ± 8% increase in PLD activity in
1321N1 cells not previously exposed to agonist. The direct activation of
PLD by BeF3~ was approximately 2.4 times the response elicited by
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GPPCH2P. This may reflect a greater capacity of the trimeric G proteins to
activate PLD, independent of receptor stimulation. The GPPCTbP- but not
the BeF3_-induced increase in [3H]PtdBut, was inhibited by BFA and C3
exoenzyme, demonstrating the involvement of ARF and Rho, and
consistent with the preference of GPPCFbP for small G proteins. Pre¬
exposure of the 1321N1 cells to 100 pM carbachol, was sufficient to cause
detectable changes in the characteristics with which the cellular
complement of PLD was regulated by G proteins (Table 3.1b). The GTP7S-
induced activation of PLD did not significantly vary from the activity in
unprimed cell, consistent with the activation of all G proteins. However
the BeF3~-stimulated PLD activity decreased by 32 ± 9% in primed,
compared to unprimed cells. Conversely the GPPCH2P-induced PLD
activity increased by 56 ± 7% in primed 1321N1 cells. Consequently these
results are in agreement with the hypothesis that exposure to agonist
leads to the increased involvement of small but not trimeric G proteins in
mechanisms leading to the activation of membrane PLD. The drastic
reduction by BFA and C3 exoenzyme, of the GPPCH2P-induced PLD
response in primed cells, confirms a key role for ARF and Rho in these
responses.
Potentially relevant structural motifs in receptors
The NPX2-3Y- and not the DPX2-3Y-containing receptors thus appear to
form functional interactions with ARF and Rho in the activation of PLD.
The conservation of the N/DPX2-3Y sequence across the evolution of
GPCRs points to an important role in the functioning of the receptor. A
recent model of the aminergic GPCRs suggests that the N/DPX2-3Y
sequence is ideally placed to receive a signal from agonist-induced
conformational changes in the ligand binding domain (Donnelly, D., et al.
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1994, Findlay, J. B. C, et al. 1993). The asparagine and tyrosine residues
conserved within the TMD 7 motif are proposed to participate in a
hydrogen- (H) bonding network, involving other TMDs (Ballesteros, J., et
al. 1998, Fanelli, F., et al. 1995, Flunyady, L., et al. 1995, Konvicka, K., et al.
1998, Liu, J., et al. 1995, Oliveira, L., et al. 1994, Perlman, J. FL, et al. 1996,
Scheer, A., et al. 1996). The role of the aspartate residue of the DPX2-3Y
motif in Fl-bonding to other amino acids has not been probed, although
in mutants of the (H and TRH receptor, aspartate could in part substitute
for asparagine with regard to receptor activation (Barak, L. S., et al. 1995,
Perlman, J. H., et al. 1997). However replacement of this conserved
asparagine with alanine in the TRH, P2, ATi and 5-HT2A receptors
significantly inhibited or abolished appropriate second messenger
responses (Barak, L. S., et al. 1995, Hunyady, L., et al. 1995, Perlman, J. H.,
et al. 1997, Sealfon, S. C., et al. 1995). Therefore the conservative nature of
the aspartate substitution in the TRH and receptors fits the idea that
aspartate can fulfil an asparagine's H-bonding commitments.
Inter-helical interactions and receptor activation
Molecular models for the arrangements of GPCRs have been described by
Baldwin et al., based upon the conservation of amino acids, hydropathy
and alignment of multiple GPCR sequences, and using the low resolution
map for rhodopsin described by Schertler et al. as a template (Baldwin, J.
M. 1993, Schertler, G. F. X., et al. 1993). The orientation of the
transmembrane helices derived from these modelling experiments place
TMDs 1, 2, 3 and 7 in close proximity to each other. Moreover, molecular
modelling of various GPCRs has consistently implicated a network of
hydrogen- (H) bonding between TMDs 1, 2, 3 and 7 in the regulation of
receptor conformation (Fanelli, F., et al. 1995, Konvicka, K., et al. 1998,
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Oliveira, L., et al. 1994, Scheer, A., et al. 1996, Scheer, A., et al. 1997)
Furthermore, these models are in agreement with the experimental
evidence from mutagenesis studies pointing to helix-helix interactions in
the ATi, TRH, M3 and aie adrenergic receptors (Hunyady, L., et al. 1995,
Liu, J., et al. 1995, Perlman, J. H., et al. 1997, Scheer, A., et al. 1996), and
numerous other receptors reviewed by Baldwin et al. (Baldwin, J. M. 1993,
Baldwin, J. M. 1994). The amino acids involved in the proposed H-
bonding network are numbered according to a scheme described by
Ballesteros and Weinstein (Ballesteros, J. A. and H. Weinstein 1995). The
scheme consists of a digit identifying the transmembrane domain (1 to 7),
and the number describing the position in the domain relative to the
most conserved amino acid in that helix, which is given the number 50.
The amino acids involved include the most highly conserved amino
acids N1.50, D2.50, D3.49, R3.50, N7.49 and Y7.53. The molecular
modelling of the M3, aie-adrenergic, TRH and 5-HT2A receptors, using
molecular dynamic or other receptor conformational simulations of the
H-bonding system implicates a group of highly conserved polar amino
acids in the regulation of receptor function (Fanelli, F., et al. 1995,
Konvicka, K., et al. 1998, Perlman, J. H., et al. 1997, Scheer, A., et al. 1996).
These investigators propose hydrogen bonding interactions between the
amino acids, N1.50, D2.50, R3.50, N7.49, and Y7.53 in these receptors. The
N7.49 and Y7.53 residues are the asparagine and tyrosine residues that are
part of the NPX2-3Y sequence. The conserved N1.50 is proposed to H-
bond with D2.50 and N7.49 in the ccib, TRH and 5-HT2A receptors, acting
as a type of polar bridge (Konvicka, K., et al. 1998, Perlman, J. H., et al.
1997, Scheer, A., et al. 1996), In the 5-HT2A receptor modelling also
suggests a H-bond interaction of between the N1.50 and Y 7.53 (Konvicka,
K., et al. 1998). In the ocib and M3 receptors, molecular dynamic
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simulations of receptor conformation propose that R3.50 H-bonds to D1.50
(Fanelli, F., et al. 1995, Scheer, A., et al. 1996). The N1.50, D2.50, N7.49, and
Y7.53 conserved amino acid residues form a "polar pocket", highlighted
previously in modelling studies (Fanelli, F., et al. 1995, Oliveira, L., et al.
1994, Trumpp-Kallmeyer, S., et al. 1992), in which the conserved amino
acid R3.50 sits. The residue R3.50 is part of the highly conserved DRY
sequence at the beginning of the second intracellular loop (i2),
mutagenesis studies have shown that the conserved DRY motif is
important in the receptor coupling to G protein (Gudermann, T., et al.
1996, Probst, W. C., et al. 1992, Savarese, T. M. and C. M. Fraser 1992, Wess,
J. 1997). Once agonist binds, the conserved aspartate (D3.49), of the DRY
motif is protonated and the polar pocket formed by the conserved amino
acids is perturbed, resulting in the displacement of the conserved R3.50.
The shift in the position of R3.50 is proposed to allow amino acids in i2
and i3 to achieve a correct conformation for G protein coupling (Fanelli,
F., et al. 1995, Scheer, A., et al. 1996, Scheer, A., et al. 1997). Studies with
wild-type and mutant rhodopsin receptors are consistent with the
proposal that the neutralisation of the acidic amino acid (Glu or Asp)
preceding the conserved R3.50, is required for the adjacent R3.50 side
chain to achieve an orientation that is suitable for receptor interactions
with G proteins (Acharya, S. and S. S. Karnik 1996, Amis, S., et al. 1994,
Scheer, A., et al. 1996, Scheer, A., et al. 1997). In agreement with this
concept, mutational studies have shown that replacement of the
conserved Glu/Asp in the ocib receptor or rhodopsin with neutral amino
acids, leads to receptors that are constitutively active (Amis, S., et al. 1994,
Cohen, G. B., et al. 1993, Scheer, A., et al. 1996, Scheer, A., et al. 1997). The
replacement of a conserved asparagine with serine in the M3 receptor,
which also causes the spatial displacement of the R3.50, was found to
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activate the receptor (Bliiml, K., et al. 1994, Fanelli, F., et al. 1995). These
findings are in agreement with the hypothesis of Oliveira et al. that
binding of an agonist may initiate a conformational change which shifts
the side chain of the conserved R3.50, and favours receptor-G protein
coupling (Oliveira, L., et al. 1994). Differences in the H-bonding
behaviour of the aspartate residue at position 7.49, compared to the
asparagine are likely to greatly effect the movement of the arginine of the
DRY motif. Therefore the 5% of class I GPCRs which carry the DPX2-3Y
motif, may exhibit an altered maintenance of the H-bonding pattern and
the ionic environment around the conserved R3.50.
Further studies with the M3 receptor demonstrate the importance of the
proline residue within the NPX2-3Y motif. Wess et al., show that the
mutation of the proline residue to alanine, reduced expression of the
mutant M3 receptor by 35 times, compared to wild type receptor. This
suggests that the conserved proline residue may play an important role in
inducing or maintaining a proper protein fold that allows efficient
receptor translocation and insertion into the plasma membrane.
Moreover the mutation also significantly inhibits the inositol phosphate
hydrolysis stimulated by carbachol (Wess, J., et al. 1993). Mutation of the
proline residue in the M3 receptor as with any other receptor, will
eliminate the kink in the a-helix that a proline residue will generate
(Brandl, C. J. and C. M. Deber 1986, von Heijne, G. 1991, Williams, K. A.
and C. M. Deber 1991). The presence of the proline kink appears to be
essential for the receptor to couple to G proteins properly. Konvicka et al.
propose that the Asn/Asp-Pro motif conserved in TMD 7 is required for
the proper function of the receptor, by acting as helix-breaker and
producing a flexible hinge that allows the TMDs to H-bond in the correct
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manner (Konvicka, K., et al. 1998). The role of prolines in the induction
of kinks in protein structure is well reported (Brandl, C. J. and C. M. Deber
1986, von Heijne, G. 1991, Williams, K. A. and C. M. Deber 1991).
However the NP and/or DP motif is proposed to induce a pronounced
Pro-kink, with which the receptor is able to enter into different patterns of
H-bonding. This matches the prediction from both computational and
empirical methodologies, based on satisfying the propensity of polar
residues buried within soluble proteins to stabilise themselves by H-
bonding to other polar residues (Konvicka, K., et al. 1998, McDonald, I. K.
and J. M. Thornton 1994).
The N/DPX2-3Y sequence is within an area of the receptor that is close to
the G protein-coupling surface of the intracellular loops, and suggested by
modelling studies to be ideally placed to receive signals from the ligand
binding domain (Donnelly, D., et al. 1994, Findlay, J. B. C., et al. 1993). The
negative effects of removing the conserved asparagine, proline and
tyrosine residues at positions 7.49, 7.50, and 7.53 point to a role for them in
maintaining the proper receptor conformation, and allowing the receptor
to transduce extracellular signals productively. The activation of a
receptor is proposed to involve the rotation of helices and relative
opening the receptor intracellular surface, to expose domains of the
receptor necessary for G protein coupling, such as the second and third
intracellular loops (Farrens, D. L., et al. 1996, Luo, X., et al. 1994, Sheikh, S.
P., et al. 1996, Wess, J. 1997). The close interaction of the NPX2-3Y- but not
the DPX2-3Y-containing receptors with ARF and Rho proteins implicates
the asparagine residue in TMD 7 in the regulation of a receptor
conformation that, upon agonist binding can selectively couple to small G
proteins (or potentially their intermediaries). The participation in the
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proposed H-bonding network through conserved amino acid residues in
TMDs 1, 2, and 3, would fulfil this regulatory role, and the pronounced
flexibility generated by the Asx-Pro combination is proposed to make this
physically possible (Konvicka, K., et al. 1998). The contrast in the G
protein-coupling of the NPX2-3Y and DPX2-3Y receptors, and their
activation of PLD, may be a result of differences in receptor conformation.
The acidic nature of the aspartate side chain may result in an altered H-
bonding pattern between TMDs, relative to the uncharged asparagine, and
an associated conformational difference. The complete conservation of
the N/DPX2-3Y sequence, and the high degree of conservation observed
for the other polar amino acids within the transmembrane helices of the
class I family, makes them unlikely as the final determinants of the wide
variety of G protein coupling observed in this family. However, the
diversity of receptor-G protein interactions, as determined by other
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Table 3.1 The effects of GTP analogues on agonist recognition by M3
receptors and on PLD activation in 1321N1 cells
Assay and treatment GTP analogue
GTPyS F" GPPCH?P
(a) Carbachol affinity for
membrane [3H]NMS binding
sites (fold increase in IC50)
control 5.23 ±0.97 4.06 ± 0.80 2.31 ± 0.34
carbachol-primed 4.48 ± 0.34 1.82 ± 0.31§ 3.46 ± 0.40
(b) Activation of PLD in
digitonin-permeabilised cells
(% increase over basal)
control 150 ± 9
+ BFA
+ C3 exoenzyme -
carbachol-primed 168 ± 10
+ BFA
+ C3 exoenzyme -
*
115 ±14 48 ±8
117 ±9 31 ±3+
95 ±11 27 ±5+
78 ± 10§ 110 ± 12:
69 ±11 38 ±9+
85 ±9 23 ±7+
GTPyS, F" and GPPCH2P were present at 100 uM, 10 mM and 200 jiM respectively.
BFA and C3 exoenzyme were used at 100 llM and 4.8 |ig/ml respectively. All
values are means ± SEM, from 4-10 separate determinations. Statistically
significant differences (p<0.05 Mann-Whitney U test) are indicated: * greater than
corresponding unprimed; § less than corresponding unprimed; ^ reversal of GTP
analogue effect.
CHAPTER 4
The activation of PLD by wild
type and mutant GnRH and 5-
HT2A receptors
4.1 INTRODUCTION
The investigation of a role for the N/DPX2-3Y sequence in the receptor
coupling to PLD, described in Chapter 3, points to the importance of this
motif in the gating of the receptor-G protein coupling mechanism.
However the experiments relied on the use of different N/DPX2-3Y motif-
containing, Gq-linked receptors native to 1321N1 cells. Therefore it was
in the context of very different receptor structures that the influence of
the conserved sequence was being examined. Despite the strong
correlation observed between the motif structure and utilisation of
particular pathways, the involvement of receptor domains distinct from
the N/DPX2-3Y sequence cannot be excluded. In an attempt to
unequivocally define the influence of the N/DPX2-3Y motif in receptor
activation of PLD through small G protein-dependent and independent
pathways, we used the Gq-linked, wild type and mutant gonadotropin-
releasing hormone (GnRH) and 5-hydroxytryptamine (5-HT/serotonin)
2A receptors. The mutant form of these receptors had the residue at
position 7.49 (the use of this numbering scheme was described by
Ballesteros et al, and in Chapter 3 (Ballesteros, J. A. and H. Weinstein
1995)) replaced with the alternative aspartate or asparagine residue.
The mouse (Reinhart, J., et al. 1992, Tsutsumi, M., et al. 1992), rat (Eidne,
K., et al. 1992, Kaiser, U. B., et al. 1992), human (Chi, L., et al. 1993, Karkar,
S. S., et al. 1992), sheep (Brooks, J., et al. 1993, Illing, N., et al. 1992), and
cow (Karkar, S. S., et al. 1993) GnRH receptors are unique amongst the
class I GPCR family, in several respects, one of them being the complete
absence of a carboxy (C) terminal tail. This region is probably involved in
the mediation of desensitization and/or downregulation of some GPCRs
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(Dohlman, H. G., et al. 1991). The C-terminal tail of most receptors
contain consensus phosphorylation sites for PKC, protein kinase A (PKA),
and the G protein-coupled receptor kinases (GRKs). Phosphorylation of
the intracellular domains of GPCRs, including the C tail, by PKC, PKA
and GRKs is implicated in the desensitization process (Hausdorff, W. P.
1990, Inglese, J., et al. 1993). The wtGnRH receptor expressed in aT3-l or
GH3 cells showed no desensitisation of the receptor-stimulated InsP
production over 90 mins (Davidson, J. S., et al. 1994, Sealfon, S. C., et al.
1992). The absence of the C-terminal tail allows the interpretation that
any influence the N/DPX2-3Y motif has on G protein coupling is
mediated through the intracellular loops (or transmembrane domains)
and not the tail.
The wtGnRH receptor was chosen primarily because of the presence of an
aspartate at position 318 (7.49, Asp318) in TMD 7, thereby generating a
DPLIY sequence, and the receptor also has an asparagine at position 87
(2.50, Asn87) within the TMD 2. This arrangement of Asp and Asn
residues appears to be unique and reciprocal to the situation found in the
majority of class I GPCRs. Although the thrombin and TXA2 receptors
described in Chapter 3, possess the aspartate at position 7.49 in TMD 7 they
do not have the atypical asparagine in TMD 2 (Hirata, M., et al. 1991, Vu,
T. K. H., et al. 1991). Furthermore the human cytomegalovirus encodes a
receptor which possesses the atypical Asn 2.50, but also has the canonical
Asn at position 7.49 (Chee, M. S., et al. 1990). Mutagenesis and computer
modelling studies of the wtGnRH receptor, reported by Zhou et al, point
to the possible H-bonding of the Asn87 and Asp318 (Zhou, W. C., et al.
1994). The investigation of the N/DPX2-3Y motif in receptor G protein
coupling and stimulation of PLD was carried out on the wtGnRH receptor
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and single and double mutant receptors. The aspartate at 318 was replaced
with an asparagine (Asn318 mutant) in the single mutant, and the double
mutant also had the asparagine at position 87 replaced with an aspartate
(Asp87-Asn318 mutant) (Zhou, W. C., et al. 1994). These mutations
restore the arrangement of conserved Asp and Asn residues present in
the majority of class I GPCRs (Probst, W. C., et al. 1992).
A wild type and mutant form of the human type 2A 5-HT receptor were
used as comparisons for the experiments conducted using the wt and
mutant GnRH receptors. The wt5-HT2A receptor , like the majority of the
class I GPCR family has a conserved asparagine in TMD 7 (7.49, Asn376)
producing an NPLVY sequence (Saltzman, A. G., et al. 1991). This
receptor also possesses the conserved aspartate at position 120 (2.50,
Aspl20) in TMD 2, and as with the mouse GnRH receptor, mutagenesis
and computer simulation of the human 5-HT2A receptor conformation
upon activation, strongly implicates H-bonding between the conserved
Asn376 and Aspl20 residues (Sealfon, S. C., et al. 1995). The wt and a
single mutant of the 5-HT2A receptor, where the Asn376 was mutated to
Asp376 were used as comparison with the sequence inversion in the
GnRH receptors (and mutant) in tests on PLD activation.
In this way the wt and mutated forms of the GnRH and 5-HT2A receptors
allowed an investigation of the effect of either an NPX2-3Y or DPX2-3Y
sequence on receptor stimulation of PLD. Furthermore, with the use of
point mutants, any change in receptor coupling to small G proteins such




GnRH receptor signalling in response to agonist
The stimulation of PLC-mediated InsP production by the cloned wt and
the mutant forms of the GnRH receptor expressed in COS 1, COS 7 and
GH3 cells has been reported elsewhere (Arora, K. K., et al. 1996, Awara, W.
M., et al. 1996, Zhou, W. C., et al. 1994), and Figure 4.1 shows the time
course for the stimulation of phosphoinositide breakdown by the wild
type and mutant forms of the GnRH receptors. The wt, Asn318 and
Asp87-Asn318 mutant GnRH receptor expressed transiently in COS 7
cells, mediated phosphoinositide breakdown (as stimulated by 100 nM)
GnRH linearly over 40 minutes. The wild type receptor elicited a 4-5 fold
increase in InsP production after 40 min compared to time zero.
However the single and double mutant receptor were weaker in their
coupling to PLC, with InsP responses at 40 min of, 39 ± 6% and 19 ± 5% of
the wt receptor response. The weaker production of InsP by the mutant
forms of the GnRH receptor was not a result of a diminished capability of
COS 7 cells transfected with the mutant receptors to stimulate
phosphatidylinositol 4,5-bisphosphate breakdown per se. Production of
InsP by AlFC (10 mM NaF and 30 uM AICI3) (presumed to cause
stimulation of trimeric G proteins) was consistently stronger in COS 7
cells transfected with the Asn318 mutant GnRH receptor, at all time
points than that mediated by the wtGnRH receptor. The weaker responses
elicited by the mutant forms of the GnRH receptor, may be manifestations
of the lower receptor number expressed on the plasma membranes of the
transfected COS 7 cells and thus the maximal available binding sites for
ligand (Bmax). The Bmax for the wt, Asn318 and Asp87-Asn318 mutant
GnRH receptors was 589 ± 39, 230 ± 41 and 148 ± 36 fmol/mg protein
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respectively as determined by membrane binding (Mitchell, R., et al.
1998).
The wtGnRH receptor also stimulated [3H]PtdBut production linearly
over the 40 min time course, with a 2-3 fold increase in PLD activation by
the wtGnRH receptor after 40 min stimulation with 100 nM GnRH.
However the Asn318 and Asp87-Asn318 mutant GnRH receptors induced
a rapid increase in [3H]PtdBut production that was 2.5 fold larger at 5 min,
than the initial increase in PLD activity stimulated by the wt GnRH
receptor (Figure 4.2). The concentration dependence for the activation of
PLD by the wild type and the Asn318 mutant GnRH receptor was almost
identical with EC50S of 0.27 ± 0.10 nM and 0.16 ± 0.05 nM respectively, and
the effect of GnRH on PLD activation by both receptors was maximal by
100 nM (Figure 4.3). This enhanced coupling to PLD by the mutant GnRH
receptor is observed notwithstanding the poorer stimulation of InsP
production and lower Bmax described above. The PLD activity stimulated
by both the Asn318 and Asp87-Asn318 mutant GnRH receptors,
desensitised rapidly, in contrast to the linear PLC responses demonstrated
by these receptors in Figure 4.1. The stimulation of trimeric G proteins
with AIF4" caused non-desensitising stimulation of both PLC and PLD
(Figures 4.1 and 4.2).
The enhanced stimulation and rapid desensitization of PLD seen with the
mutant GnRH receptor may be due to an increased rate of receptor
internalization and coupling to PLD. The presence of PLD at intracellular
compartments has been described previously (Provost, J. J., et al. 1996,
Whatmore, J., et al. 1996), and using protein tagging of the enzyme, PLD1
has been localised to the golgi, ER and lysosomal compartments (Brown,
F. D., et al. 1998, Colley, W. C., et al. 1997, Hammond, S. M., et al. 1997).
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However as shown in Figure 4.4 the inhibition of internalization using
200 jiM monodansvlcadaverine (MDC) and 30 uM monensin, increased
rather than decreased the production of [3H]PtdBut mediated by the wt
and Asn318 mutant GnRH receptors, stimulated with 100 nM GnRH.
MDC and monensin were shown to prevent the internalization of
[125I]buserelin binding in COS 7 cells expressing the wt and Asn318
mutant GnRH receptor (R. Mitchell, unpublished observations). MDC
increased by 1.84 ± 0.15 and 3.52 ± 0.34 fold the production of [3H]PtdBut by
the wt and Asn318 mutant receptors respectively. Monensin increased
the PLD activity by 1.84 ± 0.23 and 2.49 ± 0.16 fold, for the same 100 nM
GnRH-stimulation of the wt and Asn318 mutant receptors. Although
there is the possibility of non-specific effects of these internalization
inhibitors at the concentrations used, these observations provided no
evidence of a requirement for receptor internalization to increase the
receptor coupling to PLD.
Involvement of PLC/PKC and ARF in the activation of PLD by the GnRH
receptors
The observations reported in Chapter 3 suggested that GPCRs containing
the NPX2-3Y sequence couple to PLD through ARF, whilst receptors with
DPX2-3Y appear to utilise PLC in their stimulation of PLD. Therefore the
activation of PLD by the wtGnRH receptor and the Asn318 mutant of the
receptor was assessed with the ARF inhibitor BFA. The [3H]PtdBut
production stimulated by 100 nM GnRH in COS 7 cells expressing the
Asn318 mutant GnRH receptor was significantly inhibited by BFA. By a
concentration of 200 jiM BFA, the Asn318 GnRH receptor-stimulated
PLD activity was reduced by 72 ± 10%, compared to the control response
with agonist alone, with an IC50 of 54 ± 8 gM. The wild type receptor
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activated PLD in a manner that was resistant to the actions of BFA up to
200 jiM (Figure 4.5). Flowever the PLC inhibitor U73122 significantly
reduced the wtGnRH receptor's activation of PLD with a IC50 of 11 ± 1 liM.
The Asn318 mutant receptor stimulated PLD in a PLC-independent
manner, as U73122 had no significant effect on the [3H]PtdBut production
induced by this receptor (Figure 4.6).
The stimulation of PLC can lead to an activation of PKC, and the
activation of PLD by the wtGnRH receptor may be a consequence of this
PKC activation. The activation of PLD bv PKC, and the effect of BFA onJ '
this stimulation was studied by stimulation of PKC using the selective
PKC inhibitor, GF 109203X (bisindolylmaleimide) (Toullec, D., et al. 1991),
was employed to investigate the role of PKC in the stimulation of PLD by
the wt and Asn318 mutant GnRH receptors. Figure 4.7 shows that the
[3H]PtdBut production stimulated by both receptors was inhibited by GF
109203X, with IC50 values for the wt and Asn318 GnRFI receptors of 1.24 ±
0.44 and 1.29 ± 0.13 jiM respectively, suggesting a role for PKC in the
activation of PLD by both receptors. Further inhibitors of PKC such as the
regulatory domain inhibitor calphostin C, were not tested, nor was the
strategy of down-regulating PKC isoforms by prolonged preincubation
with activating phorbol esters. The stimulation of PLD by direct
activation of PKC, and the effect of BFA on this response are shown in
Figure 4.8. PKC was stimulated using the calcium ionophore, ionomycin
and phorbol 12,13-dibutyrate (PDBu). Calcium ions are necessary for the
activation of the common PKC isoforms a, (31, (32 and y. Moreover, PDBu
mimics diacylglycerol, produced through the hydrolysis of PIP2 by PLC,
and activates PKC by interacting with a specific C2 lipid binding domain.
Interestingly, in contrast with the results obtained using GF 109203X, the
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activation of PLD by ionomycin and PDBu, as presented in Figure 4.8, was
resistant to BFA, implying that the activation of PKC isoforms that bind
calcium and /or possess the C2 lipid binding domain have no role in the
pathway(s) leading from receptor to ARF in the activation of PLD.
However these results do suggest that isoforms of PKC may be
downstream or synergize with ARF in the activation of PLD.
Receptor association with small G proteins: ligand binding studies on
ARF/RhoA immunoprecipitates
The association of the M3 muscarinic but not the thrombin receptor with
ARF and RhoA described in Chapter 3, suggests that ARF and Rho
proteins can interact closely with NPX2-3Y and not DPX2-3Y receptors.
The investigation of the wt and Asn318 mutant GnRH receptor's
association with ARF and RhoA was similar to that described in Chapter
3, using anti-ARFl/3 (Martin, A., et al. 1996) and anti-RhoA (Laudanna,
C., et al. 1996) polyclonal antibodies to immunoprecipitate specific GnRH
receptor binding sites. The data in Figure 4.9 show that specific
[125I]buserelin binding sites were co-immunoprecipitated with ARF1/3
and RhoA in COS 7 cells expressing the Asn318 mutant but not the wt
GnRH receptor. The presence of specific [125I]buserelin binding in
ARF1/3 and RhoA immunoprecipitates was dependent on the
preincubation of cells with 100 nM GnRH for 15 min. Priming with
GnRH significantly increases the level of [125I]buserelin binding in
ARF1/3 and RhoA immunoprecipitates 2.24 ± 0.24 fold and 3.25 ± 0.50
fold respectively, compared to unprimed controls (p<0.05, n = 4-8). COS 7
cells expressing the Asn318 mutant receptor, not preincubated with
GnRH, demonstrated a level of [125I]buserelin binding comparable to that
achieved using control antibodies to p21Ras and extracellular signal-
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related kinase (ERK) 1/2. The specific [12-l]buserelin binding associated
with the ARF1/3 and RhoA immunoprecipitates in primed COS 7 cells
expressing the Asn318 mutant GnRH receptor, could be reduced by 54 ±
9% and 73 ± 10% respectively, using excess ART or Rho peptide antigen.
This is analogous to the specific association of the M3 receptor with
ARF1/3 and RhoA, after exposure to agonist which was described in
Chapter 3.
The differential modulation by GTP analogues of [125I]buserelin binding
to GnRH receptors
The dissociation rate of [125I]buserelin from the wt and Asn318 mutant
GnRH receptor was investigated, and the effects of GTPyS, GPPNHP,
GPPCH2P and BeF3~ on this parameter in digitonin-permeabilized COS 7
cells were studied. The wt and Asn318 mutant GnRH receptor
demonstrated an initial decrease in [125I]buserelin binding that appeared
identical. Considering the way the experiment was set up with pre¬
loading of ligand at 4°C and the dissociation at 37°C this probably
represents a temperature-dependent reduction in ligand binding (Perrin,
M. H., et al. 1989). The results in Figure 4.10 display the modulation by
nucleotides of the slower rate of ligand dissociation from the receptors
occurring over the 15-50 min period after permeabilisation and transfer to
37°C. The slower rate for the dissociation of [125I]buserelin was composed
of a single linear element, with half-lives (ti/2) of 22 ± 3 min and 26 ± 3
min, for the wt and Asn318 mutant receptor respectively. Treatment of
digitonin-permeabilized COS 7 cells with increasing concentrations of
GTPyS significantly increased the dissociation rate of [125I]buserelin from
both the wt and Asn318 mutant GnRH receptors, in an almost identical
fashion (Figure 4.10a). The dissociation rate of [125I]buserelin in the
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presence of 100 pM GTPyS increased 1.72 ± 0.05 and 1.64 ± 0.06 fold
compared to the control rate of the wt and Asn318 mutant receptors
respectively. The GTP analogue GPPNHP was as effective as GTPyS in
significantly reducing the ti/2 for the dissociation of [125I]buserelin from
the wt and Asn318 mutant GnRH receptors (Figure 4.10b). The |3y-
methylene analogue of GTP; GPPCH2P, was able to significantly decrease
the half life for the dissociation of [125I]buserelin from the Asn318
mutant, but not the wt GnRH receptor. In the presence of 100 jiM
GPPCH2P the dissociation rate from the mutant receptor was increased by
1.58 ± 0.06 fold compared to control (Figure 4.10c). The incubation of
permeabilized COS 7 cells with fluoride ions in the presence of beryllium
produced the reciprocal result to that produced with GPPCH2P- The half
life for [125I]buserelin dissociation from the wtGnRH receptor was
significantly reduced by increasing concentrations of BeF3~ (Figure 4.10d).
The ti/2 of [125I]buserelin dissociation from the mutant receptor was not
significantly affected. The involvement of ARF in the modulation of the
ligand dissociation rate by the GTP analogues was investigated using
brefeldin A. COS 7 cells were pretreated with increasing concentrations of
BFA and then stimulated with 100 JiM GTPyS. As shown in Figure 4.10a,
GTPyS dramatically reduced the half life of [125I]buserelin dissociation .
In the presence of increasing concentrations of BFA, the GTPyS-induced
increase in dissociation rate from the Asn318 mutant GnRH receptor was
reversed (p<0.05, Figure 4.10e). The pretreatment of COS 7 cells with 100
(iM BFA restored the rate for the dissociation of [125I]buserelin from the
Asn318 mutant receptor to 85 ± 8% of the control rate. The increased rate
of [125I]buserelin dissociation from the wtGnRH receptor caused by GTPyS
was not significantly changed by BFA, as shown in Figure 4.10e.
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Activation of PLD by the wild type and a mutated form of the 5-HT2A
receptor
A wild type and mutant form of the 5-HT?a receptor were used as
controls for the effect of mutation at position 318 in the GnRH receptor, to
assess the role the N/DPX2-3Y sequence has in receptor coupling to PLD.
As with the majority of class I GPCRs, the 5-HT2A receptor contains an
NPX2-3Y sequence, and the mutant form of the receptor created by Sealfon
et al (Sealfon, S. C., et al. 1995), has the conserved asparagine at position
376 replaced by an aspartate residue, thereby producing the DPX2-3Y
sequence present in the wild type GnRH receptor. The cDNAs encoding
the wt and Asp376 5-HT2A receptor were transiently transfected into COS
7 cells, and the activation of PLD in response to receptor stimulation with
increasing concentrations of 5-HT is shown in Figure 4.11. PLD was
stimulated potently by the wt and Asp376 mutant 5-HT2A receptor with
respective EC50 values of 26 ± 13 and 28 ± 13 nM. The maximum level of
[3H]PtdBut production by stimulation of the wt and Asp376 5-HT2A
receptors was 1.60 ± 0.09 and 3.70 ± 0.70 fold of basal control. There was
some evidence to suggest raised basal [3H]PtdBut production in cells
expressing the wt but notAsp376 5-HT2A receptor, which may account for
the reduced signal in those cells (data not shown). This possibility was
not further investigated in the present study. The effects of BFA on the
stimulation of PLD by the two 5-HT2A receptors, was consistent with the
results obtained using the wt and mutant GnRH receptors. The wt 5-
HT2A receptor was sensitive to BFA with significant inhibition of the PLD
response, and an IC50 for BFA of 47+11 (iM. Furthermore the Asp376
mutant was insensitive to the ARF inhibitor with only 24 ± 13%




The stimulation of PLD and PLC by the wt and Asn318 mutant GnRH
receptor highlighted a radical difference in signal transduction capabilities
of the two receptors, and the importance of the conserved N/DPX2-3Y
motif. GnRH stimulates a rapid and prominent increase in
phosphoinositide turnover in cultured pituitary and ocT3-l gonadotroph
cells (Andrews, W. V. and P. M. Conn 1986, Naor, Z. and K. J. Catt 1981,
Schrey, M. P. 1985, Snyder, G. D. and J. E. Bleasdale 1982). The stimulation
of PLC by the wtGnRH receptor is mediated by Gq/n proteins in cultured
pituitary cells and in aT3-l gonadotrophs (Andrews, W. V., et al. 1986,
Hsieh, K.-P. and T. F. J. Martin 1992, Limor, R., et al. 1989, Shah, B. H. and
G. Milligan 1994). The wt and Asn318 mutant GnRH receptor stimulated
InsP production linearly over 40 min, as shown in Figure 4.1. This in
agreement with the PLC responses observed after activation of the wt and
mutant GnRH receptors expressed in COS 1 and GH3 cells (Awara, W. M.,
et al. 1996, Zhou, W. C., et al. 1994). and the non-desensitising InsP
production, stimulated by the wtGnRH receptor, reported by Davidson et
al and Sealfon et al (Davidson, J. S., et al. 1994, Sealfon, S. C., et al. 1992).
The stimulation of phosphoinositide breakdown by the Asn318 and
Asp87-Asn318 mutant GnRH receptors was greatly reduced, compared to
the response elicited by the wtGnRH receptor. The poorer coupling to
InsP turnover is in agreement with the investigation of the mutant
GnRH receptors expressed in COS 1, COS 7 and GH3 cells (Arora, K. K., et
al. 1996, Awara, W. M., et al. 1996, Zhou, W. C., et al. 1994). The reduced
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stimulation of InsP production appears to be due to a poorer coupling of
the Asn318 and Asp87-Asn318 mutant GnRH receptors to PLC, not just
reduced expression of the mutants. Awara et al, reported a weak
stimulation of phosphoinositide hydrolysis, despite a higher expression
of mutant receptors per cell compared to wild type GnRH receptors
(Awara, W. M., et al. 1996). Moreover taking into account the lower level
of Asn318 GnRH receptor expressed on the cell surface, Arora et al, also
reported a poorer receptor coupling to PLC (Arora, K. K., et al. 1996).
Therefore the change in amino acid residues at positions 87 and 318 may
diminish GnRH receptor coupling to InsP production, perhaps as a
consequence of a change in receptor conformation and the H-bonding
network discussed previously.
Receptor structure and desensitization
The demonstration of an increase in [3H]PtdBut production elicited by the
wtGnRH receptor is in agreement with reports of PLD activity stimulated
by GnRH in ovarian granulosa and aT3-lcells (Liscovitch, M. and A.
Amsterdam 1989, Netiv, E., et al. 1991, Zheng, L., et al. 1994). As with the
PLC response, PLD activation by the wt GnRH receptor did not rapidly
desensitize. The PAF receptor, which contains a DPX2-3Y motif (Honda,
Z., et al. 1991, Kunz, D., et al. 1992, Nakamura, M., et al. 1991, Probst, W.
C., et al. 1992), stimulates PLD, and the response wanes after 15-20
minutes. However with the removal of the C-terminal tail, the PLD
response is prolonged and does not desensitise (Liu, B., et al. 1997).
Similarly the removal of the C-terminal tail of the TRH receptor,
abolishes the desensitisation of the InsP production observed with the
agonist-stimulated wild type TRH receptor (Yu, R. and P. M. Hinkle 1998).
Therefore it is logical to suggest that if the GnRH receptor possessed a C-
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terminal tail then, it too would display a desensitisation of its second
messenger responses.
Indeed InsP production stimulated by the catfish GnRH receptor, which
has a C-terminal tail, and a chimaeric receptor composed of the wt rat
GnRH receptor with the C-terminal tail of the TRH receptor did rapidly
desensitise (Heding, A., et al. 1998). However as shown in Figure 4.2, the
Asn318 and Asp87-Asn318 mutant GnRH receptors elicited a rapid
increase in PLD activity, that had reached a plateau after 10 min. The
rapid increase in PLD activity induced by agonists such as cholecystokinin
(CCK), carbachol, thrombin, vasopressin, bombesin and PAF desensitizes
after a short period of activation. (Briscoe, C. P., et al. 1994, Liu, B., et al.
1997, Murthy, K. S. and G. M. Makhlouf 1995, Nieto, M., et al. 1994,
Plevin, R. and M. J. O. Wakelam 1992). This period can be seconds in the
case of the bombesin receptor (Briscoe, C. P., et al. 1994) and up to 20
minutes as observed for the PAF and CCK receptors (Liu, B., et al. 1997,
Murthy, K. S. and G. M. Makhlouf 1995). Therefore the replacement of
the single aspartate residue at position 318 with asparagine appears to
increase the strength of the receptor coupling to PLD but not PLC, and
allow the desensitisation of the receptor activation of PLD, as observed for
other receptors. Furthermore the replacement of the asparagine at
position 87 with aspartate (in the context of asparagine at 318), does not
diminish the increase in the receptors ability to stimulate
phosphatidylcholine breakdown.
Pathways to PLD via small G proteins or PLC
The Asn318, but not the wild type GnRH receptor activated PLD in an
ARF-dependent manner as shown by the results in Figure 4.5. The BFA
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sensitivity of the Asn318 GnRH receptor stimulation of PLD, is in
agreement with the hypothesis that NPX2-3Y-containing receptors couple
to PLD via small G proteins such as ARF and Rho. The demonstration of
BFA-sensitivity in the activation of PLD by the M3, B2 and Hi, but not the
thrombin and TXA2 receptors, described in Chapter 3, implicated the
conserved TMD 7 motif in the regulation of G protein coupling. The
effect of the substitution of aspartate at position 318 in the wt GnRH
receptor with asparagine, strongly supports the idea of a pivotal role for
the N/DPX2-3Y sequence in the receptor interaction with G proteins.
Furthermore the effect that mutating the NPX2-3Y sequence in the GnRH
receptor has on G protein coupling was not a receptor-specific one, as the
substitution of the asparagine at position 376 in the human 5-HT2A
receptor, with aspartate removed the BFA-sensitivity of the 5-HT-induced
activation of PLD (Figure 4.12).
The dramatic influence of the amino acid substitution at the 7.49 position
on G protein coupling was further emphasised by the results from
experiments using the PLC inhibitor U73122. The activation of PLD by
the wtGnRH and Asp376 mutant 5-HT2A receptors, was sensitive to the
PLC inhibitor U73122. This further illustrates the apparent sensitivity of
DPX2-3Y receptors to U73122 in their activation of PLD, a suggestion
arising from the stimulation of PLD by the thrombin receptor, presented
in Chapter 3. Furthermore the Asn318 mutant GnRH and wt5-HT2A
receptors activate PLD in a U73122-insensitive manner, as with the other
NPX2-3Y receptors investigated in Chapter 3.
The modification of the GnRH and 5-HT2A signalling characteristics by a
single amino acid change, is one of many examples of a change in
receptor activation of G protein signalling pathways, due to point
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mutations. Indeed a relationship between naturally occurring point
mutant GPCRs, abnormal constitutive activity and disease states has been
reported . Mutation of an aspartate residue in the luteinising hormone
receptor, conserved within the TMD 6 of glycoprotein hormone receptors
is linked with precocious male puberty (Shenker, A., et al. 1993).
Furthermore the mutation of Lys296 and Glull3 in the TMDs 7 and 3
respectively of rhodopsin, is linked with retinitis pigmentosa (Robinson,
P. R., et al. 1992). The mutation of single amino acid residues within the
carboxy terminus of the i3, a domain considered to be directly involved in
G protein coupling, causes constitutive activation of the aie, oc?ciO and
fG-adrenergic receptors and activation of their respective Gq, Gi and Gs
coupling (Kjelsberg, M. A., et al. 1992, Ren, Q., et al. 1993, Samama, p., et
al. 1993). The modulation of one second messenger pathway and not
another by a single amino acid substitution, as seen for the differing PLC
and PLD responses of the wt and Asn318 mutant GnRH receptor is also
observed. The mutation of an alanine residue in i3 of the thyrotropin
(TSH) receptor caused the loss of the phosphoinositide hydrolysis, but not
the cAMP response (Kosugi, S., et al. 1992). Also of interest was that the
mutation of an equivalent alanine residue in the aiB-adrenergic receptor
increased the potency of agonists for stimulating PLC activity by 2 orders
of magnitude (Cotecchia, S., et al. 1990).
Interhelical interactions in GPCRs
Therefore the pervasive influence of a single amino acid change on
receptor activity and G protein coupling is a well reported phenomena.
However the consequence of changes to the conserved Asn or Asp in the
N/DPX2-3Y motif has not been detailed currently- Work reported by
several groups points to a close interaction of the asparagine in TMD 2
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and the aspartate in TMD 7, in the GnRH receptor (Arora, K. K., et al.
1996, Awara, W. M., et al. 1996, Zhou, W. C., et al. 1994). The replacement
of Asn87 in TMD 2 abolished the ligand binding properties and related
second messenger responses of the GnRH receptor (Cook, J. V., et al. 1993,
Zhou, W. C., et al. 1994). Introducing a second mutation in TMD 7,
changing Asp318 to Asn (which recreates the pattern seen in other
GPCRs) led to restoration of a receptor with high affinity agonist and
antagonist binding (Awara, W. M., et al. 1996, Mitchell, R., et al. 1998,
Zhou, W. C., et al. 1994). The double mutant also coupled to InsP
production, although the stimulation of phosphoinositide hydrolysis was
weaker than that seen with the wt GnRH receptor (Awara, W. M., et al.
1996, Zhou, W. C., et al. 1994). This is in agreement with the results
presented in Figure 4.1. Moreover this reduction in G protein coupling
does not appear to be a result of the poor expression of mutant receptor
on the cell surface. Even after taking into account the lower number of
mutant GnRH receptors, the hydrolysis of phosphatidylinositol 4,5
bisphosphate, was poorly stimulated by the Asn318 and Asp87-Asn3'18
GnRH receptors (Arora, K. K., et al. 1996, Awara, W. M., et al. 1996). The
restoration of binding and G protein coupling by a reciprocal mutation
supports the proximity of TMD 2 and 7, and the specific interaction of the
conserved polar residues in either helix.
The introduction of the Asp at position 87 in TMD 2 is proposed to
disrupt the H bonding interactions of the GnRH receptor. Aspartate is
assumed to be ionised physiologically and act as an H-bond acceptor
through its side chain. In the Asp87 GnRH receptor, the Asp residues at
position 87 and 318 would electrostatically repel each other, thereby
affecting receptor structure. Asparagine can act as both a hydrogen-bond
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acceptor and donor through its side chain. Therefore the introduction of
the Asn residue in the Asp87-Asn318 double mutant GnRH receptor,
would allow these two loci to H-bond, and participate again in the
putative network of polar interactions described previously (Fanelli, F., et
al. 1995, Konvicka, K., et al. 1998, Oliveira, L., et al. 1994, Perlman, J. FT, et
al. 1997, Scheer, A., et al. 1996, Scheer, A., et al. 1997). Flowever in the
Asp376 mutant of the 5-HT2A receptor, where there is an Asp in both
TMD 2 and TMD 7, InsP production was still stimulated by the receptor.
An explanation for the difference observed between the GnRH and 5-
HT2A receptor mutants, was proposed by Sealfon et al, who suggest that
the Asp residue, introduced into TMD 7 may be protonated and therefore
act as a hydrogen donor, like the Asn residue, normally present (Sealfon,
S. C., et al. 1995). A similar explanation for the retention of receptor
stimulation of PLC by a mutant TRH receptor, with Asp residues in TMDs
2 and 7 was reported recently (Perlman, J. H., et al. 1997). In the wt 5-HT2A
receptor the conserved Asn at position 1.50 is proposed to H-bond with
Asp 2.50 and Asn 7.49 (Konvicka, K., et al. 1998). In the mutant 5-HT2A
receptor, there may still exist H-bond interactions between the Asp
residues at positions 2.50 and 7.49 and the conserved Asn 1.50. This polar
bonding between helices may counteract the hypothetical electrostatic
incompatibility and allow some level of normal G protein coupling. A
similar explanation may be applied to the functionally competent mutant
TRH receptor, which also has Asp residues at position 2.50 and 7.49 and is
proposed to have H-bonding between positions 1.50, 2.50 and 7.49
(Perlman, J. H., et al. 1997). The local micro-enviroment of each receptor
will determine the importance of either an Asp or Asn in the
transmembrane a-helices 2 and 7. However the receptor coupling to G
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proteins and second messenger responses in all cases reported was
strongest in the wild type/evolutionarily conserved structures.
There was an enhancement of the stimulation of PLD by the Asn318 and
Asp87-Asn318 mutant GnRH receptors, despite a poor receptor coupling
to InsP production and reduced receptor number (Figure 4.2). This
further implicates the N/DPX2-3Y motif in the control of G protein
coupling. Specifically, changes in the motif of the GnRH receptor
generate an increased competency of receptor coupling to PLD. Moreover
the mutant but not wild type receptors coupled to a BFA-sensitive
pathway in the activation of PLD and could associate closely with ARF
and Rho proteins. Therefore the presence of the NPLIY motif in TMD 7
would appear to be necessary for GPCR coupling to these small G proteins
in the stimulation of PLD. The capacity of the Asn at position 318 to be an
H-bond donor, may be the important determinant in the mutant GnRH
receptor, and other GPCRs, that controls the coupling to PLD.
Investigation of the conserved aspartate in TMD 2 and asparagine in TMD
7, of the 5-HT2A receptor by Sealfon et al, implicated an H-bond
interaction between these amino acid residues (Sealfon, S. C., et al. 1995).
A mutant of the 5-HT2A receptor, with the Asn at position 376 replaced
with an Asp residue, was able to stimulate InsP production (Sealfon, S. C.,
et al. 1995). Furthermore the coupling of this Asp376 5-HT2A receptor to
PLC was only slightly reduced compared to that seen with the wt 5-HT2A
receptor. However the importance of the NPX2-3Y motif in GPCR
coupling to PLD, was underscored by the loss of the involvement of ARF
in the activation of PLD by the mutant Asp376 5-HT2A receptor (Figure
4.12).
Receptor selective interaction with G proteins
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The close association of the M3 receptor with the small G proteins
ARF1/3 and RhoA reported in Chapter 3 and by Mitchell et al (Mitchell,
R., et al. 1998), was reproduced with the Asn318 mutant but not the wt
GnRH receptor. Specific binding of the stable GnRH analogue,
[125I]buserelin to immunoprecipitates prepared using polyclonal
antibodies to ARF1/3 and RhoA, and COS 7 cells expressing the Asn318
GnRH receptor was not observed following the transient expression of
the wt GnRH receptor. This further supports the idea that the selectivity
of receptor coupling to ARF and RhoA is based on the presence of the
NPX2-3Y and not the alternative DPX2-3Y sequence. As observed for the
association of the M3 receptor with ARF and Rho proteins (Figure 3.8),
there is a prerequisite for exposure of the GnRH receptor to agonist,
which may be required in order to induce the translocation of the G
proteins to the cell membranes as reported previously (Houle, M. G., et al.
1995, Malcolm, K. C., et al. 1996, Riimenapp, U., et al. 1995), where they
may then interact with receptor. Furthermore the rate of buserelin
dissociation from the wt and Asn318 GnRH receptor was modulated in a
fashion that further suggested the selective coupling of the receptors to
trimeric and monomeric G proteins respectively (Figure 4.10).
The activation of a broad spectrum of G proteins by GTPyS or GPPNHP
decreased the wt and Asn318 GnRH receptor's affinity for buserelin, thus
increasing the rate of ligand dissociation from the receptors (Figure 4.10a
and b). Incubation of digitonin-permeabilized COS 7 cells expressing the
wt or Asn318 mutant GnRH receptor with GPPCH2P decreased the half-
life for buserelin dissociation from the Asn318 but not the wt GnRH
receptor. The work described in Chapter 3 on the modulation of M3
receptor affinity for agonist and activation of PLD points to the selective
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activation of small G proteins by Py-methylene analogues of GTP. This is
in agreement with the reported potency and selectivity of these analogues
for monomeric G proteins such as rab5, ARF and others (Gill, D. M. and J.
Coburn 1987, Hoffenberg, S., et al. 1996). Therefore the NPX2-3Y and not
the DPX2-3Y containing GnRH receptor appears to interact specifically
with small G proteins and this is consistent with the association of the M3
receptor and these G proteins reported in Chapter 3. Furthermore the
inferred selective stimulation of trimeric G proteins with BeF3~ (Bigay, J.,
et al. 1987, Kahn, R. A. 1991), reduced only the wt GnRH receptor's half-
life for [125I]buserelin dissociation. This is supportive of the hypothesis of
significant coupling of trimeric G proteins to the wt and not the Asn318
mutant GnRH receptor after agonist exposure. These results would
appear to confirm again that the two forms of the GnRH receptor couple
at least in part to two populations of G proteins, in a manner reminiscent
of the unprimed and primed M3 receptor.
Conformational changes in receptor activation
The participation of the conserved Asn/Asp in TMD 7 and the conserved
Asp/Asn in TMD 2 in the regulation of a H-bonding network has been
discussed previously in Chapter 3. The results presented in Chapter 3 and
in this Chapter suggest that changes in one locus of this network have
dramatic effects on the receptor-G protein coupling behaviour. In the
GnRH, 5-HT2A/ TRH, M3 and ocib receptors, mutagenesis and computer
molecular modelling have all suggested the conformational change
leading to the receptor coupling to G proteins was regulated by either all
or a selection of the polar network of amino acids; N1.50, D/N2.50, R3.50,
N/D7.49 and Y7.53 (Ballesteros, J., et al. 1998, Fanelli, F., et al. 1995, Luo, X.,
et al. 1994, Perlman, J. H., et al. 1997, Scheer, A., et al. 1996, Scheer, A., et al.
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1997, Sealfon, S. C., et al. 1995, Zhou, W. C., et al. 1994). The polar
network, as described in Chapter 3 undergoes a conformational change
upon ligand binding, which is suggested to lead to the increased
accessibility of the putative G protein coupling domains with the receptor
(Fanelli, F., et al. 1995, Konvicka, K., et al. 1998, Oliveira, L., et al. 1994,
Scheer, A., et al. 1996, Scheer, A., et al. 1997). Computer simulations of
the wt and a mutant Asnl20 5-HT2A receptor indicate that TMDs 5 and 6
are the foci for receptor conformational changes, initiated with TMD 7
(Luo, X., et al. 1994, Sealfon, S. C., et al. 1995, Zhang, D. and H. Weinstein
1993). Since the i3 loop which links these two a-helices is considered to
be a major G protein coupling domain in GPCRs, the movement of TMDs
5 and 6 is likely to greatly influence the receptor stimulation of second
messengers. A series of site-directed spin labelling studies using the
rhodopsin receptor, has implicated a significant movement away from
each other of TMDs 3 and 6 and a movement of i3 upon photoactivation
(Altenbach, C., et al. 1996, Farahbakhsh, Z. T., et al. 1993, Farahbakhsh, Z.
T., et al. 1995, Farrens, D. L., et al. 1996). The TMD 6 is proposed to twist by
30° on its axis and to lean outwards away from the central pocket formed
by the other TMDs (Altenbach, C., et al. 1996, Farahbakhsh, Z. T., et al.
1993, Farahbakhsh, Z. T., et al. 1995, Farrens, D. L., et al. 1996). Similarly
the i3 loop of the yeast a-factor pheromone receptor is given greater
accessibility upon agonist binding, as shown by the greater proteolytic
cleavage the i3 loop (Bukusoglu, G. and D. D. Jenness 1996).
The N/DPX2-3Y sequence was suggested to be ideally placed to receive the
signals of ligand binding to a receptor, and transduce them to the G
protein coupling domains of GPCRs (Donnelly, D., et al. 1994, Findlay, J.
B. C., et al. 1993). The results reported here and elsewhere indicate that
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the N/DPX2-3Y sequence (and specifically the identity of the polar amino
acid at position 7.49 in GPCRs) is a major determinant in the control of G
protein coupling. Through the interaction of the conserved Asn or Asp
residues at positions 7.49 and 2.50 with the other polar amino acids
forming the network of H-bonds (most crucially the conserved Asn at
position 1.50), the functionally competent conformation of receptors
appears to be maintained. One important effect of the N/DPX2-3Y motif is
the regulation of receptor coupling to ARF and Rho proteins in the
receptor-mediated activation of PLD by agonist. The ability of asparagine
as opposed to aspartate, to act as both hydrogen bond donor and acceptor,
may be the reason behind the difference in receptor activation of PLD.
The negative charge associated with the aspartate in TMD 7 may also play
a role in the local control of receptor conformation. Whatever the
influence of the different amino acid composition of the highly
conserved motif, now along with the second and third intracellular loops,
the N/DPX2-3Y motif can be seen as a central switch in the control of class
I, GPCR signal transduction.
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Recently, a family of GPCRs was recognised as being structurally distinct
from the rhodopsin (class I) family. Known as the secretin/glucagon (class
II) receptor family, this group shares few of the specific sequence motifs of
the rhodopsin receptor family and has less than 12% sequence homology
with its members, but still possesses the same predicted molecular
architecture of seven transmembrane helices and the ability to transduce
extracellular stimuli via an analogous sequence of molecular events
(Segre, G. V. and S. R. Goldring 1993). Receptors within the
secretin/glucagon family show between 30% and 51% homology with
each other and share characteristics such as the conservation of 6 specific
cysteine residues within the N-terminal extracellular domain, activation
of adenylate cyclase by coupling to the heterotrimeric G protein Gs,
multiple consensus N-glycosylation sites, a large N-terminal extracellular
domain (>120 amino acids) and multi-intron genes (Arimura, A. and S.
Shioda 1995, Laburthe, M. and A. Couvineau 1988, Laburthe, M., et al.
1996, Segre, G. V. and S. R. Goldring 1993). Recently two distinct receptors
for Vasoactive Intestinal Polypeptide (VIP) have been cloned. In 1992,
Ishihara et al. cloned the VIPi receptor using a rat lung cDNA library and
the VIP2 receptor was cloned soon after from rat pituitary (Lutz, E. M., et
al. 1993). Both receptors can potently activate adenylate cyclase via
coupling to Gs and raise intracellular cAMP levels (Ishihara, T., et al. 1992,
Kermode, J. C., et al. 1992, Lutz, E. ML, et al. 1993, Usdin, T. B., et al. 1994).
The coupling of VIP receptors to inositol phosphate (InsP) metabolism is
not so well defined, although VIP was shown to increase the breakdown
of inositol phosphates in rat astroglia (Fatatis, A., et al. 1994), and the
mouse homologue of the VIP? receptor stimulated calcium-activated
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chloride currents, which is suggestive of a coupling to the PLC pathway
(Inagaki, N., et al. 1994). Also agonist can mobilise calcium from
intracellular calcium stores in cells expressing the human VIPi receptor,
which strongly suggests the involvement of phosphoinositide breakdown
(Sreedharan, S. P., et al. 1994). Mackenzie et al. have shown that the rat
VIPl and VIP2 receptors when expressed transiently in COS-7 cells can
couple to PLC in a pertussis toxin-sensitive manner, suggesting the
involvement of a member of the Gi family of heterotrimeric G proteins
(MacKenzie, C. J., et al. 1996). Moreover the rat VIPi receptor stably
expressed in Chinese hamster ovary (CHO) cells has also been shown to
stimulate phospholipase C (PLC) in a pertussis toxin-sensitive manner
(van Rampelbergh, J., et al. 1997). Whilst the activation of PLD is
observed in response to a wide range of physiological stimuli, any ability
of the rat VIPi aRd VIP2 receptors to activate PLD has never been explored.
This question was investigated here with attention paid to the potential
role of small G proteins such as ARF in this activation. The member of
the secretin/calcitonin family of receptors most closely related to the VIPi
and VIP2 receptors is the PACAP receptor, with 51% similarity (Ishihara,
T., et al. 1992). The respective VIP and PACAP peptides ligands are also
the most alike within this peptide family, having 70% identity (Arimura,
A. 1992, Miyata, A., et al. 1990).
Independently of each other, 6 labs reported cloning of the receptor for
PACAP (Hashimoto, H., et al. 1993, Hosoya, M., et al. 1993, Morrow, J. A.,
et al. 1993, Pisegna, J. R. and S. A. Wank 1993, Spengler, D., et al. 1993,
Svoboda, M., et al. 1993). The PACAP receptor was found to have 6 splice
variants which all coupled to Gs, as with all other members of the secretin
receptor family (Laburthe, M., et al. 1996, Segre, G. V. and S. R. Goldring
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1993, Spengler, D., et al. 1993), but differed in the structure of the third
intracellular loop (i3). The receptors can exist in a short form or in one of
5 longer splice variants characterised by insertion into i3 of 28 amino acid
cassettes termed "hip", "hop-1" and "hop-2", either alone or in
combination . The short form of the receptor or splice variants containing
the hop-1, hop-2 have an almost identical potency (~ 0.4 nM) for the
PACAP-38-evoked activation of adenylate cyclase in LLC-PK1 cells.
However the PACAP-hip receptor was 15 times less potent at increasing
cAMP levels, while the PACAP-hip-hopl/2 splice variants have an
intermediate phenotype (Journot, L., et al. 1995, Spengler, D., et al. 1993).
The potency of PACAP-38 also differed in its stimulation of InsP
breakdown through the PACAP receptor splice variants. The
PACAPshort, hop-1 and hop-2 forms of the receptor stimulated InsP
hydrolysis with equal potency (as with the cAMP response), the PACAP-
hip receptor did not induce any detectable phosphoinositide breakdown in
LLC-PK1 cells, once again the PACAP-hip-hopl/2 displayed an
intermediate phenotype (Journot, L., et al. 1995, Spengler, D., et al. 1993).
A similar profile for the stimulation of calcium currents in Xenopus
oocytes was observed in oocytes micro-injected with the 6 different
receptor mRNAs. Once again the PACAP-hip receptor did not induce a
calcium current (Journot, L., et al. 1995, Spengler, D., et al. 1993). The hip
cassette may represent a non-functional insert that interferes with the
productive coupling of the PACAP receptor to G proteins. The ability of
the PACAPshort form (containing no hip or hop cassettes) and PACAPiong
form receptor (including hop-1) to activate PLD in response to agonist is
described here and the role of ARF in this activation was also addressed.
Chimaeric receptor constructs were used to address what effect the
different i3 structure of the PACAP receptor splice variants would have
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on their ability to activate PLD. The chimaeric receptor constructs
comprised the VIP2 receptor with its i3 replaced by that of the PACAPshort
or PACAPiong receptor.
5.2 SPECIFIC METHODOLOGY
Construction of chimaeric receptors
Chimeric receptors were made by Dr Eve Lutz in our laboratory by
exchanging the i3 domain of the rat VIP2 receptor and either the short
(missing amino acids 348-376 in the third intracellular loop) or the long
form of the rat PACAP receptor, at exchange sites on TMD 5 and TMD 7
(Fig. 5.9). This was achieved using cDNAs encoding the rat VIP2 receptor
(R4, pBluescript) and the short (RTb, pBluescript) and long (R7/9.1,
pBluescript) forms of the rat PACAP receptor. The first domain exchange
was made by utilising a conserved restriction (Hincll) site in the region of
the cDNAs encoding the 5th transmembrane region of the VIP2 and
PACAP receptors. After digestion with Hindi, the appropriate cDNA
fragments were gel purified then ligated with T4DNA ligase (Promega).
These were inserted into pBluescript for selection of appropriate clones by
sequence analysis of the domain exchange region. The second domain
exchange within TMD 7 was made by overlap extension polymerase chain
reaction (PCR) mutagenesis, described previously (Huang, Z., et al. 1995).
For each cDNA a set of four oligonucleotide primers were used, two
external primers derived from flanking sequences of pBluescript and two
internal primers one of which (the overlap primer) contained sequences
derived from both receptor encoding cDNAs which spanned the TMD 7
junction site. The cDNA specific primer contained sequences
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complementary to the 5' end of the overlap primer, corresponding to the
cDNA encoding the receptor portion 5' of the junction site. In the first
round of PCR amplification the 5' region encoding the N-terminal end of
the chimaeric receptor was amplified with the cDNA specific primer along
with the corresponding flanking external primer while the 3' region
encoding the C-terminal end was amplified with the overlap primer and
corresponding flanking external primer. PCR reactions were set up in 100
Lil volumes containing 15 ng cDNA, 15 pmol of the 5' and 3' primer, in
the PCR buffer with 2 mM MgCh, 100 nM dNTPs and 10% DMSO and
overlaid with mineral oil. The reaction was heated to 95°C for 5 min,
then maintained at 80°C while adding 2.5U Pfu (Pyrococcus furiosus)
polymerase (Stratagene), after which the reaction was put through 30
cycles with denaturing at 94°C (1 min), annealing at 57°C (1 min) and
extension at 72°C (3 min). After the first round of PCR, 10 |il samples
were analysed by electrophoresis. The remaining PCR reactions were
purified by extracting with the Wizard cDNA purification system
(Promega), then in the second round of PCR amplification 1 Ltl volumes
of each appropriate extract were mixed and amplified using the flanking
pBluescript primers under the same conditions as the first round of
amplification. The polymerase enzyme was removed by the Wizard
cDNA purification system and the reaction digested with either EcoRI or
EcoRl/Xhol, then run on agarose gels for size selection. These were
ligated into pBluescript for selection of appropriate clones by sequence
analysis, then inserted into the expression vector pcDNA 1 (InVitrogen,




VIP receptor signalling in response to agonist.
The VIPi and VIP2 receptors expressed stably in CHO cells clearly
displayed comparable ability to activate phospholipase D in response to
VIP. Their responses were concentration-dependent, with EC50 values of
6.19 ± 2.48 and 5.34 ± 1.22 nM respectively, as shown in Fig. 5.1. The ability
of VIPi and VIP2 receptors to activate adenylate cyclase is well
documented (Ishihara, T., et al. 1992, Lutz, E. M., et al. 1993, Usdin, T. B., et
al. 1994) and the ability to activate inositol phosphate production has also
been shown (MacKenzie, C. J., et al. 1996, Sreedharan, S. P., et al. 1994, van
Rampelbergh, J., et al. 1997). The activation of PLD by the glucagon
receptor was the first report of a class II receptor coupling to PLD (Pittner,
R. A. and J. N. Fain 1991). However the present results are, the first
explicit demonstration of the activation of PLD by the VIP and PACAP
receptors and a description of the mechanism of that activation. The VIPi
receptor elicits a maximum 1.69 ± 0.17 fold increase in PLD activity
compared to the basal activity (n = 4-8) and VIP2 displays a maximum 2.52
± 0.32 fold increase in PLD stimulation (n = 7-13). There was no
stimulation of [3H]PtdBut production by VIP in untransfected CHO cells
(unpublished observations). The coupling of the VIP receptors to
adenylate cyclase (presumably via Gs)/ was also tested, as a control to
ensure that the stable clones could couple effectively to their primary
signal transduction pathway. The VIPi and VIP2 receptors stimulated
cAMP production with EC50S for VIP of 25 ± 2 pM and 168 ± 7 pM
respectively (Fig. 5.2). The basal concentration of cAMP in the stable CHO
cells was typically 4.0 ± 0.2 pmol/assay, stimulation of the VIPi receptor
evoked an increase in cAMP concentration to a maximum of 118 ± 5
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pmol/assay compared to the 318 ± 7 pmol/assay found after VIP2 receptor
activation (both n = 6). In comparison to the VIPi receptor stable cell line
there was 25 times more receptor present on the plasma membrane of the
VIP2-carrying CHO cells, in terms of pmol receptor per mg of protein,
(Table 5.1).
Using competitive whole cell binding studies with displacement of
[125I]helodermin by non-radioactive helodermin, the Bmax of VIPi and
VIP2 receptors was found to be 0.06 ± 0.01 and 1.5 ± 0.1 pmol/mg protein
respectively. The level of the cAMP response from the VIPi and VIP2
receptors would seem to reflect the difference in Bmax of the two receptors,
whereas the PLD activity downstream of either VIP receptor shows
remarkable similarity. The contrasting nature of the signalling responses
may be a function of the difference in coupling mechanisms in the cAMP
and PLD transduction pathways and currently these differences remain
unknown. However increases in cAMP concentration stimulated by
direct stimulation of Gs with 1 or 5 jig/ml cholera toxin, or adenylate
cyclase with 1 or 5 pM forskolin did not stimulate an increase in
[3H]PtdBut in CHO cells (unpublished observations). As demonstrated in
previous chapters the coupling of GPCRs to PLD can involve the
association with small G proteins, and ARF is a major activator of PLD in
mammalian systems (Brown, H. A., et al. 1993, Cockcroft, S., et al. 1994,
Hammond, S. M., et al. 1995), so a role for ARF in the activation of PLD by
VIP receptors was investigated using brefeldin A (BFA), an inhibitor of
guanine nucleotide exchange on ARF (Donaldson, J., et al. 1992). The
results shown in Fig. 5.3 indicate for the first time that both VIPi aRd VIP2
receptors do indeed couple to PLD via the small G protein ARF as shown
by their sensitivity to BFA. The IC50 for BFA on PLD response elicited by
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the VIPi and VIP2 receptors was 44 ± 17 and 43 ± 18 pM respectively.
Agonist-induced PLD activity via the VIP2 receptor was significantly
reduced at 50|iM BFA or greater (p<0.05, n = 8-10), and by 100pM BFA or
greater at the VIPi receptor (n = 4-9). There was 65 ± 15% inhibition of the
VIPl receptor response at 200pM BFA, and similarly 61 ± 10% inhibition
of the VIP2 receptor-mediated response at the same concentration.
The activation of PLD by either VIP receptor as described above seems
most unlikely to be downstream of increased inositol phosphate
metabolism as there was no detectable increase in inositol phosphate
production in the stable CHO cell lines, in response to agonist (C.J.,
MacKenzie , unpublished observations). There have been reports by other
investigators of InsP responses of VIPi receptors in CHO cells (van
Rampelbergh, J., et al. 1997). The discrepancy in observations is likely to
represent differences due to clonal variation and method of measurement
of inositol phosphates. The stimulation by 1 uM VIP of the VIPi receptor
stably expressed in CHO cells, with a receptor density of ~ 20 pmol/mg
protein, lead to a modest 1.5 fold stimulation of InsP production, thus it
appears that in CHO cell lines the stably expressed VIP receptor does not
couple strongly to PLC (van Rampelbergh, J., et al. 1997).
PACAP receptor signalling in response to agonist
The investigation of PACAP receptor signal transduction with regard to
activation of PLD and cAMP was carried out on stable transfectants of two
splice variants of the PACAP receptor cloned from the rat (Hashimoto, H.,
et al. 1993, Hosoya, M., et al. 1993, Morrow, J. A., et al. 1993, Pisegna, J. R.
and S. A. Wank 1993, Spengler, D., et al. 1993, Svoboda, M., et al. 1993).
Activation of PLD by PACAP-38 investigated at PACAPshort receptor and
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PACAPiong receptor splice variants; the long form receptor possessing the
extra hop-1 cassette in its i3 loop (Fig. 5.4) Both PACAP receptor forms
mediated activation of PLD in response to PACAP-38 in a potent,
concentration-dependent manner. The PACAPshort and iong receptors
stimulated a maximum increase in PLD activity of 1.92 ± 0.15 and 5.74 ±
0.46 fold increase over basal control. The difference in the capability of the
two receptors to activate PLD was not reflected in the concentration of
PACAP-38 needed to stimulate a half-maximal PLD response, both
receptors exhibiting very similar EC50S for PACAP-38 of 2.31 ± 1.19 nM for
the short form and 4.16 ± 0.95 nM for the longer analogue (Fig. 5.5). The
larger PLD response elicited by the PACAPiong receptor was not a
consequence of more PACAPiong receptors on the cell surface compared to
the short form receptor as there was more short variant expressed in the
relevant CHO clone (9.2 ± 0.9 pmol/mg protein) than long variant (6.2 ±
0.1 pmol/mg protein) (Table 5.1). As with the VIPi and VIP2 receptors the
ability of the stable PACAP receptor clones to increase cAMP
concentrations by coupling to adenylate cyclase was verified and as
expected from their very similar Bmax values, the PACAP receptors
exhibited a similar capacity to increase cAMP levels. The EC50 values for
cAMP production by the PACAPshort and long variants were 27 ± 2 pM and
22 ± 2 pM respectively, with a maximum increase in cAMP concentration
to 355 ± 9 pmol/assay for the PACAPshort receptor (106 ± 3 fold over basal)
and 330 ± 37 pmol/assay for PACAPiong (81 ± 9 fold over basal), (Fig. 5.6).
Evidence for the involvement of ARF in coupling the VIPi and VIP2
receptors to PLD (as detailed above) suggests that small G proteins can play
a role in the activation of PLD by the class II family of receptors. As shown
for the first time in Figure 5.7 ARF also appears to be involved in the
stimulation of PLD downstream of PACAP receptors. Pre-treatment of
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CHO cells expressing the PACAPiong form receptor with 25 jiM BFA
markedly reduced the activation of PLD in response to PACAP-38 (p<0.05),
and BFA showed an IC50 of 41 ± 4 uM. In remarkable contrast the
PACAPshort receptor showed no significant decrease in its ability to
activate PLD until 200 pM BFA was used to pre-treat the cells and this
caused only a 36 ± 16% inhibition of enzymatic activity (p<0.05). The
efficiency and potency of both PACAP receptors' coupling to adenylate
cyclase is comparable and therefore it seems unlikely that the differences
in PLD activation observed are downstream of such congruent cAMP
signalling. The PACAP receptors under investigation in this study are
known as efficient activators of IP metabolism (Spengler, D., et al. 1993,
van Rampelbergh, J., et al. 1997) and in assays monitoring InsP breakdown
by the receptors expressed in CHO cells, there was a concentration-
dependent increase in inositol phosphates with a maximum increase over
basal control of 5.6 ± 0.3 fold for the PACAPiong form and 10.3 ± 0.4 for the
PACAPshort form and respective EC50 values for PACAP-38 of 8.1 ± 2.1 and
14.9 ± 2.6 nM (C.J., MacKenzie unpublished observations). The possibility
that PLD activation by the PACAP receptors may be downstream of their
efficient PLC activation in CHO cells was addressed using the selective
PLC inhibitor U73122 (Figure 5.8). The activation of PLD by the
PACAPiong form receptor was relatively insensitive to U73122, with only
31 ± 5% inhibition of PACAP-38-induced PLD activity seen after 90 minute
pre-treatment of cells with 20 pM U73122. The reverse was true of
PACAPshort which showed much greater sensitivity to U73122, with 64 ±
4% inhibition of PLD activity at 20 pM U73122 (p<0.01) and an IC50 for
U73122 of 5 ± lpM. These results suggest that although the two PACAP
splice variants differ by only the 28 amino acid hop-1 cassette, the long
form mainly employs an ARF-dependent mechanism to couple to PLD,
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whilst the short form activates PLD largely via PLC, and perhaps as a
consequence of a rise in intracellular Ca2+ or PKC activity. The PLD
activity stimulated in COS 7 cells by the calcium ionophore, ionomycin, or
the PKC activator phorbol 12,13-dibutyrate was insensitive to BFA
(Mitchell, R., et al. 1998). Therefore the activation of PLD downstream of
PLC activation would appear to represent a route for the stimulation of
phosphatidylcholine breakdown distinct form that involving ARF. In
studies using BFA on the PACAPiong form and U73122 on the PACAPshort
form, the stimulated PLD activity was never completely inhibited and this
may be a consequence of dual coupling to PLD. The receptors may employ
two mechanisms for activation of PLD, for example the PACAPiong form
coupling to PLD via ARF (primary) and PLC (secondary), with PACAPshort
the order would be PLC (primary) and ARF (secondary).
Chimaeric VIP2/PACAP receptors: activation of PLD in response to
agonist
The important influence of i3 in the coupling of the PACAPshort and iong
receptor subtypes to PLD, as shown by the distinctive routes of activation
of PLD observed (despite equivalent levels of agonist binding) suggested
that within the i3 of these receptors lie major determinants of G protein
coupling. The i3 of GPCRs is accepted as one of the crucial domains
controlling G protein coupling (reviewed recently by (Bourne, H. 1997,
Gudermann, T., et al. 1996, Savarese, T. M. and C. M. Fraser 1992, Strader,
C. D., et al. 1994, Wess, J. 1997)). The construction of chimaeric receptors
carrying a mainly VIP2 body but with its i3 replaced by that of the
PACAPshort °r long receptor (as shown in Fig. 5.9) allowed us to study
whether indeed the different i3 domains of the receptors were enough to
switch the coupling behaviour of the receptor. The cDNAs for the
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VIP2/PACAPshort (VP/4/7b/2.1c) and VIP2/PACAPiong (VP/2.1c)
chimaeric i3 insert receptors were transiently expressed in COS 7 cells.
The chimaeric receptors activated PLD in response to VIP to a similar
level as observed with the VIP2 receptor (Fig. 5.10), that is a 3.2 ± 0.2 fold
increase over basal elicited by the VIP?/PACAPshort chimaeric receptor
and a 2.5 ± 0.4 fold increase after VIP2/PACAPiong receptor stimulation.
The EC50S for VIP-induced PLD activation by the VIP?/PACAPshort aRd
long chimaeric receptors were 2.5 ± 1.7 nM and 5.6 ± 3.9 nM respectively,
values that are similar to the VIP? and PACAPshort and long receptors
expressed in CHO cells. The involvement of ARF in the coupling of the
chimaeric constructs was investigated and as with the PACAP receptor
splice variants expressed stably in CHO cells there was a dissimilar
sensitivity to BFA. The VIP2/PACAPiong receptor activated PLD in a BFA-
sensitive fashion and the VIP2/PACAPshort chimaeric construct
mimicked the PACAPsh0rt receptor and was BFA-resistant in the
stimulation of PLD (Fig. 5.11). The highest concentration of BFA used (200
uM) caused only 32 ± 16% inhibition of the VIP?/PACAPshort receptor
stimulated PLD activity, compared to 84 ± 16% inhibition of the
VIP2/PACAPiong receptor response where BFA displayed an IC50 of 43 ± 6
pM (p<0.05). Therefore the i3 of the PACAPiong receptor as with the VIPi
and VIP? receptors contains major determinants that dictate coupling of
the receptor to PLD via ARF. In contrast the PACAPshort 13 does not
appear to possess the required motifs or does not have them in the correct
conformation to elicit a strong association of the receptor with small G
proteins in its activation of PLD. The activation of PLD after PACAP-38
binding to its receptor may be the result of receptor connection to various
pathways, and the possession of either the hop-1, hop-2, hip or
combination of these inserts allows the receptor to select a dominant
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route. Alternative splicing of the genes coding for GPCRs introduces
another level of variation and fine control of responses to agonist, as
shown by the abolition of PLC stimulation in the rat and human PACAP
receptors carrying the hip cassette or the analogous calcitonin receptors
with a 16 amino acid insert in intracellular loop 1 (il) (Houssami, S., et al.
1994, Moore, E. E., et al. 1995, Nussenzveig, D. R. and C. N. Thaw 1994,
Pisegna, J. R. and S. A. Wank 1996, Spengler, D., et al. 1993)
5.4 DISCUSSION
Pathways to PLD activation
The results shown in Figures 5.1, 5.5 and 5.10 demonstrate for the first
time that members of the class II family of receptors can potently activate
PLD, and that this coupling may well be dependent on the small G protein
ARF in the cases of the VIPi, VIP2 and PACAPiong receptors. A
requirement for ARF would point to an activation of PLD1 or PLD2 by
these receptors in CHO and COS-7 cells (Hammond, S. M., et al. 1995,
Hammond, S. M., et al. 1997, Lopez, I., et al. 1998). However ARF
stimulated the human PLD2 enzyme only 2 fold, compared to the 20 fold
stimulation of the hPLDl enzyme (Lopez, I., et al. 1998) and furthermore
the rodent PLD2 enzyme was not detectably stimulated by ARF (Colley, W.
C., et al. 1997).
Receptor-stimulated cAMP production
The coupling of this family of receptors to the heterotrimeric G protein Gs
with concomitant activation of adenylate cyclase and rise in intracellular
cAMP levels is seen as one of the characteristics of this family of receptors
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(Laburthe, M., et al. 1996, Segre, G. V. and S. R. Goldring 1993). The VIPi,
VIP?, PACAPshort and PACAPiong receptors stably expressed in CHO cells
all elicited increases in intracellular cAMP concentration in a potent and
efficacious manner as shown in Figures 5.2 and 5.6. In all four receptors
studied, the EC50 values for cAMP production were lower than the IC50
values for displacement of bound radiolabel, this amplification of the
cAMP response after the activation of a small population of the available
receptor sites suggests the presence of spare receptors for this response
(Kenakin, T. P. 1984). An identical situation was reported by Ciccarelli et
al. who also expressed the PACAPsh0rt and PACAPiong (hop-1) receptors in
CHO cells, and described lower EC50 values compared to values for
binding of tracer (Ciccarelli, E., et al. 1995). In another study, Ciccarelli et
al. described the magnitude of the cAMP response as Bmax-dependent,
therefore taking into account the existence of receptor reserve, increasing
the concentration of VIPi receptors expressed in CHO cells increased the
maximal cAMP response that was achieved (Ciccarelli, E., et al. 1994). The
results obtained from the VIPi, VIP2/ PACAPshort and PACAPiong
receptors in this study could well be in agreement with the observation
reported by Cicarelli et al.: the VIP? receptor stimulated a maximal cAMP
concentration 2.7 fold larger than that induced by the VIPi receptor,
matching the significantly greater concentration of receptor present. The
PACAP receptors with their similar Bmax values showed equivalent
capacity to increase cAMP in response to PACAP-38.
Receptor coupling to phosphoinositide hydrolysis
The stimulation of phosphoinositide metabolism is observed for many
receptors in class II such as the cloned calcitonin, glucagon, PTH/PTHrP
and glucagon-like peptide-1 receptors (Abousamra, A. B., et al. 1992,
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Chabre, O., et al. 1992, Force, T., et al. 1992, Wheeler, M. B., et al. 1993) and
secretin increases inositol phosphate hydrolysis in native pancreatic tissue
(Trimble, E. R., et al. 1987). VIP has also been reported to increase the
breakdown of inositol phosphates in rat astroglia (Fatatis, A., et al. 1994),
and the mouse VIP2 receptor stimulated calcium-activated chloride
currents, which implicates a coupling to PLC (Inagaki, N., et al. 1994).
There is little knowledge of the range of transduction abilities of the class
II receptors. PACAP receptors can stimulate inositol phosphate
breakdown and cytoplasmic calcium concentrations not only in
transfected LLC-PK1 (Spengler, D., et al. 1993) and CFIO cells (Delporte, C.,
et al. 1995, van Rampelbergh, J., et al. 1997) but also in normal pituitary
gonadotropes (Rawlings, S. R., et al. 1993, Rawlings, S. R., et al. 1994), in rat
gonadotrope-derived aT3-l cells (Schomerus, E., et al. 1994) in PC12 cells
(Deutsch, P. J. and Y. Sun 1992) and in the neuroblastoma cell line NB-OK-
1 (Delporte, C., et al. 1993), presumably via coupling to Gq. In our CHO
cells stably expressing the PACAPsh0rt and iong receptor, there was a strong
activation of inositol phosphate production in response to PACAP-38,
with a 10.3 ± 0.4 and 5.6 ± 0.3 fold increase in inositol phosphate
production over basal activity respectively. The slightly higher expression
level of PACAPshort receptors, compared to the iong form as seen in Table
5.1 probably determines the greater InsP response as there is little evidence
for spare receptors in the activation of PLC.
Both VIPi receptors stably expressed in CHO cells (Sreedharan, S. P., et al.
1994, van Rampelbergh, J., et al. 1997) and VIP2 receptors transiently
expressed in COS-7 cells (MacKenzie, C. J., et al. 1996) have been shown to
couple to PLC in a pertussis toxin (PTx)-sensitive manner, suggesting the
involvement of a member of the Gi/0 family of G proteins. The
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investigators report that in these systems PACAP receptors couple to PLC
in a PTx-insensitive manner. Contrary to the results published by Van
Rampelbergh et al. we could detect no rise in inositol phosphate
breakdown above basal activity by our agonist-treated VIPi receptor
carrying clones, or by VIP2 receptors also expressed in this cell line (C.J.,
MacKenzie unpublished observations). The difference may be a result of
clonal difference, Robberecht's group observed a maximal 1.5 fold
stimulation of InsP breakdown by the VIPi receptor, compared to control,
when expressing 20 pmol/mg receptor protein (van Rampelbergh, J., et al.
1997). In comparison there was 0.06 ± 0.01 and 1.5 ± 0.1 pmol/mg VIPi ar^d
VIP2 receptor respectively expressed at the plasma membrane of the CHO
clones used in this study (Table 5.1). Differences in the techniques used to
measure inositol phosphate accumulation may also contribute to this
disparity. Interestingly, at the same Bmax values of 20 pmol/mg protein,
VanRampelbergh et al. reported a 3 fold stimulation of InsP production by
the PACAPshort receptor, expressed in CHO cells, demonstrating a more
efficacious coupling of PACAP receptors to phosphoinositide breakdown.
However this response is still much lower than the phosphoinositide
breakdown observed after stimulation of PACAP receptors in our system.
Further receptor-evoked signal transduction pathways
There have been scattered reports of activation of other signal
transduction pathways by VIP and PACAP, although some of these may be
downstream of the established responses described above: VIP has been
described to induce activation of nitric oxide synthase (NOS) in gastric
smooth muscle cells via Gn-2 (Murthv, K. S. and G. M. Makhlouf 1994).
VIP induces activation of the non-receptor tyrosine kinase p59fYn in
murine thymocytes (Xin, Z. C., et al. 1997), subnanomolar concentrations
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of VIP stimulate the translocation of PKC alpha, delta and zeta isoforms to
the nucleus of neonatal rat astrocytes (Olah, Z., et al. 1994). PACAP has
been shown to activate extracellular signal-related/mitogen-activated
protein kinase (ERK/MAPK) in cerebellar granule neurons (Villalba, M.
and L. Journot 1997) and PC12 cells (an important pathway in these cells
required for differentiation into a sympathetic-like neuron (Barrie, A. P.,
et al. 1997)). Similarly Zhong reported a PACAP-like neuropeptide to
activate the Ras/Raf pathway in Drosophila (Zhong, Y. 1995). Finally the
involvement of a wortmannin-sensitive signal transduction pathway in
VIP/PACAP-induced insulin release from a pancreatic-derived HIT-T15 (3-
cell line was reported by Straub and Sharp. VIP and PACAP stimulated
this activity with a pharmacological profile characteristic of the VIP2
receptor (Straub, S. G. and G. W. G. Sharp 1996), which is strongly
expressed in normal pancreatic tissue (Usdin, T. B., et al. 1994). Therefore
one of the characteristics of this family of receptors would appear to be the
ability to couple to multiple second messenger pathways. However in
contrast to the rhodopsin family of receptors where there is a detailed
understanding of many of the receptor-mediated transduction
mechanisms, and their physiological relevance, the signalling capabilities
of the class II receptor family are still largely to be explored.
Receptor determinants and motifs
The activation of PLD by the VIP and PACAP receptors is similar to the
activation of PLC, in that although the efficacy of the response is weak
compared to the increase in cAMP concentration, the concentrations of
agonist required to achieve half-maximal stimulation are low (in the nM
range) and within physiological limits. The activation of PLD by both VIP
receptors and the PACAPiong form has been implicated as being ARF-
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dependent (Figures 5.3 and 5.7). Moreover the PACAPshort receptor
appears to stimulate PLD via a coupling to PLC and is not sensitive to the
ARF inhibitor BFA. An individual GPCR, when activated by its ligand,
can recognise and activate only a limited set of the structurally related G-
proteins. Extensive investigations with receptor peptides, chimaeras and
site-directed mutants have shown that the i3 sequence determines Ga(3y
selectivity more often than does i2, or the C-terminal tail and that il rarely
determines specificity and that loop sequences near TMDs are especially
important determinants of specificity (reviewed in (Gudermann, T., et al.
1996, Strader, C. D., et al. 1995, Strader, C. D., et al. 1994, Wess, J. 1997)). On
the other hand the calcitonin receptor il is reported to be involved in
control of receptor coupling to phosphoinositide breakdown (Houssami,
S., et al. 1994, Nussenzveig, D. R. and C. N. Thaw 1994), perhaps reflecting
a slightly different mechanism of class II receptor coupling to G proteins.
The direct interaction of class II receptors with small G proteins is yet to be
proven, although as we have reported (Mitchell, R., et al. 1998) and in
previous chapters, the rhodopsin family of receptors can associate with
small G proteins. It would thus be logical to assume that the receptor can
discriminate between different monomeric G proteins in a manner
analogous to its interaction with the a subunits of heterotrimeric G
proteins. Following this line of reasoning, the BFA-sensitive receptors
therefore may possess structural determinants (absent in the PACAPshort
receptor) that allow them to couple to PLD via ARF, and as described
above, the i3 loop of GPCRs is likely to be most important domain in
terms of G protein selectivity. The differences in the coupling of the
PACAPshort and long form receptors to PLD support this idea; their
divergent ability to activate PLD can only be explained by their different i3
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loop structures. Therefore the extra 28 amino acid hop-1 cassette, present
in the PACAPiong receptor provides the interfaces required to allow the
receptor to couple to ARF, in a similar way to that available for the VIP^
and VIP2 receptors, but not for the PACAPshort receptor.
The analysis of the signalling capabilities of chimaeric receptors comprised
of the VIP2 receptor with part of TM5, the whole of the i3 loop and part of
TM6 replaced with that of either the PACAPshort and iong receptors
showed explicitly that the i3 of the PACAP receptor does indeed
determine the coupling of the receptor to PLD via ARF. Only this domain
was transferred into the chimaeric receptor and it was sufficient to obtain
a BFA-sensitive ability to activate PLD. The VIP2/PACAP chimaeric
receptors activate PLD in an VIP-dependent manner, to a similar maximal
extent as seen for the wild type VIP2 receptor expressed in CLIO cells,
thereby showing that the i3 swap does not interfere with ligand binding
and activation of the receptor, but that the i3 as shown in Figure 5.11 quite
selectively determines the BFA-sensitivity of the PACAP receptors. A
somewhat analogous situation has been reported with the presence of two
isoforms of the dopamine D2 receptor. D2Short and D2i0ng receptors are
generated by alternative splicing of the same gene, and a 29 amino acid
insert is included in the i3 of the D2i0ng receptor. The extra 29 amino acids
allow the longer dopamine receptor to couple to the inhibitory G protein
Gai2, which is not seen for the D2Short receptor (Guiramand, J., et al. 1995).
Also a 16 amino acid insert in the il of the calcitonin receptor abolishes
the receptor's ability to stimulate phosphoinositide breakdown without
affecting the adenylate cyclase activation by the receptor (Houssami, S., et
al. 1994, Nussenzveig, D. R. and C. N. Thaw 1994). Thus the alternative
splicing of receptor gene transcripts can allow another level of signalling
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complexity to be introduced, and a more subtle control of cellular activity
to be achieved.
Importance of basic amino acid residues in signal transduction motifs
Work done by Nishimoto's group has implicated a crucial role for basic
amino acid residues in the i3 of GPCRs for the functional coupling of
receptors to G-proteins. Using peptide sequences derived from the CC2-
adrenergic receptor, Nishimoto reported that peptides containing
numerous basic amino acids spaced throughout the peptide and ending
with a BBXXB or BBXB (where X = any amino acid, and the last B can be a
basic or aromatic amino acid) were strong activators of Gi/0 (Ikezu, T., et
al. 1992). The importance of a cluster of basic amino acids situated in i3
(approximately 14-18 amino acids from TMD 6) in the receptor coupling to
G proteins were suggested by work done on the ml muscarinic receptor
coupling to PLC. This region was suggested to be important in G protein
activation, but not important for regulation and selectivity (Burstein, E. S.,
et al. 1995). Similarly substitution and deletion of basic amino acids in the
i3 of the Mi and M3 muscarinic receptors or peptides derived from the i3
of the (^-adrenergic receptor, close to the i3/TMD 6 junction, reduce
receptor coupling to Gn/11 and G0 respectively (Blin, N., et al. 1995, Lee, C.
H., et al. 1993, Wade, S. M., et al. 1996). The VIP2 receptor contains a
classical BBXXB motif at the i3/TM6 junction, whereas both the VIPi and
PACAPiong form receptors contain the spaced base motif seen in the a2-
adrenergic receptor and the cluster of basic amino acids present 14-18
amino acids upstream of TM6, as detailed by the work of Burstein et al..
(Burstein, E. S., et al. 1995). The presence of the hop-1 cassette provides
the clustered motif of basic amino acids implicated in G protein coupling
by the work detailed above. The PACAPshort receptor has no classical or
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spaced base motif present in its i3 and this may be a reason for its lack of
coupling to PLD via ARF. The role of basic amino acids in receptor-G
protein coupling is based on studies of the class I family of receptors, and
as detailed work on the domains involved in G protein coupling in the
class II family has yet to be undertaken, there is no consensus of opinion
regarding receptor regions crucial to G protein coupling.
Control of receptor coupling to adenylate cyclase/PLC activation
The fold increase in cAMP concentration and phosphoinositide
breakdown observed downstream of VIP and PACAP receptor activation
in this study is dependent on the concentration of receptor present, as
reported by other groups (Ciccarelli, E., et al. 1994, van Rampelbergh, J., et
al. 1997) and the activation of PLD by both VIP receptors was similarly
dependent on Bmax. However the PACAPiong receptor elicited a 3 fold
stronger PLD response compared to the PACAPshort receptor, despite the
presence of 1.5 times more short splice variant receptor expressed on the
surface of its stable CHO clone. The PACAPsh0rt receptor appears to
activate PLD via activation of PLC as shown by the U73122-sensitive
nature of the response (Figure 5.8). The activation of PLC would lead to
the formation of inositol 1,4,5-trisphosphate (IP3) and diacylglvcerol
(DAG) (Berridge, M. J. 1993); IP3 induces elevations in the cytoplasmic
calcium concentration, and Ca2+/DAG activate PKC (Nishizuka, Y. 1992)
which has been shown to be a positive regulator of PLD (Hammond, S.
M., et al. 1995, Hammond, S. M., et al. 1997). The activation of PLD by PKC
alone would reflect an indirect and perhaps weaker pathway for coupling
of the receptor to phosphatidylcholine hydrolysis, thus explaining the
poorer stimulation of PLD activity by the PACAPshort receptor. The ability
of the VIP and PACAP receptors to stimulate increases in cAMP
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concentration and phosphoinositide breakdown in CHO cells are very
similar and the presence of the hop-1 cassette does not appear to
significantly change the cAMP responses elicited by the PACAPiong form
as compared to the short form. By analogy with the rhodopsin family of
receptors, the determinants for receptor coupling to the Gs/adenylate
cyclase and Gq/PLC systems are most probably found within the
cytoplasmic loops present and experiments on other members of the class
II family of receptors indicate a role for il and 12 in receptor coupling to
cAMP and phosphoinositide metabolism, in addition to the i3.
Heller et al. reported that substitution of the basic arginine residue with
glycine in the glucagon-like peptide-1 receptor, at the C-terminal end of i3
(Ci3), almost abolished the cAMP response (Heller, R. S., et al. 1996).
Chicchi et al. reported the importance of the KLR motif in the N terminal
part if the glucagon receptor i3 loop (Ni3) which, when deleted, lead to a
39% decrease in the cAMP response (Chicchi, G. G., et al. 1997). A
homologous KLQ motif exists in the PACAP receptors and KLR and KLT
motif in VIPi and VIP2 receptors respectively. Mutation of the equivalent
amino acids in these receptors has not been reported, but the effect on
cAMP responses might be expected to mimic the results seen in the
glucagon receptor.
Constitutive activation of the human VIPi receptor was observed after the
mutation of a highly conserved histidine at position 178 to arginine at the
TM2/il junction. The same constitutively-activating mutation in the
PTH/PTHrP receptor is associated with Jansen-type metaphyseal
chondrodysplasia (Gaudin, P., et al. 1998). These reports are consistent
with the idea that basic amino acids can have profound effects on receptor
function. In mutagenesis experiments on the PTH/PTHrP receptor Iida-
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Kleincf al. found that mutation of lysine 319 in i2 to glutamate
significantly reduced receptor coupling to phosphoinositide breakdown to
27 ± 13% of wild type, without affecting the activation of adenylate cyclase.
The conservative replacement of the positively charged lysine 319 with a
positively charged arginine had no effect on receptor signal transduction
abilities (Iida-Klein, A., et al. 1997), emphasising the importance of basic
amino acids in all aspects of receptor-G protein coupling.
Recently the phosphorylation of the secretin receptor by G protein-
coupled receptor kinases (GRKs), which lead to desensitisation of the
receptor-mediated cAMP response was reported (Shetzline, M. A., et al.
1998), The results of the study on the secretin receptor expressed in HEK
293 cells suggest that receptors of the class II family of GPCRs can be
regulated by mechanisms similar to those of the rhodopsin (class I) family.
Physiological significance of VIP/PACAP-evoked PLD activity
The physiological significance of activation of PLD by the VIP and PACAP
receptors, as with any receptor activation of the enzyme, is unclear.
However there is significant overlap in the consequences of VIP/PACAP
stimulation and PLD activation. Both VIP and PACAP can act as potent
secretagogues; indeed PACAP activity in the pituitary is proposed to be
that of a hypophysiotrophic factor (Rawlings, S. R. and M. Hezareh 1996).
To expand on that argument, PACAP immunoreactivity is detected in
hypothalamic neurons projecting to the external zone of the median
eminence of the hypothalamus, it is released into the hypophysial portal
blood system, can bind to specific receptors detected within the pituitary
and it modulates anterior pituitary cell activity, including the release of
hormones such as luteinizing hormone (LH), follicle-stimulating
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hormone (FSH), growth hormone (GH) and prolactin from normal
anterior pituitary cells (reviewed in (Rawlings, S. R. and M. Hezareh
1996)). The PACAPshort and PACAPiong receptors (carrying the hop
cassette), are the dominant forms of the PACAP receptors in the anterior
pituitary (Rawlings, S. R., et al. 1995, Spengler, D., et al. 1993), although all
forms of the PACAP receptor are observed. PACAP stimulates the release
of LH, GH and prolactin from rats in vivo (Jarry, H., et al. 1992, Leonhardt,
S., et al. 1992, Nagy, G. M., et al. 1993, Yamamuchi, K., et al. 1995).
Moreover PACAP has been observed to stimulate luteinizing hormone
release from normal gonadotrophs in vitro, in a manner that was not
blocked by a VIP antagonist, therefore suggesting the release was mediated
by binding to the PACAP receptor (Culler, M. D. and C. S. Paschall 1991).
VIP stimulates the release of prolactin from the pituitary (Reichlin, S.
1988), and also PACAP and VIP can stimulate the release of (GH) from the
somatotroph-like GH3 cell, by acting on VIP2 receptors (Murakami, Y., et
al. 1995, Propato-Mussafiri, R., et al. 1992). VIP binding to the VIP2
receptor in mouse pancreatic P cells in the presence of glucose augments
the release of insulin and PACAP is proposed to function as a non-
cholinergic neurotransmitter, stimulating catecholamine secretion from
the adrenal medulla (Przywara, D. A., et al. 1996).
Thus VIP and PACAP both regulate the secretion of hormones and PLD
has been proposed to play an important role in the regulation of secretory
vesicles and membrane trafficking in mammalian cells (Bowman, E. P., et
al. 1993, Brown, H. A., et al. 1993, Cockcroft, S., et al. 1994, Kahn, R. A., et
al. 1993, Liscovitch, M. and L. C. Cantley 1995). Recently PLD1 was
reportedly localised to secretory granules in COS-1, RBL-2H3 and
neutrophils and upon agonist stimulation translocated to the plasma
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membrane (Brown, F. D., et al. 1998, Morgan, C. P., et al. 1997).
Furthermore ARF6 was also found to translocate from secretory granules
to the plasma membrane in chromaffin cells with a concomitant
activation of PLD (Caumont, A.-S., et al. 1998, Galas, M.-C., et al. 1997).
The inhibition of this translocation with a synthetic ARF6 peptide blocked
both PLD activation and catecholamine secretion in stimulated cells
(Caumont, A.-S., et al. 1998, Galas, M.-C., et al. 1997). Thus the secretion of
hormones may depend on the stimulation of PLD and its movement
from the secretory granules within the cell to the plasma membrane.
Thus ARF-dependent PLD activation may well be implicated in the
control of secretion of prolactin, growth hormone and insulin and other
hormones in response to VIP and PACAP. The regulation of secretory
responses by VIP and PACAP receptors, through PLD, may involve the
control of both the coatomer and clathrin-mediated secretory systems, at
the trans-Golgi network, endosomal compartments and the plasma
membrane.
VIP and PACAP both promote neuronal survival and mitosis (DiCicco-
Bloom, E. and P. J. Deutsch 1992, Pincus, D. W., et al. 1990) and PLD
hydrolysis of PC results in the production of two mitogenic lipids: PA and
its metabolite lysoPA produced by the actions of a phospholipase A2. PA
has been implicated in the stimulation of PKC-C, (Limatola, C., et al. 1994,
Nakanishi, H. and J. H. Exton 1992), PLC-y (Jones, G. A. and G. Carpenter
1993) and PIP-5K as described above (Moritz, A., et al. 1992), but perhaps
more importantly, PA also regulates the activity of Ras, which plays a key
role as a molecular switch in the signal transduction pathways that are
associated with cell proliferation, differentiation and neoplasia (Barbacid,
M. 1987). The function of Ras in mammalian cells is regulated by its
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interaction with a cytoplasmic GTPase activating protein (GAP) that
stimulates its conversion to the inactive form (Trahey, M. and F.
McCormick 1987). The active form of Ras activates other proteins
including Raf, which in turn activates p42MAPK and p44MAPK/
culminating in the activation of transcription factors, implicated in
control of cell growth (Pelech, S. L. and J. S. Sanghera 1992). PA binds to
and inhibits the p21ras GTPase activating protein (GAP) (Tsai, M., et al.
1991), Moreover PA also binds to a GTPase inhibitory protein, increasing
its activity (Tsai, M., et al. 1990). Thus the action of PA is to promote the
GTP-bound active form of Ras, and enhanced Ras activity leading to an
increase in MAP kinase activity and this scheme may explain the potent
effect PA has on cellular proliferation (Tsai, M., et al. 1989, Tsai, M., et al.
1989). Also it has been observed that PA binds to a site on Raf and enables
it to translocate to the membrane where it becomes active (Ghosh, S., et al.
1996). The effects of lysophosphatidic acid are mediated by its binding to a
specific cell surface GPCR (Moolenaar, W. H., et al. 1997, van der Bend, R.
L., et al. 1992). There are reports of the isolation of the cDNA for an
lysoPA-specific receptor from mouse, human and Xenopus oocytes (An,
S., et al. 1998, Dickens, A. S., et al. 1997, Guo, Z., et al. 1996, Flecht, J. H., et
al. 1996), coupled to G proteins of the Gi and Gq families.
Lysophosphatidic acid stimulates mitogenesis in numerous cells types and
this mitogenic effect is inhibited by pertussis toxin, suggesting the
involvement of Gi, and there is much evidence that lysoPA stimulates
the Ras/MAP kinase pathway (Hordijk, P. L., et al. 1994, Howe, L. R. and C.
J. Marshall 1993, Kumagai, N., et al. 1993, McLees, A., et al. 1995,
Moolenaar, W. H. 1995). The cellular actions of PA action may be the
outcome of its breakdown, by a PA-specific PLA2, first described in
platelets by Billah et al. (Billah, M. M., et al. 1981, Lapetina, E. G., et al.
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1981), and a form of this enzyme purified form rat brain described by
Thomson et al.. (Thomson, F. J. and M. A. Clark 1995). Recently a PA-
specific PLAi enzyme was purified and cloned, with abundant expression
in bovine brain and testis (Higgs, H. N. and J. A. Glomset 1996, Higgs, H.
N., et al. 1998). Therefore part of the actions of PA could perhaps be
ascribed to the production of lysoPA and its consequences. As discussed
previously, PACAP has been shown to activate the MAP kinase pathway
in neuronal and PC12 cells (Barrie, A. P., et al. 1997, Villalba, M. and L.
Journot 1997). Therefore lysoPA and PA both have potent effects on cell
growth and the ability of VIP and PACAP to stimulate mitosis and
survival in neuronal cells may be a consequence of PLD activation and
generation of the mitogenic lipid mediators as described.
In summary this study is the first explicit demonstration that members of
the class II (secretin/calcitonin) family of GPCRs can prominently activate
PLD, downstream of receptor coupling to PLC or the small G protein ARF.
The lack of significant sequence homology (<12%) between the class I and
II families of receptors but apparent ability to activate many of the same
signal transduction pathways (and as recently observed, regulation by the
same receptor kinases (Shetzline, M. A., et al. 1998)), points to the
importance of the general seven transmembrane receptor conformation
(Baldwin, J. M. 1993, Baldwin, J. M. 1994, Donnelly, D. 1997). The
conformation and recognition sites found within the VIPi, VIP2 and
PACAPiong receptors allow them to couple tightly to ARF and thus
activate PLD in a BFA-sensitive manner. However the PACAPshort
receptor with its similar but distinct structure couples to PLD primarily
through PLC and probably the activation of a PKC isoform. The small
differences in PACAP receptor structure leading to divergent mechanisms
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for activation of PLD mirror the differences observed in the mechanism of
PLD activation by the wild type and mutant GnRH receptors, discussed in
Chapter 4. The receptor association with G proteins requires further
exploration, the use of chimaeric receptor constructs described here could
be extended to isolate the specific G protein recognition sites within the
PACAP receptor. Analogous studies of the rhodopsin family of receptors
have made extensive use of chimaeric receptor constructs, and deletion
and/or mutagenesis of amino acid residues within domains crucial to G
protein coupling, such as the cytoplasmic loops and N-terminal portion of
the receptor carboxy terminal tail (Gudermann, T., et al. 1996, Strader, C.
D., et al. 1995, Strader, C. D., et al. 1994, Wess, J. 1997), The role of other
PLD activators such as Rho family proteins, PKC and PIP2 in VIP/PACAP-
stimulated PC hydrolysis are potentially similar to that observed with






Table 5.1 Concentration of cell surface receptors stably expressed in CHO





VIPi 0.06 ± 0.01 helodermin
0.89 ± 0.09
VIP2 1.5 ±0.1 helodermin
4 ± 0.36
PACAPshort form 9.2 + 0.9 PACAP-27
13.2 ± 1.8
PACAPiong form 6.0 ±0.1 PACAP-27
6.2 ±2.1
Whole cell binding of [125I]helodermin to the VIPi and VIP2 receptors and
[125I]PACAP-27 to the PACAPshort and PACAPiong receptors expressed stably in
CHO cells. The IC50 value was determined by non-linear curve fitting (P. Fit) as
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CHAPTER 6
Overview
Members of the GPCR superfamily play a central role in cellular
communications mediating the cell response to numerous hormones,
odorants, chemokines, neurotransmitters and light. Through the
coupling to heterotrimeric G proteins receptor activation regulates
numerous intracellular effector molecules including ion channels,
adenylate cyclase and phospholipases A?, C and D. The conservation of
PLD-like enzymes across species, the ubiquitous distribution of the
enzyme in mammalian tissues and the activation by a vast array of
agonists (Bocckino, S. B. and J. H. Exton 1996, Exton, J. H. 1997, Hammond,
S. M., et al. 1995, Ponting, C. P. and I. D. Kerr 1996), points to a critical role
in the signalling of a immense array of extracellular stimuli. The
stimulation of a receptor with ligand is proposed to cause a
conformational change and expose buried regions of the receptor which
are involved in G protein coupling, such as the second and third
intracellular loops (Altenbach, C., et al. 1996, Bukusoglu, G. and D. D.
Jenness 1996, Farahbakhsh, Z. T., et al. 1993, Farahbakhsh, Z. T., et al. 1995,
Farrens, D. L., et al. 1996, Gether, U., et al. 1997, Luo, X., et al. 1994). By
using mutagenesis of amino acid residues within receptors and the
construction of chimaeric receptors numerous investigators have isolated
the receptor determinants that control coupling to G proteins, the i2 and
i3 loops are seen as the main G protein coupling domain (reviewed
extensively in (Bourne, H. 1997, Gudermann, T., et al. 1996, Gudermann,
T., et al. 1997, Savarese, T. M. and C. M. Fraser 1992, Strader, C. D., et al.
1995, Strader, C. D., et al. 1994, Wess, J. 1997). Point mutation of the aig-
adrenergic and M5 muscarinic acetylcholine receptors in the i3 loop
caused constitutive coupling to G protein as seen by the stimulation of
the phosphoinositide breakdown in the absence of agonist (Burstein, E. S.,
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et al. 1996, Kjelsberg, M. A., et al. 1992). Point mutations in TMD 6 also
cause constitutive activation of receptors, for example the mutation of a
conserved aspartate residue in TMD 6 of the LH receptor causes
constitutive activity and is linked to the disease, familial male precocious
puberty (Shenker, A., et al. 1993). The interaction of TMDs 5 and 6 is
proposed to be at the centre of this constitutive activity, as a point
mutation activating chimaeric FSH and LH receptors with TMDs 5 and 6
sequence from LH but not FSH receptors (Kudo, M., et al. 1996).
Furthermore a point mutation in TMDs 5 and 6 from the ocia and aiB
respectively, could be silenced by complementary point mutations in
TMDs 6 and 5, respectively (Hwa, J., et al. 1996). In addition the mutation
of a single residue within the TMD 3 of the aig-adrenergic receptor
caused constitutive activation of Gq but not G;. Thus the coupling
characteristics of a GPCR can be selectively modulated by single amino
acids, including those not immediately involved in G protein interaction.
The mechanism by which GPCRs stimulate PLD is known to involve the
small G proteins ARF and Rho. However the way in which the receptor
recruits and interacts with these proteins was unclear. Furthermore the
activation of PLD by members of a new family of GPCRs, including
receptors for VIP/PACAP/secretin was poorlv understood.
The present investigations were designed to characterise the association
of ARF and Rho with GPCRs, and their roles in the activation of PLD.
The influence of a highly conserved amino acid sequence in TMD 7 of
class I receptors, implicated in the maintenance of a receptor
conformation was investigated. In a parallel study, the activation of PLD
by the class II family of receptors and the significance of the i3 loop
structure in this coupling was also scrutinised.
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In the 1321N1 cell line, native receptors containing the NPX2-3Y motif in
TMD 7: M3 muscarinic acetylcholine, B2 bradvkinin, Hi histamine,
stimulated PLD in an ARF-dependent manner as shown by the sensitivity
of those responses to BFA. The thrombin or thromboxane Ai receptors
(DPX2-3Y) receptors were shown to be resistant to BFA and couple to PLD
via PLC, as the PLD response was inhibited by the PLC inhibitor U73122
(Chapter 3). The involvement of small G proteins in the activation of
PLD by the M3 but not the thrombin receptor was also established by the
inhibition of the carbachol-evoked response by the Rho inhibitor C3
exoenzyme, and a negative RhoA construct. A wild type RhoA construct
enhanced PLD stimulation by low concentrations of carbachol but not
thrombin. The activation of PLD by either the M3 or thrombin receptors
was not affected by pertussis toxin, suggesting no involvement of proteins
from the Gi/0 family. Using the M3 and thrombin receptors as typical
examples of NPX2-3Y and DPX2-3Y receptors respectively, the interaction
of the receptors with the small G proteins ARF and Rho was further
investigated. The coupling of the M3 and not the thrombin receptors to
ARF as shown in Figure 3.2, was substantiated by the detection of
[3H]NMS but not [125I]Ala-pFPhe-Arg-Cha-HArg-Tyr-NH2 binding sites in
co-immunoprecipitates produced using antibodies to ARF1/3. Moreover
the presence of [3H]NMS but not [125I]Ala-pFPhe-Arg-Cha-HArg-Tyr-NH2
binding sites were detected in co-immunoprecipitates produced using
polyclonal antibodies to RhoA. The close association of ARF and RhoA
with the M3 receptor was corroborated by the presence of authentic ARF
and RhoA proteins in co-immunoprecipitates produced using polyclonal
antibodies to the M3 receptor solubilized from 1321N1 membranes. The
presence of M3 receptors in ARF1/3 and RhoA immunoprecipitates and
ARF and RhoA in M3 immunoprecipitates was dependent on the pre-
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exposure of 1321N1 cells to agonist, suggestive of a translocation of the
small G proteins to the membrane where they may interact with relevant
targets (Cavenagh, M. M., et al. 1996, Houle, M. G., et al. 1995, Malcolm, K.
C., et al. 1996, Riimenapp, U., et al. 1995). The critical involvement of
ARF and Rho proteins in the receptor coupling to PLD, as suggested by
the results presented in Chapter 3, are consistent with previous
investigations of M3 receptor signalling (Riimenapp, U., et al. 1995,
Schmidt, M., et al. 1994, Schmidt, M., et al. 1996). Using anterior pituitary
tissue the close association of a native NPX2-3Y-containing and BFA-
resistant receptor with ARF was confirmed by the co-
immunoprecipitation of ARF with antibodies directed against the ATi
receptor. The apparent selectivity of receptor interaction with small G
proteins was reinforced by using different GTP analogues and the M3
receptor. GTP analogue activation of trimeric or small G proteins was
seen to alter the M3 receptor affinity for ligand and the activation of PLD,
in a manner suggesting the receptor coupling to PLD via small G proteins.
The GnRH receptor is unusual in that it contains an arrangement of
conserved aspartate and asparagine residues in TMDs 7 and 2, that is not
found in any other known class I GPCR (Illing, N., et al. 1992, Probst, W.
C., et al. 1992, Reinhart, }., et al. 1992, Tsutsumi, M., et al. 1992, Zhou, W.
C., et al. 1994). The role of the N/DPX2-3Y motif in GPCR-coupling to PLD
was characterised by the use of the wild type (DPX2-3Y) and Asn318
mutant GnRH receptor where the aspartate in TMD 7 was replaced with
an asparagine residue thereby restoring the conserved NPX2-3Y sequence.
In agreement with the results in Chapter 3, the Asn318 mutant but not
the wild type GnRH receptor activated PLD in an BFA-sensitive manner.
6-5
A wild type and mutant 5-HT2A receptor which had the asparagine
residue in TMD 7 replaced with an aspartate, a mutation reciprocal to that
carried out on the GnRH receptor, were used to consolidate the
importance of the conserved N/DPX2-3Y motif in the receptors coupling
to PLD. The wild type but not the mutant 5-HT2A receptor-induced
activation of PLD was sensitive to BFA. The wild type GnRH receptor
akin to the thrombin and TXA2 receptors stimulated PLD in an U73122-
sensitive manner. Furthermore the mutation of the Asp at position 318
to asparagine appears to strengthen the coupling of the mutant GnRH
receptor to PLD, as observed in the increased rates for the activation of
PLD at short time points (Chapter 4). The dramatic changes in the
activation of PLD seen after the mutation of the conserved aspartate
residue in TMD 7 were not paralleled by changes in receptor-induced
breakdown of phosphoinositides. Consistently with the co-
immunoprecipitation results from Chapter 3, the Asn318 mutant but not
the wild type GnRH receptor was found in co-immunoprecipitates
produced using the polyclonal ARF1/3 and RhoA antibodies. As with the
work on the M3 receptor, the interaction of ARF and Rho proteins with
the GnRH receptors required the pre-exposure to agonist. Therefore the
hypothesis that there is a close interaction of GPCRs with ARF and Rho
proteins in the activation of PLD was substantiated, and a requirement for
NPX2-3Y in TMD 7 was indicated. Various investigators have proposed a
network of inter-helical H-bond interactions, and that the Asn or Asp in
the N/DPX2-3Y motif and the conserved tyrosine participate in this
network (Ballesteros, J., et al. 1998, Fanelli, F., et al. 1995, Hunyady, L., et
al. 1995, Konvicka, K., et al. 1998, Liu, J., et al. 1995, Oliveira, L., et al. 1994,
Perlman, J. H., et al. 1996, Scheer, A., et al. 1996). The N/DPX2-3Y
sequence appears to participate in the control of receptor activation and
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subsequent coupling to G proteins as has been suggested by both
mutagenesis and computer modelling (Fanelli, F., et al. 1995, Konvicka,
K., et al. 1998, Oliveira, L., et al. 1994, Perlman, J. H., et al. 1996, Scheer, A.,
et al. 1996, Scheer, A., et al. 1997) .
The activation of PLD by receptors from the class II family was first shown
by investigations of the glucagon receptor (Pittner, R. A. and J. N. Fain
1991). However this report was a preliminary study that has not been
followed up with further investigation of class II GPCR activation of PLD.
As shown in Chapter 5 there was a potent and concentration-dependent
activation of PLD by VIPi, VIP2, PACAPshort and PACAPiong receptors
expressed in CHO cells. ARF appears to be involved in the stimulation of
PLD by the VIPi, VIP2 and PACAPiong receptors, while the PACAPshort
receptor couples to PLD via PLC, as shown by U73122 blockade of its
stimulation of PLD. The stimulation of cAMP production by VIPi, VIP2,
PACAPshort and PACAPiong receptors was comparable; furthermore the
stimulation of phosphoinositide hydrolysis by the PACAPshort and
PACAPiong receptors was also similar. Therefore the differences in i3 loop
structure in the PACAPshort and PACAPiong receptors apparently affect
only the stimulation of PLD. The dramatic differences in the activation of
PLD by the PACAPsh0rt and PACAPiong can only be attributed to the effect
the presence of the 28 amino acid hop-1 insert in the PACAPiong receptor.
By constructing chimaeric receptors carrying the i3 loop of the
PACAPshort or PACAPiong receptors, replacing that of the VIP2 receptor,
we investigated the role of i3 loop in the activation of PLD. The
VIP2/PACAPiong but not the VUH/PACAPghort receptor activates PLD in
an ARF-dependent manner. The PACAPshort receptor appears to be the
only receptor studied here that cannot couple to PLD via ARF, with this
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in mind we analysed the sequence of the receptors in an attempt to
discover the nature of this difference. The VIP2 receptor contains a
classical BBXXB motif at the i3/TM6 junction which has been identified
by the work of Nishimoto's group as a potential activator of G proteins
(Ikezu, T., et al. 1992). The VIPi and PACAPiong form receptors contain
basic amino acids in a similar spaced motif to that present in the 0C2-
adrenergic receptor at a position beginning 14-18 amino acids upstream of
TMD 6, as detailed by the work of Burstein et al.. (Burstein, E. S., et al.
1995). The PACAPshort receptor has no recognised conserved G protein
coupling motif in its i3 and this may conceivably be a reason for its lack of
coupling to PLD via ARF.
The activation of PLD by GPCRs has long been known to involve ARF
and Rho proteins (Bowman, E. P., et al. 1993, Brown, H. A., et al. 1993,
Cockcroft, S., et al. 1994). The recent cloning of the human and rodent
forms of PLD1 has confirmed this involvement (Hammond, S. M., et al.
1995, Hammond, S. M., et al. 1997, Park, S.-K., et al. 1997). However the
mode of interaction of the receptor with the G protein was not clear. It
appears from the data presented in this study that the rhodopsin family of
GPCRs can form functional complexes with the small G proteins ARF
and Rho. There is a close association of receptor with ARF and Rho that
has never previously been reported, although the analogous association
of GPCRs with trimeric G proteins is well reported (Georgoussi, Z., et al.
1995, Okuma, Y. and T. Reisine 1992, Raymond, J. R., et al. 1993). We
found that the formation of this association is dependent on the presence
of the highly conserved NPX2-3Y motif in TMD 7. The receptors
containing the non-canonical DPX2-3Y sequence appear to select a PLC-
dependent pathway for the activation of PLD. The class II family of
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proteins can employ the same ARF-dependent mechanism for the
activation of PLD seen in their class I cousins, with a similar selectivity at
the receptor level for an alternative PLC-dependent pathway if ARF-
association is prohibited by receptor features (Chapter 5).
The method of association of the small G proteins with receptor is
unclear although obviously close, and may involve the numerous
cofactors that have been reported including the ARF guanine exchange
factor, and a Rho-associated 50 kDa factor (Chardin, P., et al. 1996, Kwak, J.
Y., et al. 1995, Morinaga, N., et al. 1996, Randazzo, P. A. and R. A. Kahn
1994). The precise site of receptor and small G protein coupling is
unknown but the results from Ghapters 3, 4, and 5 and the literature
suggest that the determinants controlling receptor coupling reside in the
i3 loop or immediately adjacent areas which control the receptor
conformation. Results from this study provide a starting point for the
delineation of the domains and processes directly involved in
controlling GPCR activation of PLD.
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G-protein-coupled receptors of the rhodopsin family transduce
many important neural and endocrine signals. These receptors
activate heterotrimeric G proteins and in many cases also cause
activation of phospholipase D, an enzyme that can be controlled
by the small G proteins ARF and RhoA1-3. Here we show that the
activation of phospholipase D that is induced bymany, but not all,
Ca2+-mobilizing G-protein-coupled receptors is sensitive to inhi¬
bitors of ARF and of RhoA. Receptors of this type were co-
immunoprecipitated with ARF or RhoA on exposure to
agonists, and the effects of GTP analogues on ligand binding to
the receptor changed to a profile that is characteristic of small G
proteins. These receptors contain the amino-acid sequence Asn-
ProXXTyr in their seventh transmembrane domain, whereas
Figure 1 Properties of agonist-evoked PLD responses in 1321N1 cells and co-
immunoprecipitation of M3 receptors with ARF1/3 and RhoA antibodies, a, the
effects of BFA on [3H]phosphatidylbutanol ([3H]PtdBut) production elicited by: •
200(J.M carbachol, ■ 10(j.M bradykinin, ▲ 2mM histamine, O 0.5 units per ml
thrombin, or □ 30 U46619 (a TXA2-receptor agonist). IC50 values for effects of
BFA on M3l bradykinin and histamine responses were 72 ± 11, 78 ± 15 and
82±13fiM, respectively, whereas thrombin-receptor and TXA2-receptor
responses were resistant up to 200 g,M BFA. b, Production of PtdBut in response
to carbachol and thrombin is shown by hatched and open columns, respectively.
Corresponding values for reagent-treated cells are shown by adjacent black
columns. Reagents were U73122 (20|xM; U 73), pertussis toxin (200ngml_1 for
18 h; Ptx), C3 exoenzyme (4.8 (a.g ml-1: C3) and wild-type or negative RhoA con¬
structs (WT and A"). Carbachol was used at a concentration of 200 |xM except in
C3 and WT RhoA experiments, where 100 and 20m,M, respectively, were
used. Thrombin was usually 0.5 units per ml but 0.2 units per ml in WT RhoA
experiments. In a, b, values are means ± s.e.m.; n = 4-10; significant changes
from the control levels are indicated by asterisks (P < 0.05; Wilcoxon test), c,
Solubilized membrane proteins from cells preincubated with carbachol (hatched
columns) or from controls (open columns) were immunoprecipitated with sheep
anti-ARF1/3 antibody (ARF), rabbit anti-RhoA antibody (RhoA), non-immune
sheep IgG (NIS) or non-immune rabbit IgG (NIR) or combinations of these
antibodies, before labelling M3 receptors with [3H]NMS. In some ARF/RhoA
immunoprecipitations, blocking peptides were included (shown as ±). Values
are means ± s.e.m. (n = 6-9). For asterisked bars, P < 0.05 compared with
unprimed controls, and for bars with daggers P<0.05 compared with non¬
immune IgG controls (Wilcoxon test). We estimate that up to 48% and 27% of
ligand binding to solubilized M3 receptor may be associated specifically (in a
peptide-blockable manner) with ARF and RhoA immunoprecipitates after agonist
priming.
receptors capable of activating phospholipase D without involving
ARF contain the sequence AspProXXTyr. Mutation of this latter
sequence to AsnProXXTyr in the gonadotropin-releasing
hormone receptor conferred sensitivity to an inhibitor of ARF,
and the reciprocal mutation in the 5-HT2A receptor for 5-hydroxy-
tryptamine reduced its sensitivity to the inhibitor. Receptors
carrying the AsnProXXTyr motif thus seem to form functional
complexes with ARF and RhoA.
The activation of phospholipase D (PLD) (measured as forma¬
tion of [3H]phosphatidylbutanol) by a number of receptors that are
native to 1321N1 human astrocytoma cells4 was differentially
inhibited by brefeldin A (BFA), an inhibitor of guanine-nucleotide
exchange on ARF5. Activation of PLD by Hj histamine, B2 brady¬
kinin and M3 muscarinic receptors in these cells6 (as for M3
receptors expressed in HEK 293 cells7) was sensitive to BFA whereas
activation of PLD by thrombin and thromboxane A2 receptors was
BFA-resistant (Fig. la). Thrombin- but not M3-receptor responses
were attenuated by the phospholipase C (PLC) inhibitor U73122,
but neither response was affected by pertussis toxin (Fig. lb). The
Rho inhibitor C3 exoenzyme and a negative construct, CMV5
Asn 19 RhoA (ref. 8), both reduced M3- but not thrombin-recep-
tor-mediated activation of PLD, whereas wild-type RhoA increased
responses to a lower concentration of carbachol but not thrombin
(Fig. lb). These results indicate that some Ca2+-mobilizing G-
protein-coupled receptors (GPCRs) use a pathway of PLD activa¬
tion that is independent of Gq/11 (which activates PLC) and Gi/o,
yet involves ARF and RhoA.
We used co-immunoprecipitation to test whether M3-receptor-
mediated PLD activation might involve a step in which the receptor
and small G proteins interact closely. Figure lc shows that solubi¬
lized M3 receptors (levels of which were measured by binding of
[3H]N-methyl scopolamine ([3H]NMS)) could be immunopreci¬
pitated using polyclonal antibodies against ARF1/3 (ref. 9) or
RhoA10. Yields from using combinations of antibodies were less
than additive. Co-immunoprecipitation required pre-exposure to
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using control immunoreagents or in the presence of excess peptide
antigen. Use of BFA (100 ptM) during priming reduced the yield of
M3 receptors in ARF1/3 immunoprecipitates by 74 ± 19%. Thrombin
receptors, labelled with [125I]Ala-pFPhe-Arg-Cha-HArg-Tyr-NH2
([ I]TRP; ref. 11) could not be co-immunoprecipitated by anti¬
bodies against ARF/Rho after priming with thrombin agonist (data
not shown). When a control immunoprecipitating antibody (anti-
PKCa, Transduction Laboratories) was used to collect another
signalling protein known to translocate to 1321N1 cell membranes,
preincubation with carbachol caused no increase in [3H]NMS
binding to immunoprecipitates despite a 3.1 ± 0.3-fold increase
in membrane binding of [ HJphorbol 12,13-dibutyrate (data not
shown).
Immunoblotting using distinct (monoclonal) antibodies showed
that authentic ARF and Rho were present in ARF/Rho-directed
immunoprecipitates from carbachol-primed cells; ARF and Rho
were not present in immunoprecipitates when peptide antigens to
the polyclonal reagents were added (Fig. 2a, b). In the detergent/
NaCl conditions that we used, the monoclonal anti-ARF antibodies
1D9 (ref. 12) and clone 26 (Transduction Laboratories) were much
less effective or completely ineffective, respectively, at precipitating
ARF immunoreactivity and [3H]NMS-binding sites (data not
shown). An M3-receptor antiserum fraction6, but not non¬
immune IgG, caused co-precipitation of immunoreactive ARF
and RhoA after priming with carbachol (Fig. 2c, d). Similarly,
polyclonal antibodies to the AT[ receptor (BFA inhibited PLD
activation by this receptor; half-maximal inhibitory concentration
(IC50) 58 ± 5 p.M) caused priming-dependent, peptide-blockable
co-precipitation of authentic ARF (Fig. 2e) and Rho (data not
ARF(P) RhoAtpl
shown). In addition, when ATlrprimed membranes were treated
with the crosslinker ethylene glycolbis(succinimidylsuccinate) and
immunoprecipitations carried out with antibody ID9 in the pre¬
sence ofTriton X-100/SDS, specific AT!-receptor immunoreactivity
became detectable in immunoprecipitated high-molecular-mass
complexes of approximately 170K (data not shown). These results
indicate that certain receptors may be able to form physical com¬
plexes involving ARF1/3 and/or RhoA and that this may be
important in the activation of PLD.
We used GTP analogues to determine whether the effects of these
analogues on both receptor and effector properties were consistent
with the above hypothesis. The affinity ofM3 receptors labelled with
[3H]NMS for carbachol was reduced by guanosine 5'-0-(3-thio)-
triphosphate (GTPyS), BeF3 (an isostere of AlFJ (ref. 13)) and
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Figure 2 Immunoblots for ARF and Rho on immunoprecipitates generated with
polyclonal ARF1/3, RhoA and receptor antibodies. Blots a-d are from 1321N1
cells and e is from rat anterior pituitary cells. For each panel, the labels below
indicate the preincubation conditions (CCh, carbachol; AT, ATII; -, control. Labels
above show the immunoprecipitation reagents (ARF(p), sheep polyclonal anti-
ARF1/3 antibody; RhoA(p), rabbit polyclonal anti-RhoA antibody; M3, rabbit
polyclonal anti-M3-receptor antibody; Nl, non-immune rabbit IgG; AT1R(p), rabbit
polyclonal anti-ATrreceptor antibody), with (+) or without (-) blocking peptides.
Labels to the right indicate the immunoblotting reagents (ARF(m), mouse
monoclonal anti-ARF antibody; Rho(m), mouse monoclonal anti-Rho antibody).
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Figure 3 PLD and PLC responses of wild-type, Asn318 and Asp 318 plus Asp 87
Asn318 mutant GnRFI receptors expressed in COS 7 cells and receptor
immunoprecipitation with ARF1/3 and RhoA antibodies, a, b Show the time
course of [3H]phosphatidylbutanol ([3H]PtdBut) and [3H]inositol phosphate
([3H]lnsP) production evoked by 100 nM GnRFI at • wild-type, ■ Asn318 mutant
and A Asp87 Asn318 mutant receptors and by V AlFj (10mM NaF and 30 p.M
AICI3) in Asn318 mutant expressing cells. Values are percentages of wild-type
response at 40 min (means ± s.e.m.; n = 4-6). c, d Show effects of BFA and
U73122 on [3FI]PtdBut production evoked by 100 nM GnRFI at • wild-type and ■
Asn 318 mutant receptors. Values are means ± s.e.m.; n = 4-6. e, Shows binding
of [l26l]buserelinto immunoprecipitates from cells expressing wild-type orAsn 318
mutant receptors. Extracts from cells preincubated with GnRFI (hatched columns)
or from controls (open columns) were immunoprecipitated with antibodies
against ARF1/3 (ARF), RhoA (RhoA), p21Ras (Ras) or ERK1/2 (ERK). Blocking
peptides for ARF/RhoA antibodies were sometimes included (indicated as ±).
Values are means ± s.e.m.; n = 4-8. Asterisks relate to P values of <0.05 com¬
pared to controls, byWilcoxon test. After agonist priming, 26% and 33% of ligand
binding to solubilized mutant GnRFI receptor (1100-1400 o.p.m, per sample)
seemed to be associated specifically (in a peptide-blockable manner) with ARF
and RhoA immunoprecipitates whereas specific association with these precipi¬
tates of the wild-type was negligible.
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After carbachol priming, the effect ofGTPyS was unaltered, that of
BeFJ was attenuated and that of GPPCH2P was increased in a way
that was 57 ± 10% inhibited by BFA. Table lb shows that GTP
analogues activated PLD in permeabilized cells and that their effects
were modified by agonist priming14"16. After carbachol priming of
1321N1 cells, the effect of GTPyS did not change significantly but
that of BeFJ was reduced and that of GPPCHiP was greatly
increased. Agonist priming lowered the effective concentration for
halfmaximum response (EC50) for GPPCFGP from 367 ± 74 p,M to
97 ±11 p,M (6% and 22%, respectively, of the potency of GTPyS
(itself with an unaltered EC50 of 21-22 pM)). Agonist exposure
causes ARF1/3 and RhoA7,16,17 to translocate to cell membranes and
the increased effect of GPPCH2P here was abrogated by BFA or C3
exoenzyme (Table lb). Effects of A1FJ and BeFJ may involve
trimeric, but not small, G proteins13'18 (although selectivity may
be modified in vivo). In contrast, Py-methylene analogues of GTP
may retain a substantial fraction of the potency of GTPyS at ARF,
Rab5 and other small G proteins, despite being very weak activators
of trimeric G proteins and Ras19,20. Indeed in an assay of [35S]GTPyS
association to native ARF, collected from ID9 immunoprecipitates
(which were later renatured) of urea-treated extracts from
carbachol-primed 132IN 1-cell membranes, GPPCH2P retained
30% of the potency of GTPyS with mean IC50 values of 54 and
16 pM, respectively (R.M. and D.M., unpublished observations).
These results concur with the idea that agonist-induced transloca¬
tion of ARF/RhoA to membranes may promote their involvement
in some form of complex with GPCRs, and may ultimately enhance
receptor-mediated activation of PLD.
Each of the receptors that were sensitive to BFA, C3 exoenzyme or
CMV5 Asn 19 RhoA or that could be co-immunoprecipitated with
ARF 1/3 or RhoA contains the canonical AsnProXXTyr motif
(where X represents any amino acid) in transmembrane domain
VII (TMD VII), whereas the other receptors contain AspProXXTyr
instead. The wild-type gonadotropin-releasing hormone (GnRH)
receptor (which contains AspProXXTyr) and two mutants contain¬
ing an AsnProXXTyr motif (containing mutation ofAsp 318 —► Asn
or Asn 87 —♦ Asp as well as Asp 318 —► Asn (ref. 21)) were expressed
in COS 7 cells. The wild-type receptor activated PLD linearly over
30-40min, like the receptor in aT3-l cells22. In contrast, the
Asn 318 and Asp 87 Asn 318 mutants displayed initial rates of
Table 1 Effects of GTP analogues on agonist recognition by M3
receptors and on PLD activation
and GnRH
Assay and treatment gtp analogue
GTPyS F" gppch2p
(a) Carbachol affinity for
[3H]NMS-binding sites in
1321N1 cells (fold increase
in ICbo)
Control 5.23 ± 0.97





(b) Activation of PLD in
permeabilized 1321N1









rate in transfected COS7
cells (Reduction in t1/2 of
slow component (%))
Wild-type GnRH receptor 43 ± 4 36 ± 8 12 ±5
Asn 318 mutant 40 ± 5 7 ±5* 38 + 81
GTPyS, F and GPPCH2Pwere present at 100 10 mM and 200 jiM, respectively, except in
c where 3 mM F" and 100 m-M GPPCH,P were used. BFA and C3 exoenzyme were used at
100m-M and 4.8|xgmt1, respectively. Values are means±s.e.m., r —4-10. Statistically
significant differences (P < 0.05 by Wilcoxon test): *, less than corresponding unprimed
control (a, b) or wild-type control (c); t greater than corresponding unprimed or wild-type
control; 1 reversal of GTP-analogue effect.
[3H] phosphatidylutanol formation that were more than 2.5-fold
that of the wild-type receptor (Fig. 3a). Enhanced PLD coupling in
the mutants was observed despite reduced [3H]inositol phosphate
production (Fig. 3b) and reduced membrane [125I]buserelin binding
(for which values of 589 ± 39, 230 ± 41 and 148 ± 36fmolpermg
protein Bmax were obtained for cells expressing wild-type, single
mutant and double mutant receptors, respectively). PLD-activation
responses of the mutants desensitized rapidly, whereas PLC-activation
responses did not. In contrast, postreceptor stimulation of trimeric
G proteins with A1FJ caused non-desensitizing activation of both
PLD and PLC in Asn 318 mutant cells. Neither altered receptor
kinetics nor enhanced receptor internalization to allow contact with
intracellular PLD23 could explain the enhanced PLD coupling, as
[125I]buserelin association with the membrane and receptor inter¬
nalization rates in wild-type and Asn318-mutant cells were indis¬
tinguishable. In addition, 200 |xM monodansylcadaverine and
30 |xM monensin (which caused 70-80% inhibition of receptor
internalization) increased rather than reduced, both PLD responses
(data not shown).
PLD activation by the wild-type receptor was inhibited by
U73122 (IC50 of 11 ± 1 |xM) but not by BFA in concentrations up
to 200 |xM (these data are similar to data from aT3-l cells), whereas
the Asn 318-mutant response was sensitive to BFA (IC50 of
54 ± 8 |xM) but not U73122 in concentrations up to 20 |xM (Fig.
3c, d). ATP, an agonist for the native P2u receptor (which contains
the AspProXXTyr motif), and ionomycin/phorbol ester both
caused BFA-resistant PLD activation (data not shown). The gain
ofBFA-sensitive PLD (but not PLC) activation upon replacement of
the AspProXXTyr motif with AsnProXXTyr indicates that this
structural motif may be important in gating ARF/Rho-mediated
coupling to PLD. This hypothesis is supported by the greater
sensitivity to BFA (IC50 47 ±11 p-M) of PLD activation by the
wild-type 5-HT2A receptor (which contains AsnProXXTyr) than its
Asp 376 mutant (ref. 24) (24 ± 13 inhibition at 200 pM BFA)
expressed in COS 7 cells.
The importance of the AsnProXXTyr motif in the proposed
linkage between receptor and small G proteins was directly
indicated by co-immunoprecipitation of agonist-treated Asn 318
mutant but not wild-type GnRH receptors using ARF and RhoA
antibodies (Fig. 3e). Furthermore, although GTPyS increased dis¬
sociation of [12T]buserelin from both the Asn 318 mutant and the
wild-type receptor in permeabilized cells, GPPCH2P was effective
towards the mutant only and the inverse was true for BeFJ (Table
lc). The effect of GTPyS at the mutant, but not the wild-type,
receptor was inhibited (by 62 ± 12%) by 50 pM BFA.
Our results suggest a model involving a previously unrecognized
association between certain rhodopsin-family receptors and the
small G proteins ARF and RhoA. One functional consequence of
this appears to be an enhanced coupling of receptors to PLD
activation. The interaction seems to occur when an AsnProXXTyr,
but not AspProXXTyr, receptor motif is present and may be
enhanced by agonist-induced translocation of ARF/RhoA to the
plasma membrane. The form and site of interaction of small G
proteins with receptors is unknown, but it seems likely that other
proteins that act as adapters or regulators of small G protein
function25"28 may participate or mediate in the association. □
Methods
Phospholipase assays. PLD and PLC activities were monitored as
production of [3H]phosphatidylbutanol and [3H]inositol phosphates,
respectively29. For assays of PLD activity in acutely permeabilized cells,
prelabelled 1321N1 cells were primed with 100p,M carbachol (lOmin, 37°C)
or control before intracellular buffer7 was added. This buffer contained 2 mM
MgATP, 10|JiM NAD, 6 p.M digitonin, 30mM butan-l-ol, and GTPyS,
GPPCFLP or F~ (NaF in the presence of 30 p,M BeCL) and BFA or C3
exoenzyme as required. Male rat anterior hemipituitaries were labelled for
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Liposome treatment and transfection of 1321N1 cells. Cells were treated
with lipofectamine containing C3 exoenzyme (2 (jig per well, 5 h), CMV5-RhoA
constructs (0.5 |xg DNA per 4.5 cm2 well, 7 h) or control8. Rho-construct cells
were assayed after 48 h.
Solubilization and immunoprecipitation of [3H]NMS-labelled M3 recep¬
tors and [125l]TRP-labelled thrombin receptors. 132IN 1 cells (preincubated
with carbachol (100 jjlM) or the thrombin agonist Ser-Phe-Leu-Arg-Asn-NH2
(30jxM) for lOmin) were homogenized in cold Hepes buffer with peptidase
and phosphatase inhibitors. Membranes were solubilized in 5mM CHAPS,
0.1% Na cholate and 1M NaCl for 30min at 4°C. An equal volume of 20%
glycerol in CHAPS/cholate buffer without NaCl was added (with 0.6mgml~'
phosphatidylcholine for M3 receptors). Supernatant was precleared and
incubated (4°C, 18h) with sheep anti-ARFl/3 immunoglobulins (10-15 |xl/
ml; antigen ARF198_112; gift from M. J. O. Wakelam)9 or with an immunopre-
cipitating rabbit anti-RhoA IgG (2-3 p,gml-1; antigen RhoA119_132; Santa Cruz
Biotechnology)10. The ARF antiserum immunoprecipitated authentic
immunoreactive ARF from CHAPS/cholate/NaCl membrane extracts
(Fig. 2a) and from cytosol after its incubation with GTP7S and the addition
of CHAPS/cholate/NaCl but not without this treatment (R.M. and M.J.,
unpublished observations). Blocking peptides were used at 6 p.gml-1 and
control non-immune IgG at 3(xgml_1. Immune complexes were collected
with protein-G-Sepharose. M3 receptors were assayed in lOmM MgCl2,
200 mM NaCl, 10% glycerol, 3mgml_1 phosphatidylcholine, 20 mM Hepes
pH 7.5, 10 nM [3H]NMS (85 Ci mmol-1, Du Pont) with or without 10 (jlM N-
methyl atropine for 40min at 37 °C, before precipitation with polyethylene
glycol. Thrombin receptors were assayed in 10 mM MgCl2, 150mM NaCl,
0.25% BSA, 0.05% bacitracin, 0.1 mM 4-(2-aminoethyl)-benzene sulphonyl
fluoride (AEBSF), 2fjLgmT1 aprotinin, 7% glycerol, 2mgmTI phosphatidyl¬
choline, Tris HC1 (50 mM pH 7.4), [125I]TRP (ref. 11; 120,000 c.p.m. per assay)
with or without 300 nM unlabelled TRP, for 60 min at 4 °C.
Western blotting of immunoprecipitated extracts. Extracts from 1321N1
cells or male rat anterior hemipituitaries (preincubated with 10|xM ATn for
10min at 37°C) were immunoprecipitated using polyclonal anti-ARFl/3
antibodies at 20 jxlml-1 (peptide at 8p.gml_1), polyclonal anti-RhoA IgG at
5 ixgrnl-1 (peptide at 20 jxgml-1), rabbit anti-M3 receptor serum6 (antigen M3
receptor561_578) (or non-immune rabbit IgG) at 2.5 |xg ml-1 and polyclonal
anti-AT] receptor IgG at 5 |xgml-1 (antigen ATi receptor!5_24; 20 p-gml-1; Santa
Cruz). Proteins collected by protein G beads were separated by SDS-PAGE and
blots were incubated with monoclonal anti-ARF IgG (clone 26, 1:200 dilution;
Transduction Laboratories), or anti-Rho IgG (clone 26C4,1:200 dilution; Santa
Cruz). Detection was by horseradish-peroxidase-conjugated secondary anti¬
body and enhanced chemiluminescence.
Modulation of agonist affinity at M3 receptors by GTP analogues. 1321N1
cells were incubated with or without carbachol (20 jxM) and/or BFA (100 jjlM)
for 10min at 37 °C. Carbachol displacement (10-3,000 |xM) of membrane
[3H]NMS binding was measured in 10 mM MgCl2, lOOmM NaCl, 20 mM
Hepes pH 7.5, 1 nM [3H]NMS, with or without GTPyS, GPPCH2P or F~, for
60min at 37 °C.
[125l]buserelin-binding studies in transfected COS 7 cells. Receptor
constructs in pcDNAl (refs 21, 24) were transfected using DEAE dextran
(20 fxg DNA per 4 X 106 cells) and were assayed 72 h later. Membrane binding
was assayed as described30. For cell-surface binding, cells in 12-well plates were
incubated with ligand, with or without 3 jjlM GnRH, at 4°C or 37 °C as
appropriate30. Internalization was measured at 37 °C for 0-40min after pre-
equilibration with ligand for 90min at 4°C. Surface-bound ligand was
dissociated with cold 0.2M acetic acid in 0.5M NaCl. Ligand dissociation in
permeabilized cells was measured by prelabelling at 4°C, and then successive
incubations with medium containing 22 jxM digitonin and GTP analogues at
37 °C. Initial dissociation occurred identically from wild-type and Asn318
mutant GnRH receptors, reflecting a temperature-dependent reduction in
GnRH binding. From 15-50 min, slower dissociation rates were reached and
plots of ln^ against time revealed single linear components of half-lives: wild-
type: 22 ± 3min, and Asn 318 mutant: 26 ± 3 min in controls.
Solubilization and immunoprecipitation of wild-type and mutant GnRH
receptors labelled by [125l]buserelin. After preincubating cells with or
without 100 nM GnRH for 15 min, membranes were solubilized in 5mM
CHAPS and 1.5M NaCl (ref. 30). Extracts were adjusted to 0.5M NaCl and
precleared before incubating (at 4°C for 18 h) with the polyclonal antibodies
anti-ARFl/3 (10 (ilml-1) and anti-RhoA (1 (igmT1), described above, or with
mousemonoclonal anti-Ras IgG (antigen p21ras; Transduction Laboratories) or
mouse monoclonal anti ERK1/2 IgG (antigen ERK1325_345; Zymed Labora¬
tories) as controls at 1 (xgrnl- (both of which are reported to recognize native
conformations of their targets). Blocking peptides for the polyclonal reagents
were used at 2 (xgml-1. Immune complexes were collected using protein G-
Sepharose, and [125I]buserelin binding was measured in polyethylene glycol
precipitates30.
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ACTIVATION OF PHOSPHOLIPASE D BY THE VIP2 RECEPTOR
AND EVIDENCE FOR ITS ATTENUATION BY PROTEIN KINASE A.
D. McCulloch. S. Grieve. M. Johnson. E. Lutz and R. Mitchell. MRC
Brain Metabolism Unit, 1 George Square, Edinburgh EH8 9JZ UK
The recently-cloned type 2 vasoactive intestinal peptide (VIP2)
receptor is a member of the secretin/glucagon/PACAP family of large
peptide hormone receptors, characterised by seven transmembrane
spanning domains and coupling to heterotrimeric G proteins, but
distinct from the rhodopsin famiiy. Members of this family are known
to couple to the heterotrimeric G protein, Gs. We have found for the
first time that VIP stimulation of the VIP2 receptor, transiently
expressed in COS 7 cells, activates phospholipase D (PLD) which
hydroiyses the membrane phospholipid phosphatidyl choline to
produce phosphatidic acid and choline.
We have evidence that the PLD response is endogenously
attenuated by a protein kinase A-dependent mechanism since PLD
activation is greatly enhanced in the presence of the selective protein
kinase A inhibitor H89. Similar results were obtained in stably
transfected CHO ceils where PLD responses were minimal unless
protein kinase A was inhibited. Phorbol 12,13-dibutyrate-stimulated
PLD activity in CHO cells was also inhibited by the adenylate cyclase
activator forskolin.
These results demonstrate that VIP famiiy receptors, specifically
the VIP2 receptor, can activate PLD and that PKA is involved in
attenuating or desensitising this response.
